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ABSTRACT
The folate receptor (FR) was identified in 1986 and has been established as a
‘molecular Trojan Horse’ target for the uptake of folate-conjugated organic molecules
into cells. The FR is overexpressed in many malignancies, including those of the ovary,
uterus, breast, cervix, and prostate, yet it is reportedly under-expressed in normal
healthy cells. This difference in expression and the high affinity/specificity of folate
towards the folate receptor presents a promising drug delivery system. The aim of this
research was to utilise folic acid as a targeting moiety and generate simple metal folate
and novel folate-phenanthroline complexes with cytotoxic properties.

A challenging set of chemical objectives were set and resulted in the successful
generation of simple metal-folate and metal-folate-phen complexes (metal = Cu2+,
Mn2+, Fe3+ and Zn2+). In contrast to reports in the literature, NMR and IR evidence
indicates that the folate ligand coordinates the metal centre via a tridentate ONO {αCOO-,

γ-COO-, and Namide} binding mode. A challenging six-stage synthetic route yielded

the novel folate-ethylenediamine-imidazole-phen (FIMP-et) ligand and the novel
complexes [Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O and [Mn(FIMP-et)3].(ClO4)2.9H2O
were subsequently isolated in high yield and purity.

The complexes generated were then utilised in a series of biological studies using
cellular models expressing the folate receptor. Our results suggest that the effects
mediated by these complexes are not dependent on folate receptor expression. Western
blot analysis and live cell analysis identified that [Cu(fol)(phen)(H2O)].3H2O, with or
without the inclusion of folic acid, induced expression of proteins associated with
proteasomal inhibition and apoptosis. In contrast, [Mn(fol)(phen)(H2O)].4H2O was
ineffective

in

inducing

proteasomal

inhibition.

Interestingly

[Mn(fol)(phen)(H2O)].4H2O induces cell death through a mechanism independent of
proteasomal inhibition, which may involve ROS-induced autophagy.

This work advances the field of medicinal inorganic chemistry and has identified novel
mechanisms of action for metal folate targeted inorganic complexes as potential
chemotherapeutic agents, through proteasomal inhibition and ROS-induced
autophagy.
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INTRODUCTION
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I.1

Introduction to Chemotherapy

The origins of chemotherapy stem from nitrogen mustard, a chemical warfare agent
used in WWI and extensively researched by the Allies of WWII. Victims of the toxic
gas were often noted to have profoundly low levels of white blood cells as well as a
reduction in size of the lymph nodes1. In light of this, Doctors Louis Goodman and
Alfred Gilman, two pharmacologists with the US Department of Defense, saw
potential in the agent as a treatment for lymphoma, a disease often characterized by
the malignant swelling of the lymph nodes. The gaseous agent was converted to a
liquid product and named mustine – a compound which would go on to be the model
for alkylating agents still used today in modern chemotherapy2.

Shortly after this serendipitous discovery, Sidney Farber built upon the observations
made by Goodman and Gilman and demonstrated that 4-aminopteroyl-glutamic acid
(aminopterin) (Figure 1), a synthetic derivative of the B-vitamin folic acid, resulted in
remissions in children with acute leukemia3–6. Aminopterin was found to compete with
folate for the binding site of the dihydrofolate reductase (DHFR) enzyme preventing
the uptake of folic acid and consequently halting DNA replication7–9. However, the
difficult synthesis of aminopterin prompted researchers to modify the compound,
resulting in the generation of methotrexate (Figure 1) - an antifolate drug still widely
used today and the first drug shown to cure a metastatic tumor of choriocarcinoma 10.
The success of these initial chemotherapeutic agents encouraged chemists to seek new
molecules that could inhibit cell replication entirely - The era of cancer chemotherapy
had begun.
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Figure 1: The chemical structures of aminopterin and methotrexate.

Since the introduction of chemotherapy, the average rate of survival amongst adult
cancer patients has increased from 35% in 1954 to 50% in 1975 and now to the latest
(2018) average survival rate of 69%11,12. This increase in survival is largely due to
earlier detection, improvements made in anticancer therapeutics, and the introduction
of anticancer vaccines12. However, although there have been great advances in the field
of chemotherapy, many of the chemotherapeutic agents in use today still suffer the
same limitation as their predecessors, poor specificity. This is primarily because
anticancer agents often utilize the high proliferation rates of cancer cells as their
objective. However, this non-selective strategy ultimately results in the death of
healthy cells that also proliferate rapidly, such as those of the gastrointestinal tract,
hair follicles and the immune system13,14. The adverse side effects which often result,
introduce dose limiting consequences for many chemotherapeutic agents and
invariably undermine their use.
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I.1.1

Introduction to Targeted Therapies

The paragon of chemotherapy is the recognition of malignant cells by a therapeutic
agent via the identification of a unique characteristic of malignant cells, and the
preferential delivery of a chemotherapeutic agent to such cells to induce a precise
cytotoxic effect. Many examples of the effective use of this strategy can be found in
the literature, including targeted therapies in advanced stages of development and a
small number in clinical use15–18.

It is worth noting that although the development of targeted therapeutic agents was
primarily initiated to direct the toxic effects to malignant cells only, in turn reducing
damage to healthy cells19, targeted therapeutics also offer a plethora of other
advantages. These include enabling otherwise membrane impermeable drugs to enter
target cells via receptor mediated endocytosis and inducing advantageous
modifications in cell behaviour by activating a receptor’s normal signaling pathway19.

I.1.2

Folate-Targeted Chemotherapy

In 1986, Kamen et al, a group from the University of Texas South-western Medical
Centre reported that MA104 cells possess a high-affinity surface receptor for folates20.
The group proposed that folate uptake may occur by: (i) binding to the surface
receptor, (ii) internalisation via endocytosis and (iii) liberation from the receptor in an
acidic endosome20. In the early 1990’s, Leamon and Low reported that the
physiological process by which folate-drug conjugates enter folate receptor positive
(FR+ve) cells is identical to that of folic acid. Furthermore, Leamon and Low stated
that macromolecules can be non-destructively delivered into cells via folate receptor-
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mediated endocytosis if the macromolecules are covalently conjugated to folic acid
prior to addition to cells expressing the folate receptor21–23. These discoveries led to
the development of chemotherapeutic folate targeting, Often referred to as “molecular
Trojan horses”, covalent folate conjugates can leverage the high affinity/specificity of
folate towards the folate receptor (FR)23. Later in 1999, Leamon et al determined that
macromolecules attached to folic acid by either the α or γ glutamyl linkage could
associate with FR bearing cells at virtually identical levels 24. However, it is worth
noting that the different pKa values of the α and γ carboxylic acid moieties of the
glutamate tail of folic acid result in different reactivities 25.

In 2013, Chen et al, successfully elucidated the crystal structure of the human folate
receptor α (FRα) in complex with folic acid at 2.8 Å resolution (Figure 2). They
reported that the human FRα has a globular structure stabilized by eight disulphide
bonds. It was reported that the folate pteroate head binds deep within the receptor
pocket, leaving its glutamate moiety exposed outside of the pocket entrance, allowing
it to be conjugated to drugs without unfavorably affecting FRα binding26.

Figure 2: The binding interaction of folic acid and FRα as determined by Chen et al26.
-5-

In the same year, Wibowo et al published structures of human folate receptors α and
β and described the molecular interaction of human FR with antifolates Alimta,
aminopterin and methotrexate27. Wibowo added further that the pterin rings interact
with residues deep within the binding pocket via π- π stacking and are stabilized by
additional polar bonds27. The extensive interactions between the receptor and ligand
explain the high folate-binding affinity and offer a template for the design of more
specific drugs targeting the folate receptor system 26.

Of the numerous targeted therapeutic methodologies currently under development, this
review of the literature will focus specifically on those utilizing the folate moiety to
selectively target the FR which is over expressed on many cancer cell types28,29,38,30–
37

. However, it is worth mentioning that the high FR expression observed in activated

macrophages may also provide a means of preferentially targeting Mycobacteriuminfected macrophages, activated macrophages in inflammatory and autoimmune
diseases (rheumatoid, inflammatory and osteoarthritis), and may also hold promise in
the treatment of leishmaniosis39–48.

I.2

Folic Acid: Structure, Function and Its Role in disease Progression

Folic acid is a member of the family of B9 vitamins, its molecular structure can be
subdivided into three components, consisting of a pteridine moiety, linked by a
methylene bridge at carbon 6 to para-aminobenzoic acid (PABA), with an amide bond
to a glutamic acid moiety (Figure 3)49. The terms ‘folate’ and folic acid are often used
interchangeably but it should be noted that folic acid as depicted in Figure 2 is a
pharmacological agent and does not occur in nature 49. The term ‘Folate’ is generic and
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used to refer to a number of members of the B9 vitamin family. For the purposes of
this thesis, the terms folate (i.e. the deprotonated form of folic acid) and folic acid may
be used interchangeably throughout.

Figure 3: The structure of folic acid highlighting the three central components; the
pteridine ring, para-aminobenzoic acid (PABA) and the glutamate tail. The α and γ
carboxylic acid moieties are indicated.

Folic acid is used in vitamin supplements and in cell culture media due to its chemical
stability, but within cells it is first reduced to dihydrofolate (DHF) and then to
tetrahydrofolate (THF) mediated by dihydrofolate reductase (DHFR) (Scheme 1)49.
Endogenous folic acid is not found in human cells; it is derived entirely from dietary
sources, with 5-methyltetrahydrofolic acid (5-methylTHF) being the major folate
derived from dietary sources and the dominant folate found in the blood of humans
and rodents49.
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Scheme 1: Folic acid is reduced to dihydrofolic acid (DHF), which is in turn reduced
to tetrahydrofolic acid (THF) in reactions mediated by dihydrofolate reductase
(DHFR). 5-Methyltetrahydrofolic acid (5-methylTHF) is the major folate found in
blood (modified from Zhao et al)49.

Folates play an essential role in critical biosynthetic processes in mammalian cells.
These one-carbon donors are required for purine nucleotide and thymidylate synthesis
and, hence, are essential for the de novo production of RNA and DNA. Folates are also
required for vitamin B12-dependent synthesis of methionine, from which Sadenosylmethionine is formed, required for methylation of DNA, histones, lipids and
neurotransmitters49. A deficiency in folate uptake results in the impairment of
methylation of deoxyuridylate to thymidylate and initiates a process that can lead to
megaloblastic anemia50. Insufficient folate intake (less than 400 μg) in pregnant
women is associated with neural tube defects (NTD) which are abnormalities that may
occur in the brain, spine, or spinal column of a developing embryo and are present at
birth. The two most common forms of NTD are spina bifida (in which the fetal spinal
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column doesn't close completely) and anencephaly (in which most of the brain and
skull do not develop)51,52.

1.2.1

Folate Uptake into Cells and Tissues

The cellular uptake of folate is mediated by three distinct transporters; the proton
coupled folate transporter (PCFT), the reduced folate carrier (RFC), and folate receptor
(FR). The PCFT is the main transporter of folate in low pH environments, such as the
intestine53. The RFC is the predominant folate transporter expressed in normal adult
tissue, mediating the uptake of reduced folates and the antifolate drug, methotrexate
with relatively high affinity (Km for 5-methylTHF in the range of 3-7 µM; Km for
methotrexate from 1 – 5 μM)38,54,55. However, it has a very low affinity for folic acid
(Ki approx. 150-200 µM)56. The RFC is ubiquitously expressed in the intestine,
hepatocytes, choroid plexus and renal epithelial cells. It facilitates transplacental
transport of folates and folate transport across the blood-brain barrier57–60.

The FR is a glycopolypeptide with high affinity for binding and transporting
physiological concentrations of folate into cells. The human FR family comprises of
four

isoforms

–α,

-β,

-γ

and

-δ.

Of

the

four,

FRα

and

FRβ

are

glycosylphosphatidylinositol (GPI)-linked membrane bound proteins, while the third,
FRγ, is a secretory protein. The fourth isoform, FRδ, has been identified only from
genome database mining, however neither its tissue expression nor functionality have
been determined61. Both FRα and FRβ exhibit limited expression in healthy tissues
such as placenta, kidney, bladder and the choroid plexus. In the kidney, FRα is
implicated in folate transcytosis from luminal cavities to the interior environment,
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whilst in the placenta, both FRα and FRβ function to maintain maternal-to-fetal folate
transport. Furthermore, the presence of FRα in choroid plexus is critical to maintain
folate homeostasis and for the transfer from plasma to the cerebrospinal fluid 27,38.

However, most FRs are expressed on the apical surface of healthy, polarized epithelial
cells and are therefore inaccessible to circulating FR-targeted agents administered
intravenously. An exception to the rule is the kidney, in which FRα expressed in the
proximal tubules will bind to receptor targeted agents which are filtered from the blood
stream. It has been suggested that the kidneys should be protected against the cytotoxic
effects of FR-targeted agents, such as nanoparticles, liposomes and macromolecules,
as they are excluded from glomerular filtration due to their size 61.

FRα is consistently overexpressed in non-mucinous adenocarcinomas of the ovary,
uterus, breast, cervix, colorectal, prostate, brain, nose and throat 26,27,62. It exhibits a
high affinity (Kd < 10-9 M) for folic acid, a binding affinity ~10 times greater than any
other reduced form of the vitamin or the anti-folate drug, methotrexate38. It is
estimated that 95% of ovarian carcinomas overexpress FRα and that a strong
correlation exists between FRα expression and both stage of tumour progression and
histological grade63. In instances of lung cancer, the leading cause of cancer death
worldwide, non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancers
and has been shown to express FRα to a high extent64,65. It is hypothesised that the
overexpression of FRα in malignant cells confers a growth advantage to tumours by
increasing folate uptake, in turn increasing DNA synthesis and affecting cell
proliferation via alternative cell signalling pathways32. The overexpression of FRα
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may hold potential as both a therapeutic and prognostic target in a number of different
cancers, especially ovarian, colorectal and breast 65–67.

FRβ is expressed on activated synovial macrophages which are present in large
numbers in arthritic joints, where they play an active role in rheumatoid arthritis.
Furthermore, pathologies such as multiple sclerosis 68, Crohn’s disease69, ulcerative
colitis70, psoriasis71, osteomyelitis72, and even atherosclerosis73 are also believed to
be caused or aggravated by activated macrophages which express FRβ74.

I.2.2

Mechanism of Folate Uptake via the Folate Receptor

The physiological process by which both dietary folate and folate-drug conjugates
enter FR expressing cells is known as endocytosis. It involves the binding of folate or
an exogenous folate-drug conjugate to FRα and the subsequent invagination of the
plasma membrane around the receptor-ligand complex to form an intracellular vesicle
or endosome. It is reported that the endosome acidifies to ~pH 5 through the action of
proton pumps, inducing a conformational change in the receptor and the release of the
active drug from the folate delivery system 75 (Figure 4). However, the precise
pathway(s) are still widely discussed76–79.

- 11 -

Figure 4: Uptake of folate-drug conjugates. The folate-drug conjugate is taken up by
cells by binding of folate to the folate receptor. Invagination of the plasma membrane
results in receptor mediated endocytosis. The acidic pH (~5) results in dissociation of
the drug cargo and the folate receptor is recycled to the cell surface once more
(modified from Leamon et al)75. RFC: reduced folate carrier.

Receptor-mediated endocytosis offers an advantageous uptake system as it is nondestructive to the folate-drug conjugate and, as the folate receptor is known to recycle
regularly between the cytosol and cell surface, an increased drug concentration can be
obtained within the cell53,80. Given the restricted expression of FR isoforms
(particularly FRα) on healthy tissue, in addition to its high affinity for folic acid, folate-
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mediated drug delivery is advantageous to overcoming unwanted drug toxicity as well
as offering the benefit of increased drug concentration in target cells.

I.3

Coordination Chemistry

Medicinal inorganic chemistry is still considered a youthful discipline by many,
contrary to the historical use of metals in medicine in the civilizations of Mesopotamia,
Egypt, India, and China81–83. The antimicrobial agent, salvarsan (a mixture of 3-amino4-hydroxyphenyl-arsenic(III) compounds), developed by Paul Ehrlich as an effective
treatment against syphilis in 1912 is widely regarded as the birth of modern
chemotherapy and often cited as the beginning of metallodrug development 84.

Yet it was the discovery of the platinum-based anticancer drug, cisplatin, in which
medicinal inorganic chemistry truly found success 85. Cisplatin has been employed in
the treatment of various solid neoplastic malignancies including sarcomas and
carcinomas such as small cell lung cancer, testicular, ovarian, cervical, endometrial,
bladder, head and neck, gastroesophageal and germ cell cancers/tumours 86,87. It has
proven highly effective against testicular cancer in combination with other agents such
as bleomycin with cure rates up to 85%88.

Cisplatin is still extensively utilised, being a major component in first, second and third
line treatment regimens for the aforementioned cancer types 89. The clinical success of
cisplatin and its derivatives is immense, as they are among the most effective
anticancer cytotoxins available and are currently utilized in 50% of all treatment
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regimens for solid tumours. This constitutes the most impressive contribution to the
use of metals in modern cancer chemotherapy.

I.3.1

Contemporary Modes of Action of Metallodrugs

Cisplatin and its platinum-based derivatives represent the classical metal-based
therapy, inducing its cytotoxicity via DNA damage. Platinum based compounds have
been reported to enter cells via the copper transporter, Ctr1 and undergo hydrolysis
within the cell, producing a potent electrophile capable of reacting with the nitrogen
donor atoms on nucleic acids and cross-link to the N7 reactive centre on purine
residues of deoxyribonucleic acid, in turn halting cell division and resulting in
apoptotic cell death. The 1,2-intrastrand cross-links of purine bases with cisplatin
account for roughly 90% of adducts formed and have been reported to contribute to
the toxicity of cisplatin90,91.

However, due to the undesirable adverse side effects and potential drug resistance
associated with cisplatin and related platinum-based drugs, there has been increased
interest in nonclassical platinum complexes whose mechanism of action may be
distinct. Complexes containing other metals, such as copper, not only offer the
prospect of biological activity involving DNA interaction/damage but also the
potential to interact with biomolecules such as proteins and the potential to interfere
with

anomalies

associated

with

metabolic

balance/imbalance (Figure 5)92.
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processes

such

as

oxidative

Figure 5: The proposed sites of action of metal-based drugs in mammalian cells.
Copper(II) and platinum(IV) complexes have been reported to interact with DNA
either directly or via ROS generation, resulting in DNA cleavage and ultimately
apoptosis. Metals such as manganese(III), copper(II), and ruthenium(II) reportedly
induced ROS related-mitochondrial damage and autophagy. Finally copper(II) and
other metals such as gold(II), nickel(II) and zinc(II) have been found to induce
proteasomal damage, resulting in apoptosis93,94,103–112,95–102.
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I.3.1.1

Reactive oxygen species (ROS) induced DNA damage

The activity of transition metal complexes is largely associated with the generation of
ROS and the subsequent damage to proximal proteins and DNA. For example, the
hydroxyl radical (•OH), formed through Fenton or Haber–Weiss reactions catalyzed
by the reduction of Mn to Mn-1 in the presence of oxygen and a ready electron source,
such as glutathione, is credited as the most likely agent of DNA cleavage 93–95. This
reaction, in turn, results in the oxidation of bases (most notably guanine, to form 8oxoG); the generation of other radicals that result in DNA crosslinks (particularly G
and methylated-C), and double or single strand breaks in the phosphoester bonds
between specific nucleotides in DNA113.

I.3.1.2

ROS-induced autophagy

Autophagy is the self-catabolic process of sequestering and delivering damaged
organelles and protein aggregates from the cytoplasm into lysosomes for
degradation114. Autophagic cell death is morphologically associated with the induction
of autophagic vacuole formation and involves a biochemical process where organelles
are digested in double membrane autophagasomes 115. In contrast, apoptosis, (more
commonly encountered when working with metal complexes) is characterized by
exposure of phosphatidylserine on the external membrane, formation of mitochondrial
permeability transition pores, caspase 3 activation, chromatin condensation, blebbing,
and oligo-nucleosomal DNA fragmentation116,117.
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Among the effector mechanisms involved in the control and regulation of cell death
pathways, including autophagy and apoptosis, is the cellular redox status. The redox
status in the cell is determined by the balance between the rates of production and
breakdown of reactive oxygen and/or nitrogen species (ROS/RNS), including free
radicals such as superoxide (O2.-), hydroxyl radical (•OH), and non-radicals capable of
generating free radicals (i.e., H2O2)118.

In recent years, metal complexes have reportedly induced cell death by means of ROSinduced autophagy. For example, in 2009, Paris et al reported that a copper(II)
dopamine complex (Cu.DA) induced autophagic death in RCSN-3 cells (transformed
rat ganglion cell line). Fluorescent microscopy shows that Cu.DA (100 µM) induced
the formation of double-membraned autophagic vacuoles around mitochondria,
evident by co-localisation of GFP-LC3 (a protein involved in the formation of
autophagosomes) and the mitochondrial calcium marker Rhod-2AM. The authors
proposed that the autophagic events preceded late apoptotic death, due to late
oligonucleosomal DNA fragmentation observed. These results are in agreement with
reports showing that autophagy precedes apoptosis119. Additionally, complexes of
copper(II), manganese(II), ruthenium(II), and platinum(II) have been reported to
induce similar effects96–104.

I.3.1.3

Proteasome Inhibition

In recent years, the disruption or inhibition of the Ubiquitin-Proteasome System (UPS)
has been identified as a novel mechanism of several transition metal complexes. The
UPS is responsible for intracellular protein homeostasis and is the predominant
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regulator of the degradation of proteins involved in cell cycle control, gene
transcription, DNA repair, and apoptosis induction and helps to maintain normal
cellular function120. Deregulation of this pathway has been reported in various forms
of cancer such as breast, colorectal, lung and prostate, and appears to promote cancer
development through a plethora of mechanisms121.

The initial link between metals and inhibition of the proteasome was first identified in
2004 by Daniel et al who reported that copper(II) salts (10 µM), regardless of
counterion, were consistently capable of irreversibly inhibiting proteasome activity in
cell-free conditions by more than 80% whereas free organic ligands {such as
hydroxyquinoline (8-OHQ) and 1,10-phenanthroline (phen)} could not. Free
copper(II) ions failed to reproduce the same proteasomal effects in whole cells,
reducing proteasome activity by 30% at 10 µM, possibly due to poor cellular
uptake/inability to access the proteasome. However, coordination to phen or 8-OHQ
not only facilitated uptake into whole cells to induce proteasome-inhibitory effects but
also completely inhibited proteasome activity at 10 µM. Since 2004, a number of
articles reporting similar findings have also been published122–126.

The implication of metal induced ROS generation in the inhibition of proteasome
activity has also previously been investigated. Daniel et al noted that co-incubation of
CuCl2 in the presence of the anti-oxidant, N-acetylcysteine (NAC; 100 mM) had no
effect on the ability of copper to inhibit the purified 20S proteasome 127. Similarly,
Santoro et al reported that copper-treated samples (5 µM) were unable to catalyse
production of ROS in the presence of the reducing agent, Dithiothreitol (DTT; 29 µM).
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Both authors concluded that proteasome inhibition was a result of direct binding of
Cu(II) ions to the proteasome and not a result of ROS generation.

Other metals such as gold, nickel and zinc have also been reported to induce
proteasome inhibition, evident by accumulation of K48-linked ubiquitinated proteins
and the upregulation of proteasome-related substrates such as p21 and p27105–112.
Interestingly, a platinum pyrithione (PtPT) complex reported by Zhao et al was found
to target proteasomal deubiquitinating enzymes (DUBs) UCHL5 and USP14 rather
than DNA, suggesting a different mode of action than cisplatin 107.

It must be stated that although the described mechanisms have been found to induce
cell death, it is entirely likely that numerous pathways and/or mechanisms are involved
in the eventual cell death. It is now becoming more apparent that transition metalbased drugs are multi-faceted and multi-modal, and that their mechanism of action
goes far beyond DNA damage.

I.4

Folate targeting of inorganic complexes

As described in Section I.3.1.1, cisplatin and its successors interfere with replication
and/or the mitotic processes of tumour cells. In this way, they achieve potency by
damaging cancer cells more than they damage healthy cells. While this approach has
been successful, it is known to cause significant side effects, such as nephrotoxicity,
neurotoxicity, leukopenia, and thrombocytopenia, as well as nausea, vomiting, and
hair loss. Just as the design of organic chemotherapeutics has shifted from potent
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alkylators and inhibitors of DNA synthesis to more tailored, subtle reagents, the design
of novel metallotherapeutics now requires a targeted approach 128.

1.4.1

Coordination complexes of folic acid

The application of FRα-targeted molecules is not new; there have been many articles
and papers published regarding the conjugation of folates to known organic drug
molecules such as taxol, paclitaxel and doxorubicin to improve drug targeting 129–131.
The

advantageous

chemotherapeutic

potential

of

folate-targeted

inorganic

nanoparticles such as mesoporous materials132–134, gold-nanoshells135–137, quantum
dots (QD)138–140, and magnetic nanoparticles141–143 has also been established. Along
with these, the applications of other folate-targeted nanomaterials including liposomes,
micelles, dendrimers, oligonucleotides and carbon nanotubes (CNT) have been
reviewed in detail elsewhere14,34,144.

However, there is a void in the literature regarding the coordination chemistry of folic
acid and the conjugation of folic acid to metal-based molecules and even less regarding
their chemotherapeutic capabilities. A review of the literature returned fewer than forty
relevant articles concerning metal-folate complexes, many of which focus on the
synthesis and characterisation of metal-folate complexes but do not report results from
biological investigations.

The coordination chemistry of folic acid (Figure 3), is poorly characterised. Metal
complexes of pteridines are not common since they are highly π electron deficient
heterocycles but they are known to form some complexes involving their nitrogen and
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oxygen atoms (which can exist in either a carbonyl group or an iminol group depending
on which tautomeric state prevails)145. The binding properties of glutamic acid, on the
other hand, are well established and it is known to form thermodynamically stable
complexes with a range of metals146. Very few publications report the direct
coordination of folic acid to a metal even though such complexes may have interesting
biological activity and selectivity towards FRα-overexpressing cells. Table 1
summarizes the formulation, mode of coordination and any reported biological
properties for the metal folate/folic acid complexes, and relevant related compounds
that were sourced in the literature.
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Table 1: Formulae, mode of coordination and biological properties for the metal folate/folic acid complexes.
Formulae
M2(folate).nH2O (M = Mn2+, Co2+, Ni2+, Cu2+,
Zn2+, Cd2+ and Hg2+ ; n = 1-3,5 or 15)

Binding mode of the folate/folic acid
Bidentate bridging via α and γ carboxylate
groups

Biological activity

Reference

Antifungal and antibacterial activity

147

[Ag2(folate)].3H2O

Bidentate bridging via α and γ carboxylate
groups

Not reported

148

Antioxidant and anti-DNA damage
capabilities.

149

Not reported

150

M(folate)2.nH2O absorbed more efficiently in
rodent blood than metal-free folic acid

151

Not reported

148,150

Sr(folate).4H2O is a non-toxic bone promoter

152

[Cu(MTX)(H2O)] (MTX2- = the doubly
deprotonated methotrexate)
[UO2(folate)2](EV)2 (EV+ = the cation of the
basic triphenylmethane dye ethyl violet)

Bidentate bridging via α and γ carboxylate
groups
Bidentate bridging via α and γ carboxylate
groups
Bidentate chelating via the α and γ
carboxylate groups
Bidentate chelating via the α and γ
carboxylate groups
Bridging Bidentate via α and γ carboxylate
groups
Tridentate (α and γ carboxylate groups and
the amide nitrogen of the glutamate moiety)
Chelating via α carboxylate and amide
nitrogen of the glutamate moiety

Nuclease activity and cytotoxicity

153

Not reported

154

[cis-Ru(2,2’-bipy)2(folic acid)]2+

Chelating via N5 and N10 nitrogen atoms

Not reported

[cis-Pt(NH3)2(H2O)2(tetrahydrofolate)]

Chelating via N5 and N10 nitrogen atoms

Dihydrofolate reductase and folate transport
system inhibition in L1210 cell line

Bidentate chelating via α and γ carboxylate
groups

Weak-to-moderate cytotoxicity and
antioxidant effects

158

Bidentate bridging via α and γ carboxylate
groups

FR+ve selective cytotoxicity; where M = Co 2+
- in-vivo antitumour activity in mice

159,160

[(VO)2(folate)(NH4)2(SO4)2]
Ln2(folate)3.nH2O (Ln = La3+ to Gd3+, except
Pm3+; n = 6-9.5)
M(folate)2.nH2O (M = Cu2+ or Fe3+; n = 2 or,
respectively)
M(folate).nH2O (M = Mn2+, Fe2+, Co2+, Ni2+,
Cu2+, Zn2+; n = 4-6)
M(folate).4H2O (M = Ca2+ or Sr2+)

MLL’X2.2H2O (where M = Cu2+, Cd2+, Mn2+,
Fe3+, Ni2+, Pb2+ ; L = folate or niacin; L’=
glycine, and X = NO3 or Cl-),
{M2(folate)(N2H4)3(OH)2(H2O)2}n (M =Ni2+
or Co2+)

155,156
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157

The earliest reported synthesis of a metal-folate complex found in the literature was
published in 1947 by a group led by J.J. Pfiffner of Park-Davis and Company161.
Interested in the application of folic acid as an “anti-anaemic factor”, the group focused
on its isolation from liver and yeast. As part of their study, a silver salt of the B vitamin
was synthesized; involving the reaction of an aqueous solution of folic acid with silver
nitrate to generate a yellow microcrystalline product, which they formulated as
[Ag2(folate)] on the basis of elemental analysis161.

In 2008, Abd El-Wahed et al reported the synthesis and thermal characterisation of
simple binuclear transition metal-folate complexes with the general formula
M2L.nH2O (where M = Mn2+, Co2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+ ; L = folate; n =
1-3,5 or 15), generated by the reaction of sodium folate with the respective metal
chlorides147. Here, the folate anion acts as a dicarboxylate ligand, with the metal ion
coordinated to both the α and γ carboxylate groups of the glutamic acid moiety (Figure
6). Furthermore, the group conducted antifungal and anti-bacterial testing on these
simple metal-folate complexes and concluded that the cadmium(II), cobalt(II) and
nickel(II) folate complexes exhibit activity against Penicillium, Trichoderma and
Bacillus subtilis, while a mercury(II) folate complex was shown to exhibit high
activity against Penicillium, Trichoderma and Escherichia coli147. The generation of
[Ag2(folate)].3H2O, via a similar synthetic route as reported by J.J. Pfiffner et al, has
also been reported recently148.

23

Figure 6: The proposed structures of various metal folate complexes synthesized by
Abd El- Wahed et al147. (A) The structure of 4 coordinate complexes where M = Mn2+,
Co2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+ and n = 1, 3, 15, 2, 0, 3 and 0, respectively. (B)
The structure of the only six coordinate complex where M = Fe 3+ and n = 7.

In 2016, the synthesis and characterization of a similar simple vanadium(IV) folate
complex

[(VO)2(L)(NH4)2(SO4)2]

was

also

published

(Figure

7)149.

[(VO)2(L)(NH4)2(SO4)2] was isolated from the reaction of vanadyl(II) sulphate and
folic acid in solution at pH 7-8, and the complex was found to exhibit antioxidant and
anti-DNA damage capabilities149.
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Figure 7: The structure of [(VO)2(L)(NH4)2(SO4)2]149

In 2009, Hamed et al reported mononuclear iron and copper folate complexes, with
the general formula ML2.nH2O (M = Cu2+ or Fe3+; L = folate; n = 2 or 3, respectively)
whereby the metal ions are coordinated to two folate anions via the glutamate moiety
which effectively acts as a bidentate ligand on the α and γ carboxylate groups (Figure
8 (A))162. When treating white albino mice with 100 mg/kg of folic acid or the copper/iron-folate complexes, the authors found that the complexes were better absorbed in
rodent blood than folic acid itself, which they believe may be due to the increased
solubility of the metal-folate complexes. In addition, folate complexes with the general
formula ML.nH2O (M = Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Zn 2+; L = folate; n = 4-6) have
also been reported150. It is proposed that in these complexes the folate also acts as a
bidentate ligand via the glutamate moiety, but their structures were not confirmed.

In 2015, Rojo et al reported the synthesis and characterisation of calcium and strontium
folates with the general formula ML.4H2O (M = Ca2+ or Sr2+; L = folate), in which the
folate also acts as a bidentate ligand via the glutamate moiety152. The strontium-folate
complex, which was obtained by reacting a sodium salt of folic acid with strontium
chloride, was found to overcome the toxic effects associated with free Sr 2+ ions, a
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problem associated with strontium ranelate, the established anti-osteoporosis treatment
used to promote bone growth.

Interestingly, in 2015 Nagaj et al reported the copper(II) complex of the antifolate
agent methotrexate (MTX), an analogue of folic acid (Figure 1)153. Potentiometric
titrations of MTX against CuCl2 yielded the neutral complex [Cu(MTX)(H2O)]
(MTX2- = the doubly deprotonated methotrexate) at pH 7.5 and on the basis of NMR
and IR spectral evidence the authors proposed that the MTX 2- was bound to the
copper(II) centre as a tridentate ligand via the α and γ carboxylate and the amide
nitrogen functionalities (Figure 8 (B)). [Cu(MTX)(H2O)] was also shown to be an
effective nuclease agent in the presence of added hydrogen peroxide and the complex
was found to be approximately twice as cytotoxic against mouse colon carcinoma
(CT26) and human lung adenocarcinoma (A549) cell lines than methotrexate itself.
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Figure 8: (A) The proposed structure of the octahedral metal (M = Cu 2+ or Fe3+)
difolate complexes synthesized by Hamed et al162. (B) The proposed structure of the
neutral complex [Cu(MTX)(H2O)] (MTX2- = dianionic methotrexate) isolated at pH
7.5153. (C) The structure of [UO2(folate)2](EV)2 (EV = Ethyl Violet)154. (D) The
proposed structure of ΔR cis-bis(2,2’-bipyridine)-dichlororuthenium(II), [cis-Ru(2,2’bipy)2Cl2 coordinated to positions the N5 and N10 of folic acid155.
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While developing a novel analytical method for folic acid and its metabolites under
physiological conditions, Xi et al isolated the 2:1 anionic folate-uranium (IV) complex
salt [UO2(folate)2](EV)2 (where EV+ = the cation of the basic triphenylmethane dye
ethyl violet) in aqueous solution at pH 4.2-4.8154. The authors proposed that the folate
ligands are coordinated to the uranium atoms in the UO22+ moieties via the nitrogen
atom of the imido-group of the amino-carboxyl and the oxygen atom of the α -carbonyl
to form stable five-membered chelate rings (Figure 8 (C)), as determined by charge
density calculations.

In 1992 Schwederski et al reported the synthesis of the ruthenium complex cation [cisRu(2,2’-bipy)2 (FA)]2+ (FA = folic acid) in which they postulated, based on a limited
analysis, that a neutral folic acid ligand was bound to the ruthenium as an α iminocarbonyl chelate, via the carbonyl oxygen and a nitrogen atom of the pteridine
moiety156. More recently, while investigating the interaction of ruthenium complexes
with intracellular biomolecules, Scrase et al also reported the isolation of [cis-Ru(2,2’bipy)2(FA)]2+ under physiologically relevant conditions155. The complex was
characterised extensively by NMR and MS which revealed that the folic acid acts as a
neutral chelating ligand involving a nitrogen atom from the pteridine group and the
amine nitrogen of the para-aminobenzoic acid moiety (Figure 8 (D))155.

These authors also repeated the synthesis of the complexes reported by Schwederski
et al and confirmed that the two complexes were identical. Furthermore, the group
experimented with altered protonation states of folic acid and confirmed that the
binding of the neutral folic acid was contingent on its ability to act as the N-N chelate.
The authors hypothesised that the total ruthenium content of treated cells could be
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forty times greater than folate in molar concentrations and therefore, the resulting
ruthenium-folate species could interfere with enzyme binding and the one-carbon
transfer function of folates in cells. Therefore, given the low concentration of folates
in cells, any sequestration of ruthenium will alter the cellular balance of folate. As
folate metabolism has long been recognized as a key target for cancer therapy,
understanding how ruthenium complexes interact with the folate pool may be of
significance155.

The N-N chelate mode of coordination had previously been reported by Vitol et al in
a platinum(II) complex generated when the cis-diaminediaquaplatinum(II) cation was
reacted with the reduced folate tetrahydrofolate carrier at pH 7 and 37 OC to generate
the pure complex in 70% yield157. Elemental analysis, NMR and absorbance
spectroscopies confirmed that the diamine platinum moiety was coordinated to the N5
and N10 positions of the tetrahydrofolate. Although similar complexes were isolated
for 5-methylhydrofolate, 5-formyltetrahydrofolate, methotrexate and aminopterin, the
authors reported that folate and 7,8-dihydrofolate did not react with the diamine
platinum cation successfully. The biological implications of these observations were
also investigated and the cis-diaminediaquaplatinum (II)tetrahydrofolate complex was
found to be a reasonably good inhibitor of dihydrofolate reductase (Ki = 4 µM) and of
the folate transport system (50% inhibition at 200 µM) in the mouse lymphocytic
leukaemia cell line (L1210). It is noteworthy that there is no apparent cell death caused
by the cis-diaminediaquaplati-num(II)tetrahydrofolate complex at 200 µM during a
folate transport inhibition study, suggesting that it would not be capable of exerting a
cytotoxic response in the same way as cisplatin, possibly due to the lack of labile
coordination sites in its structure.
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In 2016, Fazary et al reported the synthesis and thermal characterisation of 1:1
mononuclear folate and niacin complexes with secondary glycine ligation. The general
formula MLL’X2.2H2O (where M = Cu2+, Cd2+, Mn2+, Fe3+, Ni2+, Pb2+ ; L = folate or
niacin; L’= glycine, and X = NO3 or Cl-), generated by the reaction of the respective
metal salts with glycine, followed by subsequent reaction with either a methanolic
solution of niacin or an alkaline solution of folic acid. It is reported that the folate anion
acts as a dicarboxylate ligand, with the metal ion coordinated to both the α and γ
carboxylate groups of the glutamic acid moiety (Figure 9).

Figure 9: The proposed structures of various metal folate complexes synthesized by
Fazary et al158. (A) The structure of 6 coordinate complexes of the B vitamin niacin
where M = Cu2+, Cd2+, Mn2+, Fe3+, Ni2+, Pb2+ (B) The structure of six coordinate
complexes of folic acid where M = Cu2+, Cd2+, Mn2+, Fe3+, Ni2+, Pb2+.

Furthermore, the group conducted cytotoxicity studies using Hep-2 human laryngeal
carcinoma, Daoy human medulloblastoma, MCF-7 human breast adenocarcinoma, and
WiDr human colon adenocarcinoma cell lines, as well as antioxidant studies. The
group reported that chromium(II) and lead(II) complexes of niacin and folic acid
showed weak cytotoxic activities whereas all other mixed ligand complexes of the
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vitamins exhibited moderate cytotoxic activities against the four cancer cell lines. The
manganese(II) folate glycine complex, [MnFAGCl2].2H2O, was found to exhibit good
antioxidant activity (76.36 % DPPH inhibition), whereas both cadmium complexes
[CdFAGCl2].2H2O and [CdNAGCl2].2H2O exhibited poor inhibitory effects (23.85
and 27.66 % DPPH inhibition, respectively)158.

Two very interesting nickel(II) and cobalt(II) biomolecule-based coordination
complex nanotubes (BMB-CCNT’s), with the molecular formula of the monomeric
unit {M2(folate)(N2H4)3(OH)2(H2O)2} (M = Ni2+ or Co2+) have recently been
reported159,160. These BMB-CCNT’s were synthesised in good yield by a method
involving ultrasonification of folic acid with the respective metal(II)chloride in a 1:2
molar ratio and with the addition of 10 mL of aqueous hydrazine (at pH 10.5) in an
ethanol/water mixture (20/80) followed by heating in an autoclave to 120 °C to yield
the product. Similar attempts to generate the Zn2+, Ca2+, Fe2+ and Cu2+ analogues were
unsuccessful, and the authors reported the recovery of only the corresponding metal
oxides from these reactions. The structure of the {Ni 2(folate)(N2H4)3(OH)2(H2O)2}n
nanotubes (Figure 10) was confirmed by an array of physicochemical techniques.
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Figure 10: The proposed structure of nickel(II) biomolecule-based coordination
complex nanotubes (BMB-CCNT’s), with the molecular formula of the monomeric
unit being {Ni2(folate)(N2H4)3(OH)2(H2O)2}n159,160.

The folate ligand is bound to the Ni2+ ions via its carboxylate groups, which act as
bidentate chelates and the nanotubes comprise a polymeric structure in which the metal
ions are at the centre of octahedral coordination sphere with hydrazine ligands bridging
neighbouring M2+ to each other and with hydrogen bonding involving the pteroic
moiety of the folate forming a tape-like structure (Figure 10). To demonstrate the
importance of the hydrazine in the role of the nanotube formation these workers also
reacted folic acid with nickel(II) chloride in the presence of ammonia or sodium
hydroxide instead of the hydrazine under the same experimental conditions 160. Using
transition electron microscopy (TEM) imaging the resulting complexes, for which the
authors did not provide formulation data, were found to form non-nanotubular
structures.
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The {Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes were tested for their activity against
human cervical cancer HeLa cells (FR+ve), human lung adenocarcinoma cancer A549
cells (FR-ve) and normal human embryonic lung fibroblasts HELF cells (FR-ve). The
results showed that the {Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes exhibited
comparable cytotoxicity to cisplatin and that they are selective for the FR+ve HeLa
cells ( IC50 = 0.586 µg/ml, 0.855 µg/ml and 10.139 µg/ml for the HeLa, A549 and
HELF cell lines, respectively). The {Co2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes
were also tested for their cytotoxicity and they were found to be even more selective
for the FR+ve over FR-ve cells (IC50 = 0.1.47 µg/ml, 5.43 µg/ml and 20.32 µg/ml for
the HeLa, A549 and normal human liver L-O2 cell lines, respectively). Further interest
is derived in this class of material in that the inner tubes of the
{M2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes can easily be loaded with clinical drugs
such as cisplatin or doxorubicin to yield dual action therapeutics. Cellular uptake
studies demonstrated that the drug loaded nanotubes, which are stable at physiological
pH, enter cells through an FR mediated endocytic mechanism and that they are broken
down to release the active components in the acidic environment inside the cell. The
fundamental

pharmacokinetic

profiles

and

biodistribution

of

the

{Co2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes in mice are also reported along with its
very promising in-vivo antitumour activity159.

I.4.2

Folate-metal complex conjugates as targeted therapeutic agents

As well as functioning as a ligand, folic acid can be conjugated to small or large
biologically active metal complexes through direct folate coupling or folate coupling
via a linker. The inclusion of a linker allows for effective unhindered binding of the
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folate moiety to the FR and control over the lipophilicity of the folate conjugate,
which are requirements for cellular internalization of the entire molecule through
endocytosis (Figure 4). Furthermore, cleavable linkers, such as those containing
disulphide bonds, can facilitate the release of the active payload from the folate carrier
once the folate-metal complex conjugate encounters the acidic environment of the
endosome163. Generally, unless otherwise stated, the synthesis of the compounds
involves the following methods for conjugate formation:

(i) the formation of an amide bond involving the reaction of a carboxylic acid group
(α and/or γ) of the glutamate moiety of the folic acid with an amine (-NH2)
functionality on the linker (generally an alkyl diamine molecule, PEG derivative or
amino acid) which in turn can be bound to the coordination complex via a second
amide bond (Figure 11); (ii) direct conjugation of folic acid to the active metal
complex via an amide bond. Alternative strategies involve encapsulation of active
metal complexes within folate-conjugated carriers.

Figure 11: Structural design of a folate-metal complex conjugate comprising the folate
targeted moiety, the optional linker and the amide bond formation to the active metal
complex.
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I.4.3

Platinum-based systems

As mentioned previously, platinum-based drugs play a key role in treatment regimens
of a range of cancers, but their applicability and efficacy are plagued by limitations
regarding drug resistance and adverse toxic side effects. The selective delivery of such
drugs via targeted strategies has recently been an area of intense research 164–166. Table
2 summarises the structural and biological profiles of the known platinum-folate
conjugate systems.

35

Table 2. The structural and biological profiles for FR targeted platinum anticancer conjugates.

Conjugate type

Linker

Folate-cisplatin
Folate-carboplatin

Aliphatic diamine
Aliphatic amine

Folate-PEGcarboplatin

polyethylene
glycol

Cisplatin-folate-PEGg-PAsp-Ami micelles

PEG-graft-α,βpoly((N-aminoacidyl)aspartmide]

Carboplatin-folateliposome

None

FR Targeted Platinum-Based Anticancer Conjugates
Active
Cellular uptake studies
In vitro activity
component
Cisplatin
Not reported
Not reported
Carboplatin
Reduced cytotoxicity
in FR+ve M109HiFR
Confirmed by confocal
Carboplatin
cell line in
microscopy and FACS
comparison to nontargeted analogue
Superior cytotoxicity
compared to
Confirmed by cytotoxicity
nontargeted
Cisplatin
assays in presence of excess
Cisplatin-PEG-gfolic acid
PAsp-Ami micelles
in FR+ve
KB cell line.
Confirmed using IGROV-1
2-fold increase in
cells (2-fold increase in
cytotoxicity in
Carboplatin
cellular
IGROV-1 cells
Accumulation compared to
compared to
carboplatin)
carboplatin
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In vivo activity

Refs

Not reported

167

Not reported

168

Athymic mice: similar results
to in vitro study with low
toxicity.

169

IGROV-1 ovarian tumour
xenograft mice: Low toxicity
and increased survival rate
(83%) compared to
carboplatin

170

The systematic preparations of folate conjugates of cisplatin and carboplatin were
recently reported167. The multi-step synthesis involved the direct attachment of
diamine and dicarboxylate functionalities to the glutamate moiety of folic acid
followed by reaction with the respective platinum(II) salts to yield five different
derivatives (Figure 12). Although this approach yielded desirable structures, the folatecomplex conjugates were not studied for their cytotoxicity or FR uptake capabilities
due to their poor solubility.

Figure 12: The general synthetic scheme of folate-conjugates of cisplatin-like and
carboplatin-like complexes167.

To enhance the therapeutic potential of platinum anticancer drugs, conjugation to large
polymeric carrier molecules such as polyethylene glycols (PEGs) which are known to
increase their solubilities in water have been utilised165. Although this approach can
significantly improve pharmacokinetics and tissue distribution of the drug, cell
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permeability can remain a problem due to the relatively high molecular weights of
such conjugates171. This presents a particular problem, as if platinum complexes are
released in the extracellular medium, they can act as nonspecific electrophiles,
resulting in their rapid inactivation by extracellular nucleophiles.

To overcome this issue, Aronov et al synthesised a FA-PEG-Carboplatin conjugate
(Figure 13) and studied its cellular uptake, cytotoxicity and rate of DNA platination 172.
The group also synthesized the fluorescent analogue FA-PEG-FITC (FITC =
fluorescein isothiocyanate) to enable them to explore the effects of the conjugation on
the cellular uptake of the PEG system using confocal microscopy and fluorescenceassisted cell sorting (FACS). The reported synthesis of the FA-PEG-Carboplatin is an
arduous six step procedure requiring significant purification and characterization.
Indeed, the authors claim this to be the first complete chemical characterization of PtPEG conjugates, a feat involving 1H NMR, 195Pt NMR, and 2D-[1H, 15N] heteronuclear
single quantum correlation (HSQC) spectroscopy.

Figure 13: The structure of the FA-PEG-Carboplatin conjugate172.

Using a folate receptor-enriched murine lung carcinoma cell line, M109HiFR, Aronov
et al conducted drug uptake and cytotoxicity studies as well as the determination of
Pt-adduct formation. Results showed that the folate-targeted FA-PEG-Carboplatin
conjugate was less cytotoxic than both its untargeted PEG-Carboplatin counterpart and
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the free drug carboplatin, despite exhibiting increased drug uptake via endocytosis. It
was found that the untargeted PEG-Carboplatin conjugate resulted in higher levels of
DNA platination than the folate-targeted FA-PEG-Carboplatin conjugate, thus
accounting for its low cytotoxicity. It was suggested that this unexpected phenomenon
may be due to the folate receptor-mediated endocytic pathway, in which folateconjugates are not released into the cytosol but rather are directed to acidic lysosomes
or endosomes, thereby restricting access to the nucleus. The findings suggest that the
folate-targeted conjugate FA-PEG-Carboplatin may be unsuitable as a prodrug for the
carboplatin family, as the conjugate appears to be neutralized or blocked during the
folate receptor-mediated endocytosis process, resulting in entrapment of the prodrug
in certain cellular compartments.

In an attempt to reduce toxic side effects while enhancing its antitumor activity the
incorporation of cisplatin into a polymeric folate conjugate with PEG-graft-α,βpoly[(N-amino acidyl)-aspartamide] (Cisplatin-FA-PEG-g-PAsp-Ami) has also been
studied recently (Figure 14)169. The targeted polymer-metal complex micelles were
prepared by reacting cisplatin with FA-PEG-g-PAsp-Ami in distilled water for 24
hours at 37 oC, followed by purification by dialysis and characterization by
measurement of critical aggregation concentration, particle size and morphological
observations. Cytotoxicity was determined in the oral cancer KB cell line (FR+ve), by
treating the cells with the folate targeted Cisplatin-FA-PEG-g-PAsp-Ami and
untargeted Cisplatin-PEG-g-PAsp-Ami complexes in folate deficient media for 24 h.
The results showed that the folate-targeted complex was more cytotoxic (50% cell
viability at 100 µg/ml concentration) than the non-targeted system (> 60% cell
viability at 100 µg/ml concentration), due to folate receptor mediated endocytic uptake
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of the compound. Additional inhibition assays involving excess folic acid supported
the role of FR targeting for the Cisplatin-FA-PEG-g-PAsp-Ami (70% cell viability at
100 µg/ml concentration in the presence of 1 mg/ml of added folic acid). In vivo testing
in male athymic mice exhibited similar results, indicating that Cisplatin-FA-PEG-gPAsp-Ami micelles were well-tolerated by the mice.

Figure 14: The proposed structure of a single unit of the folate conjugate CisplatinFA-PEG-g-PAsp-Ami polymer169.

In 2012, Chaudhury et al reported the intraperitoneal (IP) administration of a
carboplatin folate receptor-targeted (FRT) liposomal system to increase the therapeutic
efficacy and reducing toxicity of carboplatin for the purpose of IP treatment of ovarian
cancer170. The authors discussed the limitations of IP administration of chemotherapy
and the advantages of a drug delivery system such as an FR targeted liposomal system,
which could deliver a drug payload into FR+ve ovarian cancer cells. Initial
fluorescence studies on the ovarian adenocarcinoma cell line, IGROV-1, before
injection showed a twofold increase in cellular accumulation of the folate-targeted
platinum compared to the non-targeted carboplatin. Cytotoxicity studies showed that
13 µM of folate-targeted carboplatin could induce cell death in 50% of IGROV-1 cells
in vitro, while both the free drug and non-targeted conjugate required 24 - 45 µM,
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respectively. In vivo studies, involving an intraperitoneally grown human IGROV-1
ovarian tumour xenograft mouse model, identified that five out of six FR targeted
carboplatin liposome treated mice (83%) survived to the end of the study. In contrast,
groups treated with either the non-targeted carboplatin-liposome, carboplatin or saline
control all died within 19-39 days post-tumour inoculation. Of the 83% mice that
survived treatment, none showed weight-loss or metastasis. The authors concluded
that intraperitoneal (IP) administration of folate-targeted carboplatin liposomes has the
potential to extend the overall survival of ovarian cancer patients as well as
maintaining therapeutic efficacy with reduced risk of regimen-related toxicities.

I.4.4

Non-Platinum Systems

The anticancer properties of gallium(III) compounds have been attracting attention
since the 1970’s. The mechanism through which Ga(III) induces cell death (DNA
binding/modification, enzyme inhibition and ion transport disruption) has been
extensively investigated. However, the pharmokinetic properties, including renal
retention time and cancer cell targeting of gallium salts, prevent their widespread
chemotherapeutic use. To explore the cancer cell targeting abilities of gallium(III)
complexes, Viola-Villegas et al studied the conjugation of gallium(III) complexes of
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), via a polyethylene
glycol (PEG) linker, to the γ carboxylic acid moiety of folic acid (Figure 15 (A))173.
The authors determined the IC50 concentrations for the gallium(III) containing
compounds in both A2780/AD (FR+ve Adriamycin resistant ovarian cancer cell line)
and CHO cells (FR-ve Chinese Hamster Ovary cell line), with the IC50 being lower in
the A2780/AD cells in all cases.
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These studies revealed two interesting results; (i) the metal free conjugate and its
gallium complex were both toxic towards the FR-ve CHO cells and (ii) the metal-free
γ-FA-PEG-HDOTA showed greater cytotoxicity (IC50 = 1.35 and 0.18 mM for the
CHO and A2780/AD cell lines, respectively) than its coordinated counterpart, γ-FAPEG-Ga(HDOTA) ((IC50 = 2.93 and 1.85 mM for the CHO and A2780/AD cell lines,
respectively). Researchers concluded that gallium was ‘leaking’ from the Ga-DOTA
moiety, allowing the ligand to chelate other metals in the cellular environment.
Additional stability studies carried out in HEPES buffer and RPMI 1640 media over
72 hours coupled with HPLC and ICP techniques supported this theory. Unfortunately,
as the non-complexed γ -FA-PEG-(HDOTA) showed greater cytotoxicity than its
gallium-containing counterpart, the folate conjugate γ-FA-PEG-Ga(HDOTA) was
considered to be unsuitable as an anti-cancer agent.
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Figure 15: (A) The proposed structure of gallium(III) complexes coordinated via
DOTA and a polyethylene glycol linker to the γ carboxylic acid moiety of folic acid,
γ-FA-PEG-Ga(HDOTA) synthesized by Viola-Villegas, Vortherms and Doyle173. (FA
= Folic acid, PEG = Polyethylene glycol, DOTA = 1,4,7,10-tetraazacyclododecane1,4,7,10-tetraacetic acid) [193] (B) Proposed structure of the water-soluble folate
conjugate of zinc tetraaminophthalocyanine (ZnaPc-folate) or ZnTAPcFA174.

The water-soluble folate conjugate of zinc tetraaminophthalocyanine (ZnaPc-folate)
was recently reported (Figure 15 (B))174,175. The study of the photophysical and
photochemical properties of ZnaPc-folate revealed that an increase in the fluorescence
quantum yield of the conjugate was accompanied by a decrease in the triplet and
singlet oxygen quantum yields, a decrease that was not observed when ZnaPc was
simply mixed with folic acid (in the absence of formal conjugation) 174. Confocal laser
scanning microscopy (CLSM) was employed to determine that ZnaPc-folate was
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significantly internalised in the FR+ve KB cell line when compared to the FR-ve A549
cells. Results from competitive binding studies using folic acid suggested a FRME
cellular uptake mechanism175. Whereas ZnaPc-folate was found to be effectively
inactive against KB cells in the absence of any photo-irradiation, irradiation with twophoton excitation (TPE) of near-infrared (NIR) laser pulses caused a 10-fold decrease
in cell viability when compared to the results for sulphonated aluminium phthalocyanine (AlPcS), an approved photosensitizer for clinical applications under common
one-photon excitation of red light175. The authors suggest that ZnaPc-folate represents
a promising new generation of photosentizers for TPE-based photo-dynamic therapy
(PDT).

In 2015, Gou and colleagues explored the use of a folate-functionalised human serum
albumin (FA-HSA) carrier system as an FR targeted delivery system for copper(II)
complexes incorporating plumbagin, bipyridine and 1,10-phenanthroline ligands
(Figure 16)176. Plumbagin is a natural small molecular naphthoquinone analogue
isolated from the medicinal plant Plumbago zeylanica and which exhibits moderate
anticancer activities in vitro and in vivo177–179.
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Figure 16: Structures of various Cu(II) plumbagin polypyridyl complexes investigated
by Gou et al176. Adapted from Gou et al176.

To determine the biological action of the FA-HSA-Cu complex systems, the copper(II)
complexes were incubated with the FA-HSA conjugate in PBS and DMSO (0.5%) for
24 hours at room temperature. After incubation, FR+ve cell lines HeLa and MCF-7
and FR-ve cell line WI-38 were treated with the FA-HSA-Cu complex systems for 48
hours. It was found that the Cu(II) complexes themselves were equally cytotoxic
towards the FR+ve and FR-ve cells lines (IC50 range = 3-8 µM), however the FAHSA-copper complex systems were approximately three times more active against the
FR+ve cells (IC50 range = 0.98-3.67 µM) than the FR -ve cell line (IC50 range = 3.956.95) µM. The FA-HSA-copper complex system incorporating the [Cu(PLN)(phen)]+
(where PLN = the plumbagin anion, (Figure 16 (3)) was the most cytotoxic and further
studies revealed that it caused mitochondrial damage through production of reactive
oxygen species (ROS) in HeLa cells and inhibited the activity of cyclin-dependent
kinase-1 (CDK1) and the prosurvival Bcl-2 proteins, resulting in apoptotic cell death.
The targeted therapeutic properties of the relatively few non-platinum folate-metal
complex conjugates discussed have been summarized in Table 3.
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Table 3. The structural and biological profiles for FR targeted non-platinum anticancer conjugates.

Conjugate type

γ-Folate-PEGGa(HDOTA)

Folate-HSA[Cu(PLN)(phen)]+

ZnaPc-Folate

FR Targeted Non-Platinum Anticancer Conjugates
Active
Cellular uptake
Linker
In vitro activity
component
studies
γ-Folate-PEG-Ga(HDOTA)
is 2-fold
polyethylene
and 10-fold less cytotoxic
Ga(HDOTA)
Not reported
glycol
than metal-free γ- FolatePEG-(HDOTA) in FR+ve
A2780/Ad and FR-ve CHO.
Folate-HSA[Cu(PLN)(phen)]+
approximately 3 times more
+
HSA
[Cu(PLN)(phen)]
Not reported
active against the FR+ve
Hela and MCF7 cells than the FR-ve WI-38
cell line.
FRME Confirmed by
confocal laser
10-fold decrease in cell
scanning
viability compared to results
microscopy in
for sulphonated aluminium
ZnaPc-Folate
competitive
phthalocyanine (AlPcS), an
None
upon photobinding studies using approved photosensitizer for
irradiation
folic acid involving
clinical applications under
FR+ve
common one-photon
KB and FR-ve A549
excitation of red light
cells
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In vivo
activity

Refs

Not
reported

173

Not
reported

176

Not
reported

174,180

I.4.5

Folate-metal complex conjugates as targeted diagnostic agents

The advent of theranostic agents, which consist of a targeted drug coupled to an
imaging agent, has been a key development in modern medicine, particularly in the
treatment of cancer. This advancement would not have materialized if it was not for
the significant successes achieved in the fields of molecular imaging and in the
expansion of the knowledge-base of the synthesis of efficient targeting compounds175.

Lanthanides, europium in particular, have luminescent properties when bound to
organic, chelating ligands181. In addition, europium offers an array of advantages such
as long emission times, enabling time-resolved measurements while narrow, intense
absorption bands ensure high colour purity. Luminescent lanthanide complexes (LLC)
such as europium complexes offer increased loading capabilities as they do not exhibit
the self-quenching properties that are often observed in organic dyes. Such complexes
often show high chemical, thermal, kinetic and photo-physical stability while
exhibiting low toxicity when compared to gadolinium complexes commonly used as
contrast agents in magnetic resonance imaging (MRI)182. Therefore, it is unsurprising
that they may prove to be highly sensitive luminescent probes in biomedical studies.

In 2012, Pavich et al synthesised a folic acid-europium chelate conjugate [FAphen)Eu(BTA)3] (FA-(phen) = Folate-spcer-1,10-phenanthroline conjugate; BTA =
benzoyl trifluoroacetone) (Figure 17)183. NH2-Phen was incorporated into the
coordination sphere to prevent quenching by the diketone BTA ligand. In addition,
examining the absorption and luminescence spectra, as well as the luminescence
excitation of the newly formed complex, the group conducted cellular uptake studies
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using the FR+ve HeLa cell line. Cellular uptake of the conjugate was determined from
the intensity of europium luminescence in the cell lysates and results indicated
significant quantities of the europium conjugate (4.10 6 conjugate molecules per cell)
were internalised. Furthermore, the addition of exogenous folic acid severely reduced
cellular uptake of the conjugate by 68%, suggesting that uptake was FR-mediated183.
These results and the observed promising luminescent timeframe of 110 μs may serve
to spearhead the design of selective methods for time-resolved luminescent
microanalysis based on conjugates of folic acid with europium complexes. However,
the characterisation of the [FA-(phen)Eu(BTA)3] was poor and no data regarding the
cytotoxicity or stability of the conjugate were reported.

Figure 17: The chemical structure of the conjugate FA-(Phen)Eu(BTA)3. (Phen =
1,10-Phenanthroline, BTA = benzoyl trifluoroacetone)183.

The gadolinium(III) complex of DOTA is currently used as an extravascular contrast
agent for MRI184. In 2015, Gros et al reported the synthesis and characterisation of a
heterobimetallic copper(II) corrole/gadolinium(III) DOTA-folate complex (Figure 18)
as a potential FR-targeted bifunctional contrast agent for MRI and positron emission
tomography (PET) imaging of cancer185. The complex was obtained in high yield via
a five-step synthetic method. Preliminary studies showed that the relaxivity of the
heterobimetallic copper(II) corrole/gadolinium(III) DOTA-folate complex was higher
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in comparison to the commercially available MRI contrast agent [Gd(DOTA)(H2O)]-.
The authors did not report any data for the toxicity, cellular uptake or FR specificity
of the complex.

Figure 18: The structure of the Cu corrole, Gd DOTA folate complex185.

In the same year, Quici and colleagues reported the results of a more thorough study
of the three water soluble europium complexes conjugated via 1,4,7,10Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the α-carboxylate, the γcarboxylate and N10 (the nitrogen of the para-aminobenzoic acid group) positions of
folic acid (denoted Eu3+C1, Eu3+C2, Eu3+C3, respectively) as luminescent probes for
the selective targeting of cancer cells (Figure 19)181. The α- and the γ-carboxylate
conjugates Eu3+C1 and Eu3+C2 were generated, as a regioisomeric mixture, separated
as pure isomers by HPLC and identified by ESI mass spectrometry. Eu 3+C3 required
a seven-step synthesis and it too was obtained in high purity.
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Stability studies on all three conjugates were conducted by incubation in phosphate
buffered saline (PBS), cell culture medium and rat serum at 37 oC for 25 hr and revealed
that varying media did not affect either conjugate luminescence or spectral shape.
Results showed that the conjugates were stable after cell exposure and internalisation,
with no apparent biotransformation and no significant interaction occurring with
serum proteins.

Cytotoxicity assays and internalisation studies conducted on a range of FR+ve ovarian
cancer cell lines indicated that all three conjugates were only cytotoxic at
concentrations above 300 μM and that internalisation was both concentration and time
dependent. Internalisation studies using the FR-ve cell line A2780 showed no
internalisation of the conjugates, suggesting that the uptake was folate receptor
mediated. Furthermore, the conjugation site was found to be a critical factor with the
binding affinity following the order Eu3+C2 > Eu3+C1 > Eu3+C3 in the SKOV-3 cell
line, highlighting the importance of the pterin head and para-aminobenzoic acid body
of folic acid in receptor recognition.
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Figure 19: The chemical structures of three Europium complexes Eu3+C1, Eu3+C2
and Eu3+C3 coordinated via DOTA to various conjugation sites of folic acid181.

In a 2014 study Plush et al examined the influence that the length of the linker between
the folate head and the lanthanide-DOTA chelate had on FR mediated uptake186. They
synthesised and characterised water-soluble folate-targeted lanthanide probes (Ln(III)
= Eu(III), Tb(III) or Gd(III)) in which the Ln(DOTA) moieties were connected to the
folate heads via an aliphatic (–CH2-)n chain (where n = 1 or 5) (Figure 20).
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Figure 20: Structures of the water-soluble folate-targeted lanthanide probes (Ln(III)
= Eu(III) or Gd(III)) in which the Ln(DOTA) moieties were connected to the folate
heads via an aliphatic (–CH2-)n chain (where n = 1 or 5)186

More recently, in 2018, Plush et al reported the multistep synthesis, photophysical and
cellular properties of four new imaging agents, folate and methotrexate labelled
luminescent lanthanide complexes Eu-FA, Eu-MTX, Tb-FA and Tb-MTX (Figure
21)187. Cellular uptake and cytotoxicity studies were performed on a panel of FR-ve
non-malignant cells, and FR+ve and FR-ve malignant cells. Fluorescence was not
observed in any of the FR-negative non-malignant cells. Furthermore, no enhanced
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fluorescence was observed in FR-ve malignant cells A549 and PC-3 following 24
hours incubation. However, the authors reported that all four Ln(III) complexes
showed strong fluorescence emission in malignant FR+ve cells following 24 h
incubation, indicating FR-mediated uptake of both MTX and folate conjugates. EuMTX and Tb-MTX conjugates were found to induce significant antineoplastic activity
in the FR+ve HeLa cell line within 48 hours. Cell death was also observed for the FAmodified complexes, Eu-FA and Tb-FA, but to a reduced degree compared with that
of MTX-modified complexes. Furthermore, Eu-MTX was found to be more cytotoxic
than free MTX in solution, suggesting that there may be a synergistic effect between
the Eu3+ ion and MTX. The authors concluded that the use of such complexes may
allow for the visualisation and monitoring of the selective accumulation of cytotoxic
agents within cancer cells which may offer significant advantages in the development
of new therapeutics187.

Figure 21: The structures of four lanthanide complexes; Eu-FA, Tb-FA, Eu-MTX and
Tb-MTX. (A) Ln-FA (B) Ln-MTX (where Ln3+ = Eu3+ or Tb3+) in which the
Ln(DOTA) moieties were connected to folic acid via a carbostyril antenna and
ethylenediamine linker158
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In addition to PET, single photon emission computed tomography (SPECT) is another
highly sensitive cancer imaging technique which has attracted significant interest in
the development of folate-based tracers to target FR expressing cancers188–190. For the
development of folate-conjugates of such nuclear imaging agents, 99mTc has emerged
as the preferred radionuclide for applications in SPECT. One of the best studied
examples of such FR-targeted technecium radionuclides is
99m

99m

Tc-EC20 in which

Tc(V) is complexed to a peptide (Cys-Asp-Dap-D-Glu-Pte) which is linked to a

folate moiety (Figure 22 (A))191. Clinical trials found that 99mTc-EC20 was an excellent
imaging agent, with very high tumour uptake192. It was also found that a single
intravenous injection of

99m

Tc-EC20 resulted in detectable uptake in 68% of patients

and was well tolerated by adult patients. Consequently, the authors suggested that
99m

Tc-EC20 imaging was a safe, non-invasive procedure that may identify FRs in

recurrent or metastatic disease without the need for biopsy192. However, due to the
presence of high FR expression in the kidneys and bladder, accumulation of

99m

Tc-

EC20 caused problems with very significant renal uptake of radioactivity. It has been
reported that this problem may be resolved to a significant extent by pre-treatment with
antifolates such as Pemetrexed, however it may result in patients experiencing further
stress193. In recent years there have been several attempts to improve the efficacy of
99m

Tc-labeled folate conjugates by modifying the nature of the linkers, the chelating

agents and the radiosynthon but the problem with high accumulation in the kidneys
has persisted due to the highly hydrophobic nature of the

99m

Tc-labeled folate

conjugates194,195.

In 2017, Banerjee et al reported the synthesis and biological evaluation of a

99m

Tc-

labeled folate conjugate with the lipophilic [99mTcN(PNP)]2+ inorganic moiety {where

54

N(PNP)=N-(2methoxyethyl)-2-(diphenylphosphino)-N-(2-diphenylphosphino)
ethyethanamine} (Figure 22 (B))196. The 99mTc-labeled folate conjugate was generated
by conjugating a cysteine-based (O-S) bifunctional chelating group to the γ-carboxylic
acid of folic acid to yield the targeted vector. This, in turn, acts as an O-S chelate upon
complexation with [99mTcN(PNP)]2+, yielding the [99mTcN(PNP)]2+-folate conjugate
(Figure 22 (B)). The conjugate was found to be significantly lipophilic (LogP o/w =
0.87). Unfortunately, in vitro studies on FR+ve KB cells revealed that this new 99mTclabeled folate conjugate exhibited a ten-fold decrease in affinity for the FR than native
folic acid. However, in vivo studies involving normal Swiss mice revealed that the
[99mTcN(PNP)]2+-folate conjugate was effectively cleared by the kidneys which is in
itself a significant development. The authors propose that the inclusion of an
appropriate aliphatic spacer in the structure of the [ 99mTcN(PNP)]2+-folate conjugate
as a possible route to improving the FR uptake of this class of potential radiotracer.
Table 4 summarises the structural and biological profiles for folate-metal complex
conjugates with targeted diagnostic potential.

Figure 22: (A) Structure of folic acid radioconjugate, 99mTc-EC20192 (B) Structure of
a new 99mTc-folic acid radiotracer prepared using [99mTcN(PNP)]2+ metal fragment197
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Table 4: The structural and biological profiles for folate-metal complex conjugates with targeted diagnostic potential.

Conjugate type

Linker

[FA(phen)Eu(BTA)3]

ethylenediamine

Europium complexes
conjugated via DOTA to αcarboxylate, the γ-carboxylate
and N10 positions of folic
acid
FA-NH–(CH2)n-NH[Ln(DOTA)]
(Ln(III) = Eu3+, Tb3+ or Gd3+;
n = 2 or 6)
Heterobimetallic Cu(II)
corrole/Gd(III) DOTA-folate
complex

Tetraazacyclodode
cane-1,4,7,10tetraacetic acid
(DOTA)
The diamine
chain
-NH–(CH2)n-NHethylenediamine

FR Targeted metal complexes as diagnostic agents
Active
Cellular uptake studies
component
Luminescence measurements in
[FA(phen)Eu(BT
FR+ve HeLa cells and competitive
A)3]
binding studies
with folic acid
Uptake in FR+ve SKOV-3 cells was
conjugation
Dependent (Eu3+C2>Eu3+C1>
Eu3+C3) with no uptake in FR-ve
A2780 cells.
Effectively internalised by
FR+ve HeLa cells with the shorter
[Ln(DOTA)]3+
linker yielding
superior uptake
[Cu(corrole)]2+
and
Not reported
[Gd(DOTA)]3+

In vitro
activity

In vivo activity

Ref

Not reported

Not reported

183

Non-toxic
below 300
µM

Not reported

181

Not reported

Not reported

186

Not reported

Not reported

198

Low
cytotoxicity

Very high tumour uptake in
a mouse model and in
clinical trials. Significant
FR mediated renal uptake.

195,199

Low toxicity

In normal Swiss
mice the conjugate was
effectively cleared from the
kidneys

197

99m

99m

Tc-EC20

[99mTcN(PNP)]2+-O-S-folate
conjugate

Tc(V) is complexed
to a
peptide (Cys-AspDap-D-Glu-Pte)
which is linked to
a folate moiety via
a diamine group
cysteine-based (OS)
chelating group to the
γ-carboxylate of
folic acid.

Extensively
studied with very
high cellular
uptake in FR-ve
cell lines in-vitro

99m

Tc-EC20

[

99m

10-fold less
affinity for FR+ve
KB-31 cells than
folic acid

2+

TcN(PNP)]
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I.5

Conclusion

As it stands, folate-targeted drug therapy is proving to be a rich vein of research into
the diagnosis and treatment of many forms of cancer. This is emphasised by the
continuous stream of literature regarding the topic published since the early 2000’s.
However, there is a dearth of published material in relation to studies conducted on
folate-targeted metal-based therapies over the same time frame. From the data
available, it is apparent that the subject area is in its infancy and has the potential to
contribute greatly to cancer research, both in therapeutics and diagnostics.

Folic acid is an interesting ligand for metal complex formation, but its coordination
chemistry is not well developed. Incorporating simple folate ligands into biologically
active metal complex systems may offer a simple strategy for improving their selective
uptake in FR+ve cells. This remains an avenue yet to be exploited with the issue of
metal complex solubility presenting a significant challenge, as encountered in the work
reported thus far.

The success of the platinum drugs in treating a range of cancers is compromised by
issues relating to toxic side effects, drug resistance and the lack of tumour selectivity.
Promising recent results show that incorporation of drugs such as cisplatin and
carboplatin into folate- or folate-carrier- systems has the potential to overcome these
problems to some extent by improving their delivery and/or selectivity. Very few nonplatinum metal complex conjugates with folic acid have been reported in the literature,
and most of the studies conducted to date lack substantial in vitro and/or in vivo data.
Notwithstanding this, it is an avenue that offers significant potential to develop

57

targeted therapeutic approaches in areas such as chemotherapy and molecular imaging
for diagnostics.

If this approach is to be fully exploited there are experimental challenges to overcome.
The synthesis, purification and characterisation of metal complex-folate (and/or folatecarrier-) conjugates are quite often difficult, presenting problems in relation to
biomedical applications. Furthermore, the expression levels of the folate receptor in
different cell types has been a topic of significant interest with data in the literature
being somewhat confusing and conflicting, and a situation that requires caution when
assaying the selectivity of potentially active compounds. Notwithstanding these
challenges, where over-expression of the folate receptor is well documented and a key
cellular feature of diseases such as cancer, inflammation, tuberculosis and parasitic
infection, the coupling of the biologically active inorganic complexes with folate
receptor targeted capability is a highly desirable goal, offering the opportunity to avoid
unwanted side-effects during diagnosis and treatment.
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PROJECT RATIONALE
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R.1

The rationale for the current project

1,10-phenanthroline (phen) (Figure 23) is a heterocyclic organic compound which is
known to form stable biologically active complexes with a range of metals200. Indeed,
so called ‘metal-free’ phen has been characterised as exhibiting a range of biological
capabilities in its own right. However, it is believed that phen sequesters trace metals
with the resulting metal complexes believed to be the actual biologically active
species. Ostensibly, the activity of phen-based complexes can be significantly
modulated by modifying the structure of phen by either extending its backbone at the
-5,6- position or by the substitution of the aromatic protons by suitable substituents
(Figure 22)200. Metal-phen complexes exhibit significant potential as broad-spectrum
agents capable of eliciting cytotoxicity towards diseases and infections manifested by
cancer201–205, bacteria206–208, tuberculosis209 fungi210,211 and viruses200.

Figure 23: Structure of 1,10-phenanthroline (phen) with numbering for substituents
and examples of modified phen structures.
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Our group has previously found that copper(II), manganese(II) and silver(I) complexes
of 1,10-phenanthroline incorporating dicarboxylate ligands are of particular interest as
they have been found to exhibit excellent in-vitro anticancer activity (some examples
of these complexes are shown in Figure 24)201–204,212. Although the mechanism of
action of this class of complex is not yet fully understood, it is known that the type of
metal present and the choice of dicarboxylate ligands has a profound effect on their
structure, physico-chemical and biological properties. To date all of the complexes
examined have been found to be promiscuous, exerting their cytotoxic effects nonselectively, causing damage to healthy as well as malignant cells. The goal now is to
attempt to modify these complexes with a view to increasing their chemotherapeutic
potential via greater selectivity for cancer cells.
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Figure 24: The structure of some of the copper (A)201–203, manganese (B)203 and silver (C)213 phen-based dicarboxylate complexes
previously studied.
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R.2

Aims and objectives of the current project

The aims of the current project were:
(i)

To generate metal phenanthroline complexes with folate targeting moieties
(where M = Cu2+, Mn2+, Fe3+, Zn2+ and Ag1+)

(ii)

To assess the FR-targeting capabilities and biological activity of selected
novel metal-phenanthroline-folate complexes against FR+ve and FR-ve
cell lines.

To achieve these aims the main objectives of the project were:

(i)

To complete a comprehensive review of the literature to determine
what is known about (a) the coordination chemistry of folic acid and
the biological properties of metal-folate complexes and (b) the
synthesis and biological profiles of metal complexes containing folate
conjugated ligands.

(ii)

To exploit folic acid (through its glutamate moiety) as a potential
dicarboxylate ligand in the synthesis of novel metal-folatephenanthroline complexes.

(iii)

To develop a method for the synthesis of folate-phen conjugates and
their coordination to transition metals.

(iv)

To assess the cytotoxic activity of relevant complexes in FR+ve and
FR-ve cell lines

(v)

To elucidate, where possible, aspects of the mechanism of action of the
active compounds in cellular systems.
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RESULTS &
DISCUSSION
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D.1

Novel metal complexes containing folate and 1,10-phenanthroline

ligands

As discussed in the introduction the coordination chemistry of folic acid has not been
explored extensively to date, with just a small number of papers reporting its
complexation to metals147,148,176,150,155,161,162,169,170,172,173 (Table 1). These reports in the
literature describe the folate predominantly acting as a classical dicarboxylate ligand
when reacted to form simple metal complexes. In such complexes the glutamate group
of the folate is generally reported to doubly deprotonate and can form mononuclear,
binuclear or polymeric complexes. Our group has previously reported extensively on
the cytotoxic profiles of mono- or bi-nuclear and polymeric copper(II), manganese(II)
and silver(I) complexes containing simple aromatic or aliphatic dicarboxylates that act
as bridges between M2+(phen)n moieties (M = Cu or Mn; n = 1 or 2) (Figure 24). At
the outset of this project a key objective was to employ the simple folate as a
dicarboxylate ligand and attempt to generate bis-phenanthroline metal complexes
similar to those previously studied. This section describes the attempts to synthesise
simple metal-folate and metal-folate-phen complexes (where M = Cu2+, Mn2+, Zn2+,
Fe3+ and Ag+; and phen = 1,10-phenanthroline).

D.1.1 Synthesis of simple metal-folate complexes

Abd El Wahed et al had previously described the facile synthesis of metal folate
complexes with the general formula M2(folate).nH2O (where M = Mn2+, Co2+, Ni2+,
Cu2+, Zn2+, Cd2+ and Hg2+ ; L = folate; n = 1-3,5 or 15)147. The complexes were
generated by the reaction of sodium folate with the respective metal chlorides. The

65

complexes were characterised as binuclear containing the folate anion as a
dicarboxylate ligand, with the metal centres coordinated to the α and/or γ carboxylate
groups of the glutamic acid moiety in a chelating mode (Figure 5).

Following this approach, the mononuclear Cu2+, Mn2+, Fe3+ and Zn2+ complexes 1 - 4
were generated in good yield by neutralising a methanolic suspension of folic acid with
sodium hydroxide followed by addition of the respective metal chloride (Scheme 2).
Complexes 1 - 4 were isolated as brown, yellow, red-brown and yellow powders,
respectively, and they were formulated as mononuclear complexes as shown in Table
5. The synthesis of the yellow binuclear complex [Ag2(folate)] had also been reported
as far back as 1947 involving the reaction of an aqueous solution of folic acid with
silver nitrate161. However, all attempts to generate a silver(I)-folate complex were
unsuccessful in the current study.

Furthermore, extensive attempts to generate the binuclear complexes reported by Abd
El Wahed et al were unsuccessful. These attempts included:
(i)

Increasing the pH of the reaction to enhance the deprotonation of the
carboxylate groups (from pH 7 to pH 9).

(ii)

Varying the solvent (water, ethanol, methanol, etc.) in an attempt to
improve solubility.

(iii)

Altering the ratio of metal chloride and folic acid in the reaction (from
1:1 up to 4:1).

(iv)

Omitting the final neutralisation step described by Abd El Wahed et al.
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It is noteworthy that other authors have reported mononuclear complexes generated
from reactions employing similar methods151. These complexes were characterised as
containing folate with the glutamate acting as a bidentate chelate, and the general
formula ML2.nH2O, where M = Cu2+ or Fe2+; L = folate; n = 2 or 3, respectively (Figure
7).

Scheme 2: Synthetic route for complexes 1 – 4

Table 5: Analytical data for simple metal-folates 1 - 4
Mw

Yield

(g/mol)

(%)

573.98

68

Found (Calc) %

Complex

[Cu(fol)(H2O)3].H2O (1)

[Mn(fol)(H2O)3].3H2O (2)

[Fe(fol)(H2O)2(Cl)].4H2O (3)

[Zn(fol)(H2O)3].3H2O (4)

601.40

637.76

611.85

C

H

N

M

39.65

3.80

17.42

11.29

(39.76)

(4.21)

(17.38)

(11.07)

37.85

4.20

16.30

9.37

(37.95)

(4.69)

(16.08)

(9.13)

35.99

4.42

15.45

9.05

(35.78)

(4.43)

(15.37)

(8.76)

38.10

4.99

16.42

9.74

(37.70)

(4.61)

(16.02)

(10.69)

68

71

62
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Due to the poor solubility of complexes 1 – 4, their UV-visible spectra were recorded
in the solid state. Samples were mounted on a quartz slide inside an integrating sphere
(IS) and measured using diffuse transmission. The spectra of folic acid and complexes
1 – 4 are shown in Appendix 1, 4 and 5. The UV–visible spectrum of folic acid exhibits
absorbance bands at 220, 290, and 380 nm which may be assigned to (π→π*), (π→π*),
and (n→π*) transitions respectively147,214. The absorption spectra of complexes 1 – 4
exhibit similar features with two broad peaks between 282 – 290 and 383 -394 nm,
respectively.

The TGA thermograms of folic acid and complexes 1 – 4 were studied to 800 oC. The
TG curve of folic acid showed that the organic ligand melts at 220 oC with
simultaneous decomposition (Figure 25)147,151. The complexes 1 - 4 all showed thermal
decomposition over three stages, corresponding to the loss of the uncoordinated and
coordinated water and the loss/decomposition of the folate ligand, respectively.

Figure 25: The thermogravimetric analysis (TGA) of folic acid and complexes 1 – 4.
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Magnetic measurements were performed using the Gouy method. The calculated
magnetic moment (µeff) values of complexes 1 and 2 {1.78 and 6.11 B.M.,
respectively} are typical for high spin divalent complexes . Complex 3 has a µeff value
of 2.71 which suggests a low spin Fe 3+ complex215. Furthermore, these values are all
indicative of complexes that contain metal centres that are magnetically
independent216. [Zn(fol)(H2O)3].3H2O (4), a diamagnetic complex, experiences
repulsion for the applied magnetic field, appearing to lose mass (resulting in a negative
value). Therefore, complex 4 does not exhibit a magnetic moment.

The IR spectra for folic acid and complexes 1 – 4 are shown in Figure 26 and Appendix
4 and 5 respectively. Complexes 1 – 4 all have very similar spectra which reflect
similar structural characteristics for this series of complexes. The IR spectrum of folic
acid exhibits a distinct absorption band at 1695 cm−1 due to the stretching vibration of
ν(C=O) of the carboxyl group (Figure 26). The coordination of carboxylate groups to
the metal centres is supported by IR spectral evidence for all three complexes with the
appearance of a νasym (OCO) band {1607 - 1602 cm-1} and νsym (OCO) band {1410 –
1401 cm-1} in their spectra (Table 6). The ΔOCO values for all the complexes (190 –
203 cm-1) are indicative of carboxylate groups bound to the metal centre in a unidentate
coordination mode217. Complexes 1 – 4 were found to have very limited solubility in
water and common organic solvents which prevented conductivity studies and full 1H
and 13C NMR spectral analysis.
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Figure 26: IR spectrum of folic acid.

Table 6: Characteristic carboxylate bands in the IR spectra of complexes 1 – 4
Band Assignment
Complex
COO (assym)

COO (sym)

Δ OCO

[Cu(fol)(H2O)3].H2O (1)

1606

1414

192

[Mn(fol)(H2O)3].3H2O (2)

1607

1407

200

[Fe(fol)(H2O)2(Cl)].4H2O (3)

1604

1401

203

[Zn(fol)(H2O)3].3H2O (4)

1601

1398

203

However, identification of the donor atoms involved in the simple metal folate
complexes 1 – 4 can be explored using a

13

C NMR technique. It is known that

coordination of paramagnetic cations to donor atoms in a ligand results in the
significant decrease or disappearance of

13

C NMR signals related to neighbouring

carbon atoms218. Thus, the interaction of folate with small volumes of CuCl2 solution
(Cu2+:folic acid = 1:100) was investigated, with the decrease/loss of (i) both the α and
γ carboxylate carbon signals (C1 and C2; Figure 27); (ii) C15 of the glutamate tail, and
loss of the signal for the carbonyl carbon atom neighbouring the amide nitrogen on the
glutamate moiety (C3) (Figure 27). These findings, in conjunction with the IR data,
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support the presence of a tridentate ONO {α-COO-, γ-COO-, and Namide} binding mode
for the folate ligand in this series of metal complexes.

Furthermore, it was also found that the

13

C NMR signals from the pteridine ring

decreased or disappeared when the Cu2+ was added to the folic acid (Figure 27 (C)). It
is not believed that this part of the folate molecule is involved in the binding to the
metal. Similar results were reported by Nagaj et al153 for the neutral copper(II)
complex [Cu(MTX)(H2O)] (MTX2- = the doubly deprotonated antifolate agent
methotrexate, an analogue of the folate di-anion) (Figure 8 (B)). Stacking interactions
involving the self-association of heterocyclic aromatic compounds such as purines and
pyrimidines, structurally related to folates, has been observed219–221. It was also
previously reported by Poe et al that the stacking of folates at neutral pH resulted in
the formation of a dimer consisting of two molecules in a “stretched out”
configuration. Consequently, both pteridine and p-aminobenzoic acid rings may
participate in stacking interactions in a head-to-tail arrangement222 (Figure 28). A
similar ‘dimerisation’ process may also be occurring in the present study and may
explain the decrease/disappearance of 13C NMR signals corresponding to the pteridine
moiety.
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Figure 27: A) Folic acid with numbered carbon atoms B) 13C NMR of folic acid in
D2O and C) CuCl2.2H2O and folic acid (1:100) in D2O
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Figure 28: The proposed folic acid dimer, showing the head-to-tail configuration, as
described by Poe et al222.

Proposed structures consistent with the physico-chemical data for complexes 1 – 4 are
shown in Figure 29. These proposed structures are similar to the structure of the neutral
copper(II) complex [Cu(MTX)(H2O)] which was reported by Nagaj et al153. On the
basis of similar 13C NMR and IR spectral evidence the authors also proposed that the
MTX2- bound to the copper(II) centre as a tridentate ligand via the α and γ carboxylate
and the amide nitrogen functionalities was also involved (Figure 8 (B)).

The involvement of the amide nitrogen in the coordination chemistry of the folate
ligand has also been reported in the case of the 2:1 anionic folate-uranium(IV) complex
salt [UO2(folate)2](EV)2 (where EV+ = the cation of the basic triphenylmethane dye
ethyl violet). In [UO2(folate)2]2- the folates are coordinated to the uranium atom in the
UO22+ moiety as chelates via the nitrogen atom of the imido-group of the aminocarboxyl and the oxygen atom of the α-carbonyl to form stable five-membered chelate
rings (Figure 8 (C)).
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Figure 29: Proposed structures for complexes 1 – 4

74

D.1.2

Reaction of simple metal-folate complexes 1 - 4 with 1,10-

phenanthroline

D.1.2.1

Reactions of complexes 1 – 4 with 1,10-phenanthroline (phen)

Attempts were made to react complexes 1 - 4 with the chelating ligand 1,10phenanthroline (phen) in an effort to generate the respective mononuclear bis-phen
complexes (intended structure is shown in Figure 30). [Cu(fol)(H2O)3].H2O (1) was
reacted with two equivalents of phen to yield complex 5 (Scheme 3). Complex 5 was
isolated in high yield, as a lime-green powder, was partially soluble in warm DMSO
only, and it was formulated as [Cu(fol)(phen)(H2O)].3H2O (5) (Table 7). All attempts
to generate bis-phen derivatives of complex 1 were unsuccessful (regardless of the
amount of phen used (up to 4 equivalents) in the reactions, reaction times or changes
in other conditions). This fact supports the postulation that the folate is acting as an
ONO tridentate ligand in complexes 1- 4, which precludes the coordination of more
than one phenanthroline moiety to the copper centre. Furthermore, regardless of
reaction conditions (time, solvent or the use of excess phen) exhaustive attempts to
react phen with either [Mn(fol)(H2O)3].3H2O (2), [Fe(fol)(H2O)2(Cl)].4H2O (3), or
[Zn(fol)(H2O)3].3H2O (4) yielded only unreacted complexes and metal-free phen.

Scheme 3: Synthetic routes for complex 5
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Figure 30: Intended structure for metal-folate-(bis-phen) complexes

Table 7: Analytical data for complexes 5 - 8
Mw

Yield

(g/mol)

(%)

754.19

68

Found (Calc) %

Complex

[Cu(fol)(phen)(H2O)].3H2O (5)

[Mn(fol)(phen)(H2O)].4H2O (6)

[Fe(fol)(phen)(Cl)].5H2O (7)

[Zn(fol)(phen)(H2O)].4H2O (8)

D.1.2.2

763.59

799.95

774.04

C

H

N

M

49.45

3.78

17.70

8.43

(49.37)

(4.28)

(16.71)

(7.35)

48.49

3.65

16.51

8.15

(48.76)

(3.92)

(16.66)

(7.19)

46.42

4.31

16.73

7.15

(46.54)

(4.28)

(15.76)

(6.98)

48.38

3.97

16.59

7.45

(48.10)

(4.43)

(16.29)

(8.45)

98

44
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Reaction of metal bis-phenanthroline complexes with sodium folate

In an attempt to generate binuclear folate complexes containing bridged bis-phen
moieties (Mn+(phen)x) reactions of the chloride salts of [Cu(phen)2]2+, [Mn(phen)2]2+,
[Fe(phen)3]3+, and [Zn(phen)]2+ with di-sodium folate were explored. The
[M(phen)x]n+ chlorides were synthesised by reacting the metal chloride with two
equivalents of 1,10 phenanthroline. The cations [Cu(phen)2]2+ and [Mn(phen)2]2+ were
obtained as bis-phen derivatives, as previously reported223–225. [Zn(phen)]2+ was
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obtained as a mono-phenanthroline analogue, as previously reported226. Although no
tris(phen)iron(III) trichloro complex can be found in the literature, similar Fe(III) tris
phen complexes with alternative counterions such as NO 3 have been synthesised and
characterised227.

Reaction of two equivalents of [Cu(phen)2]2+ with di-sodium folate did not yield the
expected dinuclear bis-phen derivative but rather the mono-phen complex
[Cu(fol)(phen)(H2O)].3H2O (5) was recovered in good yield (Scheme 4). Under
similar conditions [Mn(phen)2]2+, [Fe(phen)2]3+ , and [Zn(phen)2]2+ all reacted with disodium folate to give analogous complexes, obtained as yellow, red and yellow
powders, respectively. Complexes 5 – 8 were all partially soluble in warm DMSO and
DMF and formulated as shown in Table 6. As observed with complexes 5, only one
phenanthroline per metal centre was successfully incorporated into complexes 6 - 8.

Scheme 4: Synthetic routes to complexes 5 – 8 involving the reaction of the respective
[M(phen)x]n+ chlorides (x = 1 or 2; n = 1 or 2) with di-sodium folate
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Due to the poor solubility of complexes 5 – 8, their UV-visible spectra were also
recorded in the solid state, and their spectra, along with those of folic acid and 1,10phenanthroline are shown in Appendix 6 - 7. The UV-Vis spectra of complexes 5 – 8
are similar to those of complexes 1 – 4, with a new peak observed at 265 nm, indicating
the presence of the 1,10-phenanthroline ligand.

The IR spectra for folic acid and complexes 5 – 8 are shown in Figure 26 and Appendix
6 – 7, respectively. Complexes 5 – 8 all have very similar spectra which reflect similar
structural characteristics for this series of complexes. When compared to the spectra
of complexes 1 – 4 (Appendix 4 - 5), the IR spectra of 5 – 8 are more complex and
contain new absorption bands in the region of 840 – 844 cm-1 and 724 – 729 cm-1
which are characteristic of the presence of the phen ligand in the complexes 228. The IR
spectrum of folic acid exhibits a distinct absorption band at 1695 cm −1 due to the
stretching vibration of ν(C=O) of the carboxyl group (Figure 26). This ν(C=O) band
disappears in the IR spectra of the four complexes with the appearance of νasym (OCO)
bands {range: 1607 - 1602 cm-1} and a νsym (OCO) bands {range: 1410 – 1401 cm-1}
(Table 8). The ΔOCO values for all four complexes (190 – 203 cm-1) are indicative of
carboxylate groups bound to the metal centre in a unidentate coordination mode229.
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Table 8: Characteristic IR bands of complexes 5 - 8
Band Assignment

Complex

COO

COO

Δ

(assym)

(sym)

OCO

C-H

C-H

Bending

Bending

(phen)

(phen)

[Cu(fol)(phen)(H2O)].3H2O (5)

1603

1407

196

855

722

[Mn(fol)(phen)(H2O)].4H2O (6)

1609

1410

199

847

727

[Fe(fol)(phen)(Cl)].5H2O (7)

1602

1406

196

845

725

[Zn(fol)(phen)(H2O)].4H2O (8)

1606

1393

213

852

730

The TGA thermograms of folic acid and complexes 5 – 8 were studied to the
temperature 800 oC. As previously indicated the TG curve of folic acid showed that
the organic ligand melts at 220 oC with simultaneous decomposition (Figure 31)147,151.
1,10-phenanthroline, on the other hand, shows a steep decomposition occurring in two
defined steps (at 127 oC and 276 oC, respectively). The complexes 5 - 8 all showed
thermal decomposition over three stages, corresponding to the loss of the
uncoordinated and coordinated water and the loss/decomposition of the folate and
phen ligands, respectively.

Figure 31: Thermogravimetric analysis of folic acid, 1,10-phenanthroline (Phen) and
complexes 5 – 8.
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The room temperature magnetic moments of powdered samples of complexes 5 – 8
were also recorded. Whereas the values for 5 and 6 (1.82 B.M and 5.32 B.M
respectively) are indicative of high spin divalent complexes, the magnetic moment for
7 (2.71 B.M) was slightly higher than expected (2.0 – 2.5) but indicative of a low spin
Fe3+ complex215. Furthermore, these values are consistent with complexes with no
significant exchange interactions between the metal centres.216 Divalent and
diamagnetic complex 8 does not generate a magnetic moment.

Proposed structures that fit the physico-chemical data of complexes 5 – 8 are shown
in Figure 32.
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Figure 32: The proposed structures of 1,10-phenanthroline derivatives of simplemetal folates 5 – 8
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D 1. 3

Conclusion

All attempts to generate the binuclear complexes [M2(folate)(H2O)n] (M = Cu2+, Mn2+,
Fe3+, Zn2+ and Ag+) using previously published methods (and with significant
modifications) were unsuccessful. Instead, these reactions, as undertaken in the current
study, yielded the novel mononuclear complexes [Cu(fol)(H2O)3].H2O (1),
[Mn(fol)(H2O)3].3H2O (2), [Fe(fol)(H2O)2(Cl)].4H2O (3), and [Zn(fol)(H2O)3].3H2O
(4) in good yield (> 60%). In complexes 1 – 4 the folate acts, ostensibly, as a tridentate
ONO ligand.

Only the copper(II) complex [Cu(fol)(H2O)3].H2O (1) was found to react directly with
1,10-phenanthroline. Attempts to generate the binuclear metal complexes
[{M(phen)2}2(folate)] (M = Cu2+, Mn2+, Fe3+ and Zn2+) via a reaction between the
respective (Mn+(phen)2)-chloride salt and disodium folate yielded the novel
mononuclear

complexes

[Cu(fol)(phen)(H2O)].3H2O

(5),

[Mn(fol)(phen)(H2O)].4H2O (6), [Fe(fol)(phen)(Cl)].5H2O (7), and [Zn(fol)(phen)(H2O)].4H2O

(8) in moderate to high yields (40 – 97%). In complexes 5 – 8 the folate is

again believed to act as a tridentate ONO ligand with only one phen coordinated to the
copper centre.
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D.2

The chemotherapeutic potential of the simple metal-folate complexes

At the outset of the current project there were no reports in the literature of any
cytotoxic profiles or folate receptor (FR) mediated cyto-selective studies involving
simple metal complexes containing the folate ligand. However, in 2016 the novel FRselective

coordination

complex

nanotubes

with

the

general

formula

{M2(folate)(N2H4)3(OH)2(H2O)2}n (M = Ni2+ or Co2+), which exhibit excellent
anticancer therapeutic potential, were reported 230,231. In these complexes the folate acts
as classical bridging dicarboxylate ligand with the metal centres coordinated to the α
and γ carboxylate groups of the glutamic acid moiety leaving the pterin ring
unhindered in relation to its binding function in the pocket of the folate receptor.

To explore the chemotherapeutic potential of the simple metal-folate complexes
generated

in

the

present

study the

copper

and

manganese

complexes

[Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O (5), [Mn(fol)(H2O)3].3H2O (2)
and [Mn(fol)(phen)(H2O)].4H2O (6) were selected for biological assessment. The
known cytotoxic cationic bis-phen complex cations [Cu(phen)2]2+ and [Mn(phen)2]2+
were also included in this study to gauge the impact of the folate ligand on the
cytotoxic profiles of complexes 5 and 6.

D.2.1

Determination of the biological activity of [Cu(fol)(H2O)3].H2O (1)

and [Cu(fol)(phen)(H2O)].3H2O (2)

As previously mentioned in section I.3.1, the exploration of the biological effects of
simple metal folate complexes is in its infancy. Our work therefore sought to elucidate
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the mechanism of action of these complexes and to determine if these simple metal
folates had potential for development as cytotoxic agents. In addition, the presence of
folate was used in an attempt to target the complexes through the folate receptor. Initial
studies were undertaken to identify the potential cytotoxic and cytoselective
capabilities of a simple copper(II) folate complex, [Cu(fol)(H2O)3].H2O (1) and its
1,10-phenanthroline derivative, [Cu(fol)(phen)(H2O)].3H2O (2) (Figure 33) in FRoverexpressing cell lines.

Figure

33:

The

proposed

structures

of

[Cu(fol)(H2O)3].H2O

(1)

and

[Cu(fol)(phen)(H2O)].3H2O (5)

D.2.2

Expression of folate receptor alpha protein levels in cell lines

In order to test the specific targeting of complexes through the FRα and identify
appropriate cell models for experimentation, the protein expression levels of the
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receptor in several cell lines was measured using Western blot. Current literature
available on the expression of the FRα is variable and makes it challenging to identify
the most relevant cell models. For example, the breast cancer cell line MCF-7 has been
reported to express normal levels of folate receptor 232, while more recently this cell
line has been reported to overexpress the receptor233. Indeed, some authors have even
reported the use of the MCF-7 cell line as negative controls for folate receptor 232,234–
236

. Furthermore, in 2012 the well characterized cervical cancer cell line HeLa, was

reported to express high FRα levels in one publication 237 and low levels in a paper
published in 2013238,239.

SKOV-3 are commonly used as an FR+ve (FR-overexpressing) cell model240 and
A549 are used as an FR-ve (FR-underexpressing) cell model180,241. RPE-1 cells were
chosen as a non-malignant FR-ve cell line242. To determine if these cell lines do
express the FR levels previously described, western blot analysis was carried out.
SKOV-3 (human ovarian adenocarcinoma), A549 (human lung carcinoma), RPE-1
(immortalised human retinal epithelial) and MelJuSo-UbG76V-YFP (human melanoma)
were cultured in folate-free RPMI 1640 medium, harvested at 80% confluency and
total protein isolated for western blot analysis. β-actin was used as a control, however
due to the different expression of β-actin in these cell lines, Ponceau red staining was
used as a positive control for gel loading.

A549 cells were found to exhibit a detectable level of FRα protein, in agreement with
the current literature243–245, despite the fact that they are commonly described as FRve cell lines. Li et al did not identify any detectable mRNA for FRα in A549 cells,
however tumour xenograft tissues expressing A549 cells had detectable FRα protein
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expression243. SKOV-3 cells expressed high levels of FR-α protein (Figure 34). The
FR-α expression in MelJuSo-UbG76V-YFP has not been investigated to date, with no
literature available regarding FR-α expression in this cell line. Interestingly, MelJuSo
exhibited the highest FR-α expression level. RPE-1 cells also expressed detectable
levels of FR-α. The current literature suggests that cultured RPE-1 cells exhibit low or
negligible FR-α expression at mRNA level, so this result was unexpected242,246.
However, we measured protein expression in contrast to other studies measuring
mRNA levels. It should be noted that FRα is expressed in mammalian retina,
specifically located on the choroidal-facing basolateral membrane of the RPE cell. The
retinal pigment epithelial cells are polarized, having two distinct regions of the plasma
membrane that are morphologically and functionally different. However, RPE-1 cells
in culture lose this polarity as they are bound to an impermeable structure and therefore
lack FRα expression242,246. It could be postulated that the immortalisation process
alters FRα expression or that culture in folate-depleted medium has induced nutrient
deprivation, in turn promoting receptor expression.
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Figure 34: Expression of the Folate Receptor alpha (FR-α) in cell lines. Western blot
analysis was carried out on 100 µg of total protein isolated from SKOV-3, A549,
MelJuSo-UbG76V-YFP and RPE-1 cells cultured in folate-free RPMI medium as
outlined in E.4.1, using an anti-folate receptor alpha antibody. Anti

-actin antibody

was used as a control. Reversible Ponceau red staining was used as a loading control.
Data represent one of two independent experiments yielding similar results.

Given that SKOV-3 are a commonly used cell model for FR-α overexpressing cells
and have been well-characterized, SKOV-3 was chosen as the FR-α overexpressing
cell line for cytotoxicity assays and A549 were used as the FR-α underexpressing cell
line. In addition, we did not have access to the MelJuSo UbG76V-YFP cell line for initial
cytotoxicity experiments. Due to the unexpected FR-α expression found in RPE-1
cells, this cell line was not used as an FR-ve model.
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As stated previously, folate receptor expression has been shown to vary in cell lines.
In HeLa cells, FR-expression was shown to be cell cycle dependent, with the highest
FR levels being observed in the S-phase247. FR levels have also been found to decrease
as cell confluency increases248. Additional factors such as folate supplementation or
deprivation in cell culture media may also play a role in the variability of FRexpression249. Furthermore, as discussed previously regarding the RPE-1 cell line,
differences in FR-α expression may exist in cultured cells and intact tissues 242,246,250.
While it is clear that various conditions can influence the expression of the FRα in cell
models, we measured FRα protein expression under folate free media conditions and
used the same cellular conditions in all other experiments.

D.2.3

[Cu(fol)(phen)(H2O)].3H2O is cytotoxic in eukaryotic cells

Cellular models of SKOV-3 (FR overexpressing) and A549 (FR underexpressing)
were used to test the cytotoxicity and cytoselectivity of [Cu(fol)(H2O)3].H2O (1) and
its 1,10-phenanthroline derivative, [Cu(fol)(phen)(H2O)].3H2O (5). Copper(II) bisphenanthroline ([Cu(phen)2]2+ was used as a non-targeted complex. Cells were treated
with the complexes for 24 hours in folate free RPMI-1640 medium and cell viability
was measured using the Alamar blue assay. The Alamar Blue assay encompasses an
oxidation-reduction indicator that both fluoresces and changes colour in response to
chemical oxidation of growth medium as a result of cell death. A decrease in cell
viability results in a colour change from pink (reduced, fluorescent) to blue (oxidised,
non-fluorescent).
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In a preliminary screen conducted to elucidate if [Cu(fol)(H2O)3].H2O (1) and
[Cu(fol)(phen)(H2O)].3H2O (5) resulted in any cytotoxic effects and to determine a
suitable concentration range for subsequent studies, SKOV-3 and A549 cells were
treated with 2.5 – 100 µM [Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O (5),
folic acid, CuCl2, and 1,10-phen for 24 hours. Cisplatin was used as a positive control
and DMSO/EtOH (0.5%) were used as negative controls.

Results show that complex (1) was non-cytotoxic in A549 cells from 2.5 – 50 µM but
did show some effect at 100 µM (Figure 35). In SKOV-3 cells, there were effects on
cell viability (approx. 20% reduction) at concentrations of 50 and 100 µM. In
comparison, complex (5) appeared to induce a concentration-independent cytotoxic
effect, reducing cell viability by 90% in both SKOV-3 and A549 cells from 10 µM,
which did not change further up to 100 µM. Cisplatin was found to be effective in a
concentration-dependant manner, reducing cell viability by 42% at 10 µM and 68 %
at 100 µM in A549 cells. A similar effect was observed in SKOV-3 cells, when at 10
µM, a 44% decrease in viability was observed and a 68% decrease at 100 µM. Folic
acid exhibited little or no cytotoxicity up to 100 µM in both cell lines as expected, as
folic acid is an essential component in cell culture media and required for the
conversion of homocysteine to methionine and DNA synthesis 251. However, CuCl2
significantly reduced A549 viability (52%) when used at 25 µM whereas it only
reduced SKOV-3 viability by 19% at the same concentration. 1,10-phenanthroline
induced a concentration-independent cytotoxic effect from 2.5 – 100 µM in both cell
lines. It is believed that 1,10-phenanthroline is capable of chelating metal ions within
cell culture media (e.g. Cu2+ ions) to generate biologically active species known to be
capable of inducing cellular damage203,252.
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Figure 35: Cytotoxic effects of [Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O
(5) and starting materials (folic acid, CuCl2, 1,10-phen) in SKOV-3 cells (human
ovarian adenocarcinoma) and (B) A549 cells (human lung carcinoma). Cells were
treated with DMSO (0.5%; negative control for [Cu(fol)(H2O)3].H2O (1),
[Cu(fol)(phen)(H2O)].3H2O (5), folic acid, and cisplatin), EtOH (0.5%; negative
control

for

CuCl2

and

1,10-phen)

[Cu(fol)(H2O)3].H2O

(1),

[Cu(fol)(phen)(H2O)].3H2O (5), folic acid, CuCl2, 1,10-phen, and cisplatin
(concentration range 2.5 – 100 μM). Cells were harvested, and cell viability was
measured using the Alamar Blue assay. Results are representative of three independent
experiments (n = 3) and show mean ± standard deviation (SD).
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Based on the results from the preliminary screening (Figure 34), subsequent
cytotoxicity studies were carried out in the concentration range of 1-10 µM. Cells were
treated with complex 5, its non-targeted comparator, [Cu(phen)2]2+, and cisplatin.
DMSO/EtOH (0.05%) was used as a negative control. As complex 1 was not found to
be particularly cytotoxic at lower concentrations and even up to 50 µM, it was not used
in further studies. Results showed that treatment of SKOV-3 cells for 24 hours with
3.16 µM of complex 5 resulted in a 55 % reduction in cell viability, with 5.62 and 10
µM reducing viability further to only 6% after 24 hours treatment (Figure 36 (A)).

In contrast, in A549 cells which express low levels of the folate receptor, treatment
with 3.16 µM of 5 resulted in only a 10% reduction in cell viability, which was
significantly different to SKOV-3 cells (p < 0.05). However, at 5.62 and 10 µM,
complex 5 also reduced viability substantially by 85 and 93% after 24 hours treatment
(Figure 36 (B)). The EC50 values calculated for complex 5 in SKOV-3 and A549 cell
lines are 3.13 µM and 3.79 µM respectively. The EC 50 values calculated for
[Cu(phen)2]2+, which does not contain folate, are 2.00 µM (SKOV-3) and 3.45 µM
(A549). Treatment of both cell lines with cisplatin did not significantly affect cell
viability after 24 hours (≤ 20%), although there was slightly more of an effect on
SKOV-3 cell viability than on A549. The data suggest that there is a difference in cell
viability of high/low FR expressing cells at concentrations under 5 µM following
treatment with complex 5 and [Cu(phen)2]2+, however treatment over 5 µM (5.62 µM
– 10 µM) resulted in more than a 90% reduction in cell viability in both cells lines.
This data shows that the effects of complex 5 are only different at 3.16 µM but are not
different at higher concentrations in SKOV-3 cells expressing significant levels of FR
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compared to A549 cells with lower expression of FR, suggesting that it is unlikely that
the folate moiety can increase the cytoselectivity of complex 5.

Figure 36: Cytotoxic effects of [Cu(fol)(phen)(H2O)].3H2O (5) in (A) SKOV-3 cells
and (B) A549 cells. Cells were treated with DMSO (0.05%; negative control for
complex 5 and cisplatin), EtOH (0.05%; negative control for [Cu(phen) 2]2+), complex
5, [Cu(phen)2]2+, and cisplatin (concentration range 1.00 – 10.00 μM). Cell viability
was measured using the Alamar Blue assay. Results are representative of three
independent experiments (n = 3) and show mean ± standard deviation (SD). * shows
a significant difference between A549 and SKOV-3 cells (p < 0.05).
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D.2.4

The cytotoxic effect of [Cu(fol)(phen)(H2O)].3H2O is not FR-α

mediated

The similar EC50 values of both the targeted complex 5 and the non-targeted
[Cu(phen)2]2+ against SKOV-3 cells and A549 cells suggest that the FR may not be
involved in selective cellular uptake. However, to rule out the involvement of the FRreceptor targeted uptake of complex 5, one population of SKOV-3 cells were cultured
in folate-depleted RPMI 1640 medium for one week, while another population of
SKOV-3 cells were cultured in RPMI 1640 medium supplemented with 100 µM folic
acid (FAH2), for the same period to saturate the FR 253. Cell culture media were
changed every second day for one week. Following one-week incubation, cells were
treated with 1.00 – 10.00 µM complex 5 for 24 hr and cell viability was measured
using the Alamar blue assay. The FR has a high affinity for folic acid and the reported
Kd for folic acid is less than 1 nM254, therefore, it is expected that folate receptors will
be fully saturated following treatment with 100 µM folic acid.

The EC50 values calculated for cells treated with complex 5 were as follows: SKOV-3
(+FAH2) 4.18 µM; SKOV-3 (-FAH2) 3.95 µM, which indicated a similar effect on
SKOV-3 cell viability in the presence or absence of excess folic acid (Figure 36). Our
result suggests that the targeting of folate-containing [Cu(fol)(phen)(H2O)].3H2O (5)
into cells expressing the folate receptor may be folate receptor independent as there
was no discernible difference between cell viability (uptake of the complex) even when
the folate receptor was saturated.
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In comparison to Figure 36 (A), there is an unexpected marked difference in cell
viability at 3.16 µM in Figure 37 {45% viability (Figure 36 (A)) versus 85% (Figure
37)}. It is not clear why this difference occurred between experiments but the
triplicates from each experiment showed similar results. From 5.62 µM to 10 µM, both
treatments result in similar effects on cell viability {similar to results in Figure 36 (A)}.

Figure 37: The effects of complex 5 are not mediated through the folate receptor.
SKOV-3 cells were cultured in RPMI 1640 medium supplemented with 100 µM folic
acid, and folate free RPMI 1640 medium for one week prior to treatment with 1.00 –
10.00 μM of complex 5. Cells were incubated for 24 hours and cell viability measured
using the Alamar Blue assay. Results are representative of three independent
experiments (n = 3) and results are show as mean ± standard deviation (SD).

94

The crystal structure of the human folate receptor alpha in complex with folic acid was
resolved in 201326. FRα has a globular structure stabilized by eight disulphide bonds
and has a deep open folate-binding pocket, with the folate pteroate moiety buried
inside the receptor. The glutamate moiety sticks out of the pocket entrance, allowing
it to be conjugated to drugs without adversely affecting FRα binding. It may be
postulated that the ONO tridentate coordination of complex 5 sterically inhibits
docking of the pterin moiety into the receptor pocket. However, it is not currently
known if complex 5 remains intact or dissociates into folic acid and a [Cu(phen)] 2+
moiety prior to cellular uptake. Stability studies are required to better understand the
structural integrity of complex 5.

If the complexes are not entering the cell through the FRα, intact or otherwise, they
may enter the cell by another mechanism such as the human copper transporter,
hCTR1255,256. Furthermore, the lipophilic nature of 1,10-phenanthroline may aid
cellular uptake of the copper(II) complex by passive diffusion 257. Further work is
required to determine the mechanism of uptake of these complexes into mammalian
cells.

D.2.5

Treatment of MelJuSo-UbG76V-YFP cells with [Cu(phen)2]2+ and

[Cu(fol)(phen)(H2O)].3H2O results in accumulation of ubiquitinated proteins.

Recent studies suggest that copper(II) phenanthroline complexes, such as
[Cu(IAA)2(phen)] (IAA = Indole-3-acetic acid) and [Cu(IPA)2(phen)] (IPA = indole3-propionic acid) may function as proteasome inhibitors due to their inhibition of the
proteasome and induction of apoptosis in vitro in cell lines122. Previous research by
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Verma et al showed that 1mM 1,10-phenanthroline inhibited the essential Rpn11
isopeptidase activity of purified 20S proteasome samples258. Santoro et al investigated
the effects of copper(II) ions on the 20S proteasome in cell-free conditions and
suggested that copper(II) ions may induce proteasomal inhibition by affecting the
gating dynamic of the 20S proteasome through the irreversible closure of α-rings259.
In the same study, they identified the accumulation of polyubiquitinated proteins in
HeLa cells following treatment with copper chloride and concluded that Cu(II) ions
affect proteasome activity at multiple levels. Similar results were reported by Chen et
al who showed that treatment of breast cancer cell lines MDA-MG-231 with disulfiram
(which can bind copper and is used clinically to treat alcoholism), when coordinated
to copper, resulted in inhibition of proteasomal activity260. Zhang et al postulated that
both copper(II) and 1,10-phenanthroline were required to induce proteasomal
inhibition and that 1,10-phenanthroline played an important role in the observed
proteasome inhibition and apoptotic effects of copper(II) complexes 122.

The MelJuSo-UbG76V-YFP cell line was used as a dual reporter model of proteasomal
inhibition and cell survival261. This cell line expresses a ubiquitin-YFP (yellow
fluorescent protein) fusion protein that is constitutively targeted for proteasomal
mediated degradation and a nuclear localised red fluorescent (RFP) protein to allow
quantification of cell number. The accumulation of the Ub-YFP reporter indicates
inhibition in proteasomal function whereas a reduction in RFP signal indicates reduced
proliferation or cell death. To examine the effects of copper(II) complexes on
proteasomal activity, MelJuSo-UbG76V-YFP cells were treated with 0.157 – 5 µM of
[Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O (5), and [Cu(phen)2]2+.
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Bortezomib was used as a positive control at a concentration of 50 nM. DMSO-treated
or EtOH-treated cells (0.05%) were used as negative controls.

Accumulation of UbG76V-YFP was examined by time-lapse microscopy. As expected,
cells treated with complex 1 did not display YFP-positivity and remained viable
throughout the experiment (Figure 38 and 39). Cells treated with complex 5,
[Cu(phen)2]2+ (5µM), and Bortezomib (50 nM) rapidly became YFP-positive after
addition of the complexes and displayed a rounded, apoptotic morphology even after
12 hours of exposure (Figure 38). Interestingly, a subpopulation of cells treated with
complex 5 did not become YFP-positive and remained viable over the 72-hour period
(Figure 38 and 39). In addition, proteasome inhibition correlated with cell death as
indicated by a decrease in nuclear RFP signal {Figure 39 (A & B)}. Interestingly
[Cu(phen)2]2+ resulted in more rapid cell death as a result of proteasomal inhibition
than treatment with complex 5 {Figure 39 (A & B)}.

These results indicate that complex 5 and [Cu(phen)2]2+ could both function as
proteosomal inhibitors and further experimental work was undertaken to identify if
copper(II) phen was specific as a proteasome inhibitor compared to other
phenanthroline-containing complexes.
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Figure 38: Treatment of MelJuSo-UbG76V-YFP cells with complex 5 and [Cu(phen)2]2+ results in proteasomal inhibition. MelJuSoUbG76V-YFP cells treated with 5 µM complex 1, complex 5 and [Cu(phen)2]2+ and examined by time-lapse microscopy. Data represent
one of two independent experiments showing similar results.
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Figure 39: Treatment of MelJuSo-UbG76V-YFP cells with complex 5 and
[Cu(phen)2]2+ results in proteasomal inhibition. Cells were treated with 5µM complex
1, complex 5 and [Cu(phen)2]2+ for 72 hours (A) green fluorescence, and (B) red
fluorescence. An increase of green fluorescent protein (GFP) and decrease of red
fluorescent protein (RFP) indicates proteasomal inhibition. Data represent one of two
independent experiments showing similar results.
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D.2.6

Copper(II) Phenanthroline is specific as a proteasome inhibitor

To determine if copper(II) phenanthroline was specific as a proteasome inhibitor
compared to other phenanthroline-containing complexes, MelJuSo-UbG76V-YFP cells
were treated with [Cu(phen)2]2+, [Mn(phen)2]2+, 1,10-Phenanthroline or Bortezomib
for 72 hours.

Accumulation of UbG76V-YFP was examined by time-lapse microscopy on treated
cells. Our data show that cells treated with [Cu(phen) 2]2+ (3.14 µM) and those treated
with Bortezomib (50 nM) became YFP-positive within 24 hours indicative of
proteasomal inhibition (Figure 40). Cells treated with concentrations greater than 10
µM of [Cu(phen)2]2+ were apoptotic before the first image was taken (≤3 hours)
therefore the YFP signal could not be detected. Both [Mn(phen) 2]2+ and 1,10phenanthroline treated cells did not express YFP up to 72 hours of treatment, however
a decrease in cell viability, evident by a decrease in red fluorescence, and a change in
morphology was observed from 48 – 72 hours (Figure 40). Our results confirm that
copper(II) phenanthroline is specific as a proteasomal inhibitor when compared to
another phenanthroline-containing complex (e.g. manganese(II) bis-phenanthroline or
1,10 phenanthroline). Previous research demonstrates that although copper chloride
inhibits chymotrypsin-like activity of purified 20S proteasome with an IC50 value of
∼7.5 μmol/L, a 95% reduction in its activity is seen in intact MDA-MB-231 cells260.
Additionally, Zhang et al suggests that phenanthroline encourages the uptake of copper
into intact cells to induce proteasome inhibition 122. Therefore, it is believed that both
copper(II) and 1,10-phenanthroline are required to induce proteasome inhibition.
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Figure 40: Copper(II) phenanthroline treatment results in proteasomal degradation. MelJuSo-UbG76V-YFP cells were treated with phen,
[Mn(phen)2]2+, [Cu(phen)2]2+ (3.14 µM) and Bortezomib (50 nM). Cells were exposed to 3.14 µM metal phenanthrolines and the free
ligand, 1,10-phenanthroline, and Bortezomib (50 nM). Cells were treated for 72 hours and imaged using time-lapse microscopy every 3
hours. Images are from one experiment.
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D.2.7

Effect of [Cu(fol)(phen)(H2O)].3H2O and [Cu(phen)2]2+ on proteins

involved in apoptosis and proteasome activity

Our results to date indicated that complex 5 and [Cu(phen)2]2+ have the potential to act
as proteasome inhibitors and that these effects were specific for Cu(II) containing
complexes. To further investigate the mechanism of proteasomal degradation by
complex 5 and [Cu(phen)2]2+ complexes, western blot assay was carried out using
antibodies to key proteins involved in the response to proteasomal inhibition,
endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) and apoptosis.
MelJuSo-UbG76V-YFP cells were treated with complex 5, [Cu(phen)2]2+ (1.58 µM – 5
µM), or Bortezomib (50 nM) for 6 hours and 18 hours.

Western blot analysis identified that complex 5 and [Cu(phen)2]2+ induced
accumulation of K48 (lysine 48) linked polyubiquitin and the Ub-YFP reporter at 2.81
and 5 µM indicating proteasome inhibition (Figure 41). The K48 antibody identifies
polyubiquitinated chains linked through the Lys48 residue of ubiquitin, commonly
associated with proteins targeted for proteosomal degradation 262. Regulators of the ER
stress response, heat shock protein 6 (HSPA6) and glucose-regulating protein 78
kDa/immunoglobulin heavy chain binding protein (GRP78/BIP), were induced
following treatment; however, the [Cu(phen)2]2+ showed a more rapid induction of
these proteins already after 6 hours compared to complex 5.

Next, we investigated the effect of [Cu(phen) 2]2+ and complex 5 on regulators of cell
cycle progression and apoptosis. Both compounds induced the accumulation of cell
cycle regulators p53 and p21, with [Cu(phen)2]2+ treated cells displaying a more rapid
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response. Similarly, both compounds also induced the accumulation of activated
caspase-3 indicating the activation of the intrinsic apoptotic pathways (Figure 41). In
both experiments of 6 hours and 18 hours, treatment with 5 µM [Cu(phen)2]2 did not
result in accumulation of K48 Ub. It is unclear why this occurred as other proteins
indicating ER stress, proteasomal inhibition and apoptosis were induced, although
some differences were observed after 18 hours treatment with 5 µM e.g. p21, HMOX1 and GFP. Taken together, these results show that treatment with complex 5 and
[Cu(phen)2]2+ result in accumulation of proteins involved in proteasomal inhibition and
apoptosis, with [Cu(phen)2]2+ resulting in a more rapid effect.

103

Figure 41: Complex 5 and [Cu(phen)2]2+ induce proteins involved apoptosis and
proteasome inhibition. Western blot assay was performed on MelJuSo-UbG76V-YFP
cell extracts treated with 1.58 – 5 µM complex 5 and [Cu(phen)2]2+, and Bortezomib
(50 nM) for (A) 6 h and (B) 18 h. Antibodies to HSPA6, Ubiquitin K48, Green
Fluorescence Protein (GFP), GRP78 BiP, p53, Heme Oxygenase 1 (HMOX-1),
Caspase3 (Casp-3), and p21 proteins were utilised in western blot as per the
experimental section. β-actin was used as a loading control. Data represent one of two
independent experiments with similar results.
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Both complexes also induced the expression of HMOX-1 within 6 hours of cells
treated with 5 µM complex 5 and 2.81 - 5 µM [Cu(phen)2]2+, and HMOX-1 is induced
by a variety of stimuli including ROS generation. The effect of ROS generation on the
proteasome is unclear. Both Daniel et al and Santoro et al suggest that oxidative
damage is not the direct cause of proteasomal inhibition, but that copper directly
interacts with and inhibits the proteasome 127,259. Furthermore, the deubiquitinating
enzyme, RPN11/POH1, located on the 19S regulatory cap (Figure 42), has been found
to be particularly sensitive to 1,10-phenanthroline in cell-free conditions in the
millimolar range (1 – 10 mM)258,263. Considering this, the generation of ROS by
complex 5 and [Cu(phen)2]2+ is not believed to be involved in the inhibition of the
proteasome but may be involved in a concurrent mechanism.

Currently, our hypothesis is that the copper(II) phenanthroline moieties of complex 5
and [Cu(phen)2]2+ may directly interact with the deubiquitinating enzyme machinery,
specifically the metalloprotease RPN11/POH1 which is known to interact with 1,10phenanthroline264 to exert their proteasome inhibitory effects (Figure 42). If this is the
case, these copper(II) phenanthroline complexes may represent a novel class of cell
permeable RPN11/POH1 proteasome inhibitors.

Attempts to elucidate the precise site of interaction of complex 5 with the proteasome
were made – competitive labelling experiments using HA-tagged ubiquitin vinylsulphonone (HA-UbVS), an active site probe of cysteine DUBs (USP14 and UCHL5)
were conducted. The metalloprotease RPN11/POH1 is not labelled by the HA-Ub-VS
probe, therefore alterations in POH1 activity would not be evident using the probe.
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Unfortunately, results of these experiments were inconclusive, warranting further
investigation (see Section C.2)

Figure 42: Copper(II) phenanthroline complexes mediate their effects through the
Ubiquitin-Proteasome system. (1) Ubiquitin (Ub) is conjugated to proteins destined
for degradation by an ATP-dependent process that involves enzymes E1, E2, and E3
(2) The copper(II) phenanthroline moiety may interact directly with DUB enzyme
RPN11/POH1 located on the 19S regulatory cap, and (3) prevent deubiquitination of
Ub-labelled proteins. (4) Ub-labelled proteins may accumulate in the cell, resulting in
apoptotic cell death.
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D.2.8

[Cu(fol)(phen)(H2O)].3H2O and [Cu(phen)2]2+ are cytotoxic in

multicellular tumour spheroids.

As mentioned previously, current proteasome inhibitors such as Bortezomib are
ineffective against solid tumours265. Therefore, the potency of copper(II)
phenanthroline complex 5 and [Cu(phen)2]2+ against 3D tumour spheroids was
investigated. Multicellular spheroids are superior to 2D monolayer cultures in
mimicking in vivo solid tumours266–268. Numerous differences reported between 2D
and 3D cell models regarding responses to therapeutic agents and pivotal cellular
processes such as cell morphology, differentiation, signalling pathways, cell-cell
interactions, and cell-matrix interactions demonstrate the importance of 3D cell
models in drug screenings 268. In light of this, many clinically used drugs (e.g. Taxol,
and Bortezomib) that show excellent in vitro activity against monolayer cell models
show limited potency in spheroids 269,270.

Multicellular tumour spheroids (MCTs) were formed using SKOV-3 cells as described
in section E.4. Cells were treated with 1.77 – 10 µM complex 5, [Cu(phen)2]2+, and
Bortezomib (17.70 – 100 nM) for 72 hours and examined by time-lapse microscopy
(Figure 43). The spheroid volume was also measured for each treatment and is shown
in Figure 44. Treatment with complex 5 and [Cu(phen)2]2+ (10 µM) resulted in
disaggregation of spheroids (Figure 42 (A)). Spheroids treated with Bortezomib (10 –
100 nM) showed no disaggregation over the duration of the experiment, which
indicates that Bortezomib is not effective in 3D cellular models in line with previous
literature.
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This is the first report on the effects of metal-based proteasome inhibitors against 3D
tumour spheroids which show promising results in multicellular 3D models. However,
further studies are required to better understand the cytotoxicity of complex 5 and
[Cu(phen)2]2+ in 3D tumour spheroids – i.e. do they still function as proteasome
inhibitors in 3D models or does the generation of ROS or RNS play a more significant
role in cell death given the hypoxic environment of the 3D spheroid?
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Figure 43: Complex 5 and [Cu(phen)2]2+ cause disaggregation of SKOV-3 spheroids.
(A) SKOV-3 cells treated with 10 µM complex 5 and [Cu(phen)2]2+ examined by timelapse microscopy. DMSO treated cells (0.1%) were used as a negative control and
Bortezomib (100 nM) as a positive control. B) SKOV-3 cells treated with 10 µM of
Complex 5 and [Cu(phen)2]2+ for 72 hours. DMSO (0.1%) and Bortezomib (100 nM)
were used as controls. Images taken using an inverted microscope (X40 total
magnification). Data represent one of three independent experiments with similar
results.
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Figure 44: Complex 5 and [Cu(phen)2]2+ cause disaggregation of SKOV-3 spheroids.
(A) SKOV-3 cells treated with 10 µM complex 5 and [Cu(phen)2]2+ examined by timelapse microscopy. DMSO treated cells (0.1%) were used as a negative control and
Bortezomib (100 nM) as a positive control. Spheroid volume was calculated for each
treatment. Data represent one of three independent experiments with similar results.

D.2.9

Conclusion

Our data suggests that complex 1, [Cu(fol)(H2O)3].H2O does not affect cell viability
in cell lines up to 50 µM, although there were some effects in A549 and SKOV-3 at
higher

concentrations.

In

contrast,

its

1,10-phenanthroline

derivative,

[Cu(fol)(phen)(H2O)].3H2O (5), showed promising in vitro activity at ≤ 5 µM within
24 hours treatment. Complex 5 was found to be cytotoxic against both FR
overexpressing SKOV-3 cells and FR underexpressing A549 cells, suggesting that the
complex may enter the cell through a mechanism other than transport via the folate
receptor. Additional folate saturation studies support this. Although the mechanism of
cellular uptake is unknown at this time, complex 5 was found to induce proteasomal
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inhibition and subsequent apoptosis. The non-targeted [Cu(phen)2]2+ complex was also
found to induce proteasomal inhibition and apoptosis, albeit more rapidly.

Finally, both complex 5 and [Cu(phen)2]2+ were found to be active in 3D-tumour
spheroids in the low micromolar range, resulting in their disaggregation. Our overall
conclusion is that copper(II) phenanthroline complexes have the potential to function
as potent proteasome inhibitors in the low

M range and may be developed into new

metal-based anticancer agents, showing efficacy in 2D and 3D cell models.
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D.3

The biological activity of manganese(II) folate and it’s 1,10-

phenanthroline derivative

Having examined the potential effects of novel copper(II) folate complexes, we also
examined [Mn(fol)(H2O)3].3H2O (2) and [Mn(fol)(phen)(H2O)].4H2O (6) (Figure 44)
to identify their potential as cytotoxic and cytoselective agents and to establish the
difference in their biological profiles when compared to [Cu(fol)(H2O)3].H2O (1) and
[Cu(fol)(phen)(H2O)].3H2O (5).

Physiologically, Cu2+ and Mn2+ are involved in a range of biochemical processes.
However, copper(II) and manganese(II) differ in their structural properties and their
biological activities in a number of ways. For example in antioxidant systems such as
the dismutation of superoxide (O2•–) to O2 and H2O2 via superoxide dismutase (SOD)
enzymes, it is noted that manganese(II)-containing SOD enzymes react with O2•– more
slowly than the Cu/ZnSOD enzyme271. Additionally, Mn2+ systems are reportedly less
prone to form the reactive hydroxyl radical (•OH) via Fenton chemistry, but rather
function via the disproportionation of H2O2 into water and oxygen203,271. Furthermore,
as Mn2+ is a d5, high spin, weak field metal, it lacks crystal field stabilisation energy
(CFSE), resulting in less stable complexes more likely to dissociate from its ligand 271.

D.3.1

[Mn(fol)(phen)(H2O)].4H2O is cytotoxic in eukaryotic cells

Similar to section D.2.1, the cytotoxicity and cytoselectivity of [Mn(fol)(H2O)3].3H2O
(2) and its 1,10-phenanthroline derivative, [Mn(fol)(phen)(H2O)].4H2O (6) (Figure 45)
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were investigated. Manganese(II) bis-phenanthroline ([Mn(phen)2]2+ was used as a
non-targeted complex.

Figure

45:

The

proposed

structures

of

[Mn(fol)(H2O)3].3H2O

(2)

and

[Mn(fol)(phen)(H2O)].4H2O (6)

In a preliminary screen conducted to elucidate if [Mn(fol)(H2O)3].3H2O (2) and
[M4(fol)(phen)(H2O)].3H2O (6) were cytotoxic and to determine a suitable
concentration range for subsequent studies, SKOV-3 and A549 cells were treated with
3 – 100 µM complex 2, complex 6, and the non-targeted [Mn(phen)2]2+ counterpart for
24 and 48 hours. Cisplatin was used as a positive control and DMSO (0.1%) as a
negative control. Similar to complex 1, it was found that complex 2 did not induce
marked cytotoxic effect in either SKOV-3 or A549 cell lines within 24 or 48 hours
from 3 – 100 µM (Figure 46). At 24 hours, complex 6 (17.73 µM) reduced cell viability
by 51% in SKOV-3 and 29% in A549. [Mn(phen)2]2+ induced a similar effect, reducing
cell viability by 47% in SKOV-3 and 20% in A549 at 17.73 µM. However, at 48 hours,
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complex 6 induced a 70% reduction in cell viability in SKOV-3 at 17.73 µM and only
a 45% reduction in A549 at the same concentration. Again, [Mn(phen)2]2+ induced a
similar effect.

Figure

46:

Cytotoxic

effects

of

[Mn(fol)(H2O)3].3H2O

(2),

[Mn(fol)(phen)(H2O)].4H2O (6) and [Mn(phen)2]2+ in SKOV-3 cells (A & B) and
A549 cells (C & D). Cells were treated with DMSO (0.1%), [Mn(fol)(H2O)3].3H2O
(2), [Mn(fol)(phen)(H2O)].4H2O (6), [Mn(phen)2]2+, and cisplatin (concentration
range 3 – 100 μM; Log0.25 dilution) for 24 and 48 hours. Cells were harvested, and cell
viability was measured using the Alamar Blue assay. Results are representative of
three independent experiments (n = 3) and show mean ± standard deviation (SD).
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As complex 2 failed to induce a cytotoxic effect within 48 hours, even at 100 µM, it
was not used in subsequent studies. However, complex 6 was found to induce a
significant cytotoxic effect at 48 hours, particularly in FR-overexpressing SKOV-3
cells (Figure 45 (B)). This delayed cytotoxicity may be due to the reportedly slow
reaction of Mn2+ with superoxide271. In light of this, subsequent studies were
performed for 48 and 72 hours in the concentration range of 2 – 20 µM, using complex
6 and its non-targeted comparator, [Mn(phen)2]2+. In this case, bortezomib was used
as a positive control from 20 – 200 nM and DMSO (0.1%) was used as a negative
control. Cell viability was measured using the Alamar blue assay.

Subsequent studies showed that treatment of SKOV-3 cells with 6.31 µM of complex
6 resulted in a 49% reduction in cell viability (p <0.005), however an increase in
concentration up to 20 µM only reduced cell viability by an additional 14% after 48
hours treatment (Figure 46 (A)). After 72 hours treatment, cell viability was reduced
by 77% when treated with 6.31 µM complex 6, and by 84 and 93% with 11.24 and 20
µM complex 6 (Figure 46 (B)). There was a similar effect with Bortezomib and with
[Mn(phen)22+] with [Mn(phen)22+] being more effective than Bortezomib even at 2
µM. After 72 hours treatment, there were notable differences between the triplicates
in each experiment as evidenced by the large error bars in Figure 47 (B and D). This
may be due to the 72-hour treatment without a change of culture medium and
accumulation of potentially toxic compounds.

Interestingly, there was a difference between the effects of complex 6 in SKOV-3
compared to A549 cells. When comparing Figure 47 (A) and (C), at concentrations
higher than 2 µM, there was decreased cell viability in SKOV-3 (FR-overexpressing
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cells) compared to A549 (FR-underexpressing cells) after 48 hours treatment
(significant, p <0.005), which was also visible after 72 hours treatment (significant, p
<0.05; compare panels B and D). These results suggest that the effects of complex 6
may be mediated via the folate receptor.

In A549 cells which express low levels of the folate receptor, treatment with 6.31 µM
of complex 6 resulted in only a 15% reduction in cell viability after 48 hours with 50%
viability remaining even after treatment with 20 µM, (Figure 47 (C)). After 72 hours,
treatment of A549 cells with concentrations of complex 6 up to 20 µM resulted in an
80% reduction in cell viability, which was concentration dependent at concentrations
higher than 3.54 µM . The EC50 values calculated for complex 6 in SKOV-3 and A549
cell lines are 4.92 µM and 7.63 µM at 48 hours, and 4.50 µM (SKOV-3) and 4.64 µM
(A549) at 72 hours, respectively. The EC50 values calculated for [Mn(phen)2]2+, which
does not contain folate, are 1.59 µM (SKOV-3) and 7.85 µM (A549) at 48 hours.
Bortezomib has EC50 values of 3.45 nM (SKOV-3) and 9.67 nM (A549) at 48 hours.
The data suggest that there is a difference in cell viability of high/low FR expressing
cells when treated with complex 6 at 48 hours. However, the differences in EC50
between the cell lines with a non-folate containing complex and Bortezomib would
suggest that these differences may not relate to folate receptor expression.
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Figure 47: Cytotoxic effects of complex 6 in SKOV-3 cells (human ovarian
adenocarcinoma) (A & B) and A549 cells (human lung carcinoma) (C & D). Cells
were treated with DMSO (0.1 %), complex 6, [Mn(phen)2]2+ (2 – 20 µM), and
Bortezomib (20 – 200 nM) for 48 and 72 hours. Cells were harvested, and cell viability
was measured using the Alamar Blue assay. Results are representative of three
independent experiments (n = 3) and show mean ± standard deviation (SD). Asterisk
(*) shows (p <0.05) whereas (**) and (***) shows (p < 0.005) and (p <0.001).
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D.3.2

The cytotoxic effect of [Mn(fol)(phen)(H2O)].4H2O is not FRα

mediated

The EC50 values of complex 6 against A549 cells is 1.5 times greater than that of
SKOV-3 cells after 48 hours treatment which could suggest the involvement of the
FRα in transporting complex 6 into cells. To further investigate if the FR-receptor is
involved in targeted uptake of complex 6, a similar method described in section D.2.4
was used. The FR was saturated with folic acid for one week and cells were treated
with 2 – 20 µM complex 6 for 48 hr (Figure 48) and cell viability was measured using
the Alamar blue assay.

The EC50 values calculated for cells treated with complex 6 for 48 hours were as
follows: SKOV-3 (+FAH2) 5.91 µM; SKOV-3 (-FAH2) 5.27 µM, which show a
similar effect on SKOV-3 cells in the presence or absence of excess folic acid (Figure
47). This result suggests that the targeting of the [Mn(fol)(phen)(H2O)].4H2O (6) may
not be through the folate receptor and that the effects seen on cell viability are due to
other mechanisms. In addition, the effects on cell viability with manganese complexes
occur after a much longer timeline than those seen with copper complexes. We can
only speculate at this stage that the complexes are entering the cell via a transport
mechanism or by passive diffusion. The current literature suggests that manganese(II)
complexes may enter cells through a number of transport mechanisms, including: the
divalent metal transporter 1 (DMT1)272, a manganese citrate transporter273,274, a store
activated Ca2+ channel275, the ZIP8 mechanism276,277, and the ZIP14 mechanism278–280.
However, DMT1 transports metal ions and therefore its capacity to bind and/or
transport complex 6 or [Mn(phen)2]2+ is unknown.
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Figure 48: The effects of complex 6 are not mediated through the folate receptor.
SKOV-3 cells were cultured in RPMI 1640 medium supplemented with 100 µM folic
acid (FAH2), and folate free RPMI 1640 medium for one week prior to treatment with
2 – 20 μM of complex 6. Cells were incubated for 48 hours and cell viability measured
using the Alamar Blue assay. Results are representative of three independent
experiments (n = 3) and results are show as mean ± standard deviation (SD).

D.3.3

[Mn(fol)(phen)(H2O)].4H2O and [Mn(phen)2]2+ do not induce

proteasome inhibition.

When comparing the activities of Cu and Mn containing complexes, it was previously
observed that [Mn(phen)2]2+ did not result in proteasomal inhibition following
treatment at 3.14 µM for 72 hours (Figure 39). To elucidate its potential proteasomal
effects, complex 6 was further investigated. MelJuSo-UbG76V-YFP cells were treated
with 2 – 20 µM of [Mn(fol)(phen)(H2O)].4H2O (6) and [Mn(phen)2]2+ to determine if,
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like their copper(II) phenanthroline counterparts, they were capable of inducing
proteasomal inhibition. Bortezomib was used a positive control at a concentration of
20 - 200 nM. DMSO-treated cells (0.1%) were used as negative controls.

Accumulation of UbG76V-YFP was examined by time-lapse microscopy, which
indicates inhibition of proteosomal function. Cells treated with bortezomib (20 - 200
nM) rapidly became YFP-positive after treatment, displaying a rounded, apoptotic
morphology within 24 hours of exposure (Figure 49). However, cells treated with
complex 6 and [Mn(phen)2]2+ did not display YFP-expression throughout the
experiment, even up to 72 hours treatment. A distinguishing feature of these
experiments was that within 48 – 72 hours, cell growth/division ceased and changes in
cell morphology became apparent at a microscopic level as evident in Figure 48 in the
number of cells evident (compare DMSO treated cells, complex 6 and [Mn(phen)2]2+
at 72 hours). An observed decrease in RFP in cells treated with complex 6 and
[Mn(phen)2]2+ also indicated reduced cell viability.
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Figure 49: Effects of Complex 6 and [Mn(phen)2]2+ on the proteasome. MelJuSoUbG76V-YFP cells were treated with complex 6 and [Mn(phen)2]2+ (11.24 µM) and
Bortezomib (63.10 nM) for 72 hours. DMSO (0.1%) treated cells were used as a
negative control. Images were collected using time-lapse microscopy every 3 hours.
Images shown are from one experiment at 72 hours.
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D.3.4

Treatment

of

MelJuSo-UbG76V-YFP

cells

with

[Mn(fol)(phen)(H2O)].4H2O delays cell migration and proliferation.

The apparent inhibition of cell growth observed in Figure 48 prompted the exploration
of complex 6’s effects on MelJuSo-UbG76V-YFP cell migration. MelJuSo-UbG76V-YFP
cells are derived from cutaneous melanomas which are highly metastatic skin tumours
resulting from the malignant transformation of melanocytes 281,282. Late stage
melanomas (i.e. stage IV melanoma) are characterised by their ability to metastasize
or migrate to other parts of the body with a mean survival time of 7.5 months from
diagnosis283. The liver, lungs, bones and brain are most often affected by these
metastases284,285.

MelJuSo-UbG76V-YFP cells were seeded into 35 mm dishes and allowed to reach 100%
confluency as a monolayer. A sterile pipette tip was used to scratch a straight line along
the equator of each dish. One dish was supplemented with folate-depleted RPMI 1640
media containing [Mn(fol)(phen)(H2O)].4H2O (complex 6) (20 µM). Another dish
containing 0.1% DMSO was used as a negative control. Both were scratched at time
of treatment. A third dish was supplemented with folate-depleted RPMI 1640 media
containing [Mn(fol)(phen)(H2O)].4H2O (6) (20 µM) and was scratched 24 hours after
treatment. Media was replenished every 24 hours and images of the scratch site were
taken every 24 hours for a total of 72 hours.

Our results showed that DMSO (0.1%) treated cells almost entirely filled the wound
site within 72 hours, showing that normal growth and proliferation was occurring
(Figure 50). In stark contrast, treatment of MelJuSo-UbG76V-YFP cells with complex
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6 (20 µM) greatly hindered the mobility/proliferation of these cells and 70 – 80% of
the wound site remaining unoccupied at 72 h (Figure 50). Pre-treatment of cells with
complex 6 24 hours prior to scratch resulted in a similar outcome. These results show
that complex 6 treatment of melanoma cell lines impairs their ability to proliferate as
well as hindering their mobility.
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Figure 50: Complex 6 (20 µM) hinders mobility of MelJuSo-UbG76V-YFP cells within 48 – 72 hours. A confluent 35 mm dish of MelJuSoUbG76V-YFP cells was scratched across the equator and treated with 20 µM complex 6 or DMSO (0.1 %) for 72 hours. A third set of
MelJuSo-UbG76V-YFP cells were pre-treated with complex 6 (20 µM) 24 hours prior to scratching. Media was replenished every 24 hours
and images of the scratch site were taken every 24 hours for a total of 72 hours. The experiment was repeated twice yielding the same
result. Results are presented from one experiment. Total magnification X40.
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D.3.5

[Mn(phen)2]2+ and [Mn(fol)(phen)(H2O)].4H2O may induce cell

death via ROS induced autophagy.

The generation of reactive oxygen species by manganese(II) complexes is well
reported203,286,287. However, it is only within the last decade that the mechanism of
action of manganese(II) complexes in mammalian cells was reported 97,98,102,203,288. The
current literature suggests that manganese(II)-induced ROS results in mitochondrial
damage, and subsequently leads to both apoptotic and autophagic cell death 97,98,102.
Therefore, to explore the findings in our previous experiments of the inhibition of cell
growth and proliferation by treatment with Mn-containing complexes, the possibility
of autophagic cell death in MelJuSo-UbG76V-YFP cells treated with complex 6 was
investigated using cell morphology analysis, western blot analysis and flow cytometry.

D.3.5.1

Cell morphology

As evidenced in the wound scratch assay experiments on treatment of MelJuSoUbG76V-YFP cells with complex 6 (20 µM) (section D.3.4), a distinct visible change in
cell morphology occurred {Figure 51 (A)}. Between 48 – 72 hours, cell nuclei
appeared swollen and chromatin were condensed. In addition, granularity of the
cytoplasm increased greatly. A key morphological change associated with autophagy
is the development of autophagosomes; double-membraned vesicles that form around
cellular material to be degraded by autophagy, resulting in the increased cell
granularity/complexity observed in treated cells 289,290. Furthermore, the chromatin
condensation and enlargement of the nuclei observed is considered a morphological
hallmark of apoptosis291,292. Similar results were observed in SKOV-3 cells treated
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with complex 6 (20µM) (Figure 51 (B)). Flow cytometry experiments measuring cell
size {forward scatter; and complexity {Figure 51 (C) and (D)} using
tetramethylrhodamine ethyl ester (TMRE) staining confirmed an increase in SKOV3 cell size and complexity {i.e. increased granularity, nuclear condensation and
enlarged nuclear size as shown in Figure 51 (B)}, in comparison to DMSO (0.1%)
treated cells. Taken together these results suggest that both autophagic and apoptotic
pathways are involved in the death of cells treated with complex 6293.

D.3.5.2

Regulation of proteins involved in Autophagy and ROS regulation

Western blot analysis of proteins involved in autophagy, ROS generation, and
mitochondrial damage was carried out to determine if these proteins were regulated by
treatment with complex 6. MelJuSo-UbG76V-YFP cells were treated with complex 6,
[Mn(phen)2]2+ (6.31 – 20 µM), or Bortezomib (50 nM) for 48 hours and total protein
was isolated and resolved by SDS-PAGE

Western blot analysis identified that complex 6 (6.31 – 20 µM) and [Mn(phen)2]2+
(6.31 – 20 µM) suppressed the expression of p62, a protein reported to be readily
degraded upon initiation of autophagy294,295 (Figure 52). p62 is a multifunctional
protein which functions in signal transduction and interacts with ubiquitin and
polyubiquitin chains and delivers ubiquitinated cargo to autophagy and the
proteasome296. Cells treated with complex 6 (6.31, 11.23 and 20 µM) and
[Mn(phen)2]2+ (6.31, 11.23 and 20 µM) were found to increase in HMOX-1 expression,
suggesting an increase in ROS. Interestingly, treatment with [Mn(phen) 2]2+ resulted in
a larger increase in HMOX-1 expression than complex 6, suggesting it may be more
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effective at increasing intracellular ROS levels. In addition, HSP60 expression was
suppressed in cells treated with complex 6 (11.23 – 20 µM) and [Mn (phen)2]2+ (6.31
– 20 µM) at 48 hours.

Figure 51: Treatment of cells with complex 6 causes morphological changes at
cellular level (A) MelJuSo-UbG76V-YFP cells were treated with Complex 6 (20 µM)
for 48 hours (B) SKOV-3 cells treated with complex 6 (20 µM) for 48 hours. Cells
were viewed in an inverted microscope x 200 magnification (C) Flow cytometry was
carried out on SKOV-3 cells treated with (C) DMSO (0.1 %) and (D) 20 µM complex
6 for 48 hours. Data represent results from one experiment.
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HSP60 is a mitochondrial chaperone that is commonly upregulated in cancer cell lines,
orchestrating a cytoprotective pathway via the stabilisation of survivin levels and
suppressing p53297,298. A decrease in HSP60 expression may suggest ROS induced
damage to the mitochondria. DMSO (0.1%) treated cells maintained high expression
of both p62 and HSP60 at 48 hours, but showed no expression of HMOX-1, as
expected. Cells treated with Bortezomib (50 nM), which is active within 24 hours,
were non-viable at 48 hours and therefore no protein expression was observed (Figure
52).

Figure 52: Complex 6 and [Mn(phen)2]2+ suppress expression of proteins involved in
autophagy and mitochondrial damage. Western blot assay was performed on MelJuSoUbG76V-YFP cell extracts treated with 6.31, 11.23 and 20 µM complex 6 and
[Mn(phen)2]2+, and Bortezomib (50 nM) for 48 hr. Antibodies to HSP60, p62, and
Heme Oxygenase 1 (HMOX-1) were utilised in western blot as per the experimental
section. α-Tubulin was used as a loading control. Data represent results from one
experiment.
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D.3.5.3

Mitochondrial depolarisation

As chromatin condensation, a key morphological change associated with apoptosis,
was observed, we investigated the possibility of apoptosis in treated cells. This was
carried out by monitoring changes in mitochondrial transmembrane potential (ΔΨm).
During apoptosis, the pro-apoptotic Bcl-2 family proteins Bax and Bak are activated
and insert into the outer mitochondrial membrane, increasing mitochondrial
permeability. Proteins such as cytochrome C (cyt-C), apoptosis-inducing factor (AIF),
Smac/DIABLO and Omi/HrtA2299–303 are released to form the apoptosome.
Apoptosome formation results in the activation of effector caspases that are
responsible for most of the biochemical and morphological changes during
apoptosis304.

SKOV-3 cells were used in this experiment as MelJuSo-UbG76V-YFP cells contained
fluorescent proteins which would likely interfere with fluorescent measurements.
SKOV-3 cells were treated with complex 6 (20 µM) or 0.1% DMSO for 48 hours.
Depolarisation measurements were obtained using flow cytometry and the fluorogenic
dye TMRE. Using flow cytometry, it was found that complex 6 induced 6.74%
depolarisation (Figure 53) – a marginal value in comparison to values reported
elsewhere (e.g. carbonyl cyanide m-chlorophenyl hydrazine (CCCP), an established
protonophore and known uncoupler of ΔΨm, was found to depolarise 55.3% of the
sample population (SKOV-3 cells)102. Although this experiment was only carried out
once due to time constraints, this result shows that complex 6 does not directly activate
apoptosis as the primary mechanism of cell death to account for the 63% decrease in
cellular viability {Figure 47 (A)}.
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Figure 53: Complex 6 does not depolarise the mitochondrial membrane. SKOV-3
cells were treated with complex 6 (20 µM) (black) or DMSO (0.1 %) (red) for 48
hours. Cells treated with DMSO (0.1%) without TMRE were used as a negative
control. TMRE was measured using flow cytometry. Data represent results from one
experiment.

Although further clarification of the role of autophagy and/or apoptosis in complex 6induced cell death is required, current results are intriguing and are supported by the
current literature. To fully understand the mechanisms at work, additional
investigation is needed. For example, examining the expression of LC3, a protein
directly bound to p62 and involved in autophagic flux, would further support our
hypothesis of autophagy305. Markers of autophagy are available commercially and will
be used to confirm autophagy in future studies. In addition, treatment of cells with
autophagic inhibitors such as 3-methyladenine (3-MA) and/or inducers (rapamycin
and suberoylanilide hydroxamic acid) could also be used to confirm our hypothesis102.
Examination of apoptotic proteins such as p53 and caspases may offer additional
insight.
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D.3.6

Cell cycle analysis

The eukaryotic cell cycle is divided into four distinct phases – mitosis (M), gap 1 (G1),
DNA synthesis (S), and gap 2 (G2). The M phase of the eukaryotic cell cycle
corresponds to mitosis; the period of cell division. This phase is followed by G 1, the
period between mitosis and initiation of DNA replication. It is during this time that
cells are metabolically active and continue to grow without DNA replication occurring.
The S phase follows, during which DNA replication takes place. The completion of
DNA synthesis is followed by the G2 phase, when cells continue to grow and protein
synthesis initiates in preparation for mitosis306.

In order to investigate the toxicity mechanism of complex 6, the effects on SKOV-3
cell cycle phase distribution was examined. Again, SKOV-3 cells were used in this
experiment as MelJuSo-UbG76V-YFP cells contained fluorescent proteins which would
likely interfere with results. SKOV-3 cells were treated with complex 6 (20 µM) or
0.1% DMSO for 48 hours. Cell cycle analysis was conducted using propidium iodide
(PI) to stain DNA. Using flow cytometry, it was found that complex 6 induces a
decrease (8.9%) in the G2/M phase and slight increase within the S (synthesis) phase
(3.4%) when compared to DMSO (0.1%) treated cells {Figure 54 (A) & (B)}. This
may suggest that treatment with complex 6 over 48 hours induces cell cycle arrest in
SKOV-3 cells in S phase and prevents cells progressing to G2/M phase.
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Figure 54: Effects of Complex 6 (20 µM) on SKOV-3 cell cycle after 48 hours
treatment. A) SKOV-3 cells were treated with DMSO (0.1%) and Complex 6 (20 µM)
for 48 hours and cell cycle analysis was performed using PI staining for DNA content.
Flow cytometry was carried out on a Beckman Coulter Gallios flow cytometer and
data was analysed using the FlowJo software (version 10). B) Bar graphs show relative
percent of cells in each phase. The data shown represents two experiments with similar
results.
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D.3.7

The effect of [Mn(fol)(phen)(H2O)].4H2O on 3D spheroids

Multicellular tumour spheroids were formed using SKOV-3 cells as described in
section E.4.4. Cells were treated with 2 – 20 µM complex 6, [Mn(phen)2]2+, and
Bortezomib (17.73 – 100 nM) for 72 hours and examined by time-lapse microscopy
(Figure 54). The spheroid volume was also measured for each treatment and is shown
in Figure 55.

Treatment with complex 6 and [Mn(phen)2]2+ (20 µM) did not result in disaggregation
of spheroids nor change in spheroid volume when compared to the untreated cells
(Figure 55 (A)). Bortezomib-treated spheroids (100 nM) appear to show an increased
spheroid volume in comparison to spheroids treated with Complex 6 and
[Mn(phen)2]2+, however show no disaggregation over the duration of the experiment
(Figure 55 & 56). These results suggest that manganese(II) complexes 6 and
[Mn(phen)2]2+ are ineffective against spheroids. However, it should be noted that as
complex 6 and [Mn(phen)2]2+ require 48 hours to induce an effect in 2D monolayer
systems (Figures 45 and 46), it may be that a longer treatment time is required to see
an effect against spheroids, although experiments were carried out for 72 hours.
However, it is clear from our results that there are different mechanisms of action
between copper(II) and manganese(II) complexes, with copper(II) complexes
affecting 3D models and manganese(II) complexes having no effect after 72 hours.
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Figure 55: Complex 6 and [Mn(phen)2]2+ do not cause disaggregation of SKOV-3
spheroids. (A) SKOV-3 cells treated with 20 µM complex 6 and [Mn(phen)2]2+
examined by time-lapse microscopy. DMSO (0.1%) and Bortezomib (100 nM) were
used as controls. B) SKOV-3 cells treated with 20 µM of Complex 6 and
[Mn(phen)2]2+ for 72 hours. DMSO (0.1%) and Bortezomib (100 nM) were used as
controls. Images taken using an inverted microscope (X40 total magnification).
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Figure 56: Complex 6 and [Mn(phen)2]2+ treatment do not result in disaggregation of
SKOV-3 spheroids. (A) SKOV-3 cells treated with 20 µM complex 6 and
[Mn(phen)2]2+ examined by time-lapse microscopy. DMSO treated cells (0.1%) were
used as a negative control and Bortezomib (100 nM) as a positive control. Spheroid
volume was calculated for each treatment. Data represent one of three independent
experiments with similar results.

D.3.8

Conclusion

This study suggests that complex 2, [Mn(fol)(H2O)3].3H2O, is inactive in the range 3
– 100 µM, whereas the 1,10-phenanthroline derivative, [Mn(fol)(phen)(H2O)].4H2O
(6), showed in vitro activity at ≤ 8 µM within 48 hours against both FR-overexpressing
SKOV-3 cells and FR-underexpressing A549 cells. Folate saturation studies suggest
that complex 6 enters the cell through a mechanism other than by direct uptake through
the folate receptor.

Treatment with complex 6 and [Mn(phen)2]2+ was found to affect expression of
proteins involved in autophagy and mitochondrial damage (p62 and HSP60), while
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also inducing ROS generation, supporting the hypothesis of ROS induced autophagy.
Increased granularity observed in treated cells may indicate formation of
autophagosomes, formed during autophagy, while chromatin condensation may
suggest an additional apoptotic component in the observed cell death. However, a
marker of autophagy is required to confirm the presence of autophagosomes.

The inability of complex 6 to depolarise the mitochondrial membrane of treated cells
may suggest that complex 6 does not activate apoptosis as the primary mode of cell
death. Consequently, it is postulated that the manganese(II) complex 6 induces ROS
generation and potential mitochondrial damage, resulting in a sequential cell death that
involves autophagic and possibly apoptotic pathways. However, the exact sequence
and details of this mechanism remain unclear and warrant further experimental
investigation. Complex 6 was found to be ineffective against 3D tumour spheroids at
20 µM.
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D.4

Conjugates of folic acid with imidazole-phenanthroline derivatives

As well as its ability to act as a ligand in its own right, folic acid can also be conjugated
to small or large biologically active metal complexes through either direct folate
coupling or folate coupling via a spacer to create potentially FR-selective cytotoxic
compounds (Tables 2 and 3). Although not always required, the inclusion of a spacer
allows for effective unhindered binding of the folate moiety to the FR and control over
the lipophilicity of the folate conjugate, which are requirements for cellular
internalization of the entire molecule through endocytosis (Figure 4). It should be
noted that the synthesis, purification and characterisation of metal complex-folate
conjugates are quite often difficult, presenting problems in relation to biomedical
applications. This section describes the attempts to synthesise folate-phen conjugates,
using a range of potential spacer moieties, as potential alternative ligands to the 1,10phenathroline.

D.4.1

The “first generation” targeted folate-imidazole-phenanthroline

ligand and its copper(II) and manganese(II) complexes

The two novel metal-folate complexes [Cu(FIMP-1)2](ClO4)2.2H2O (9) and
[Mn(FIMP-1)3](ClO4)2.2H2O (10) (FIMP-1 = the ‘first generation’ folate-imidazolephenanthroline) were synthesised using the method developed previously by this
group (P. Mc Carron, M. McCann and M. Devereux, unpublished results) (Figure 57).
The FIMP-1 ligand consists of an imidazole-phenanthroline moiety conjugated
directly to folic acid via amide linkage while the metal centre {copper(II) or
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manganese(II)} is coordinated through the chelating phenanthroline moiety (Figure
56).

Figure 57: Structures of [Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-1)3](ClO4)2.2H2O

(10)

Preliminary biological studies were performed on the ‘first generation’ FIMP-1 ligand,
[Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-1)3](ClO4)2.2H2O (10), using the FR-

138

overexpressing cell line, SKOV-3, and the FR-underexpressing cell line, A549, to
explore their FR selective capabilities.

Folic acid and 1,10-phenathroline are the key components of the ‘first generation’
FIMP-1 ligand and exert their own autonomous cell activity. Folic acid is an essential
component in cell culture media due to its role in cell development and in the
conversion of homocysteine to methionine 251 and is therefore not expected to have a
cytotoxic effect on cell lines SKOV-3 and A549. Figure 58 shows that treatment with
folic acid did not significantly affect cell viability; however, some effects could be
seen at higher concentrations (100 μM).

The FIMP-1 ligand contains a 1,10-phenanthroline moiety which is also capable of
coordinating metal ions within cell culture medium. Furthermore, the ligand may also
compete with folic acid for FR binding, in turn preventing the necessary uptake of folic
acid into cells. These actions may account for the cytotoxicity observed in SKOV-3
cells when treated with 50 and 100 μM of the metal-free FIMP ligand, resulting in a
reduction of cell viability by approximately 50% which again appeared to be nonconcentration dependent. However, it was found that the FIMP-1 ligand also exerted
a significant effect on the viability of A549, particularly at the higher concentration of
100 μM.

In contrast, cells treated with 1,10-phenanthroline showed ~50% viability (SKOV-3)
with A549 cells retaining only 20% viability. Furthermore, it was evident that the
cytotoxic effects exerted by 1,10-phenanthroline were concentration independent. It is
believed that 1,10-phenanthroline is capable of chelating metal ions within cell culture
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media (e.g. Cu2+ ions) to generate biologically active species known to be capable of
inducing such cellular damage203,252.

Figure 58: Cell viability following treatment with complexes 9 and 10. A549 (FRunderexpressing) and SKOV-3 (FR-overexpressing) cells were grown to 80%
confluency as described in Section E.9. Cells were treated for 48 hrs with 10, 50 and
100 μM of complexes 9 and 10, FIMP-1 ligand, folic acid and 1,10-phenanthroline.
Cell viability was measured using the Alamar Blue assay. The experiment was
repeated three times and the data shown are Mean ± SD.

A similar result was observed when cells were treated with [Cu(FIMP1)2](ClO4)2.2H2O (9), which caused a greater reduction in the cell population of FRunderexpressing A549 than FR-overexpressing SKOV-3. It may be postulated that the
‘first generation’ FIMP-1 ligand and [Cu(FIMP-1)2](ClO4)2.2H2O (9) can exert a
cytotoxic response through a mechanism other than endocytosis via the FR. However,
further investigation is required.
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Although the activity for [Mn(FIMP-1)3](ClO4)2.2H2O (10) is very similar at 10 µM
concentration in both the FR-overexpressing and FR-underexpressing cell lines
(approximately 50% - equivalent to the EC50 value), significant differences were
observed when the concentration was increased to 50 and 100 μM (with reductions in
viability from 23% to 14% observed in FR-overexpressing cells and from 49% to 45%
in FR-underexpressing cells, respectively). The effects observed in the FR+ve SKOV3 cells may be concentration dependent, unlike the effect observed in A549 cells
treated with [Mn(FIMP-1)3](ClO4)2.2H2O (10) which reduced all viability to ~50%,
regardless of concentration. Although preliminary results suggest that the Mn(II)
complex [Mn(FIMP-1)3](ClO4)2.2H2O (10) effect may be mediated via the FR, work
is required to further elucidate both the cytotoxicity and cytoselectivity of this
complex.

The solubilities of [Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-1)3](ClO4)2.2H2O
(10) were a particular issue in their biological assessments but the results obtained
were encouraging and prompted the pursuit of more appropriate complexes
incorporating ligands similar to this “first generation” FIMP-1 molecule.

D.4.2

The synthesis of novel “second generation” functionalised folate-

imidazole-phenanthroline (FIMP) ligands

Building on the observed preliminary results for the “first generation” FIMP-1 ligand
and its copper(II) and manganese(II) complexes, the synthesis of a series of three novel
“second generation” FIMP ligands was undertaken. All three novel second generation
FIMP-2 ligands differ from the ‘first generation’ analogue in that they contain a linker
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intended to increase the distance between the targeted folate group and the metalbinding IMP moiety in the molecules (Figure 59). To achieve this, three different types
of linkers were chosen: (1) the first contains an ethylenediamine linker intended to
simply reduce steric hindrance; (2) the second contains an ethereal oxygen chain to
improve water solubility; and (3) the third possesses a disulphide bond which can be
cleaved within the cell to release the cytotoxic cargo. A brief summary of the synthetic
steps required are listed in Table 9 and a proposed synthetic route to the ‘second
generation’ FIMP-2 ligands is shown in Scheme 5.

Figure 59: The structures of the ‘first generation’ FIMP-1 ligand and the proposed
‘second generation’ FIMP-2 ligands (functionalised linkers highlighted in red). (A)
ethylenediamine linker (B) ethereal oxygen linker (C) disulphide bond.
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Table 9: A summary of the synthetic steps undertaken for the attempted synthesis of
the novel ‘second generation’ functionalised folate-imidazole-phenanthroline (FIMP2) ligands.
Step
Step 1
Step 2

Synthetic Steps
Synthesis of 1,10-phenanthroline-5,6-dione.
Synthesis of four imidazo-phenanthroline ligands
(IMPs).

Step 3

N-Boc protection of three diamine functional
linkers.

Step 4a
Step 4b

Conjugation of N-boc-diamine linkers to folic acid.
Conjugation of N-boc-diamine linkers to IMPCOOH.

Step 5

Deprotection of N-boc-ethylenediamine-IMP

Step 6

Conjugation of folic acid and ethylenediamine-IMP
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Scheme 5: A simplified schematic of the proposed synthesis of the novel functionalised FIMP-2 ligand A (based on similar synthetic
procedures from the literature). The synthesis of FIMP-2 ligands B and C were attempted using a similar approach.
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D.4.3

Synthesis of 1,10-phenanthroline-5,6-dione {Step 1}

Until recently, 1,10-phenanthroline-5,6-dione (phendione) was synthesised under
severe conditions, involving reflux of 1,10-phenanthroline with an excess of potassium
bromide in a mixture of concentrated sulfuric acid and nitric acid307. Although initial
yields were promising (86%), attempts to scale up resulted in a sharp decrease in
product yield308,309.

In 2010, Zheng et al reported the novel synthetic method which involved the room
temperature reaction of 1,10-phenanthroline and potassium bromate in a 60% sulfuric
acid solution on a 20 gram scale310. Phendione was recovered in high yield (90%) and
pure form. As phendione is essentially used as a starting material in the synthesis of
the FIMP-1 and FIMP-2 ligands, the ability to work on a large scale, and obtain a high
yielding, high purity product was imperative. Consequently, using the synthetic
method described by Zheng et al, phendione (11) was obtained as yellow crystalline
needles in high yield (83%) and pure form. The synthetic route to phendione (11) is
presented in Scheme 6.

Scheme 6: The synthetic route to 1,10-phenanthroline-5,6-dione (11)
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Phendione (11) was characterised using IR and NMR spectroscopy. The 1HNMR
spectrum of 11 (Appendix 8) shows three distinct doublets of doublets (dd) peaks in
the aromatic region at 7.57, 8.48 and 9.10 ppm respectively. These three peaks
correspond to the six protons present on the symmetrical molecule (Figure 60). The
peaks representing H1 are located furthest downfield as H1 is deshielded by the
neighbouring nitrogen atoms. The peaks corresponding to H2 are furthest upfield at
7.57 ppm due to the shielding effects of H1 and H3. Finally, the peaks corresponding
to H3 are positioned at 8.48 ppm. The IR spectrum of 11 (Appendix 8) contains
characteristic peaks at 817 cm-1 and 740 cm-1 due to C-H bending.

Figure 60: 1,10-phenanthroline-5,6-dione (11) illustrating numbering scheme for 1HNMR analysis.

D.4.4

Synthesis of imidazo-phenanthrolines (IMP) {Step 2}

A key step in the synthesis of the first and second generation FIMP ligands is the
synthesis of the imidazo-phenanthroline precursors IMP-NO2 (12) and IMP-COOH
(13), respectively (Figure 61).
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Figure 61: Structures of IMP ligands (12 - 15)

The reported synthesis of 12 and 13 is dependent on the acid catalysed reaction of
1,10-phenanthroline-5,6-dione (11) with excess ammonium acetate to provide a stable
1,10-phenanthroline-5,6-di-imine intermediate. This subsequently reacts with the
desired aldehyde to undergo an aldol-type condensation reaction, forming a second,
unstable intermediate. Finally, a two hydrogen shift resulting in the loss of a water
molecule causes the formation of the final imidazo-phenanthroline conjugate311
(Scheme 7). This method requires extended reflux times and leads to low-to-moderate
yields311,312.
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Scheme 7: The mechanism illustrating the formation of the imidazole-phenanthroline
ligand (modified from Steck et al)311

To improve the overall outcome for the synthesis of this class of IMP compound it was
decided to explore the use of microwave technology. To test the suitability of this
novel approach, imidazole-phenanthroline-phenyl {IMP-phenyl (14)} was first
synthesised as shown in Scheme 8. This reaction was very successful, indicated by a
product in high yield (87%) and with excellent purity. The method was subsequently
applied to the syntheses of the IMP-NO2 (12) and IMP-COOH (13), which are required
for the synthesis/attempted synthesis of the first and second generation FIMP ligands.
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The microwave synthetic method deployed is novel, resulting in an accelerated
reaction time, reducing the previously reported 3 hour reflux 311,312 to a fifteen minute
reaction. Furthermore, the products were obtained with minimal work up in very high
yield and excellent purity. This improvement is attributed to the “superheating” which
can occur at ambient pressure through the high efficiency conversion of microwave
radiation to heat.

Scheme 8: Synthetic route to IMP ligands 12 - 14. (R = H, COOH, NO2)

IMP-COOH (13) is required for the attempted synthesis of the three novel “second
generation” functionalised FIMP ligands, in which the COOH group is used to form
an amide bond with an unprotected NH2 group of a diamine linker. The IMP-NO2 (12)
is the precursor of IMP-NH2 (15) (Figure 61) which is required to produce the “first
generation” FIMP-1 ligand via amide bond formation between the amine functionality
of 15 and the COOH group of folic acid. The conversion of IMP-NO2 (12) into IMPNH2 (15) is via a hydrogenation reaction, involving a 10% palladium/carbon catalyst
and hydrazine monohydrate as the hydrogen source. The synthetic route is shown in
Scheme 9.
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Scheme 9: Synthetic route for IMP-NH2 (15).

Table 10 presents the full 1H NMR data for compounds 12 - 15. The R-groups (Figure
62) differ in their electron donating and electron withdrawing properties. As a result,
the protons that show the most significant change in chemical shift are located on the
phenyl ring. Both the NO2 and COOH groups are electron withdrawing and draw
electron density away from nearby protons; in turn, deshielding protons on the phenyl
ring result in a downfield chemical shift. The electron donating NH2 group of 15 has
lone pairs adjacent to the phenyl ring which increase the electron density on the ring,
leading to an upfield shift of the phenyl protons. In all 1HNMR spectra, the chemical
shifts of protons on the nitrogen atom present on the imidazole ring were not observed.
This may be because the protons are highly active and readily exchangeable between
the two nitrogens of the imidazole ring in solution313,314.
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Figure 62: IMP-R ligand illustrating numbering scheme for 1H-NMR analysis.
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Table 10: 1HNMR resonances for IMP-R ligands with various functional groups carried out in DMSO-d6. The integration and peak
splitting are shown in brackets.
12
Proton

13

14

Proton
(ppm)

Proton
(ppm)

15
Proton

(ppm)

(ppm)

H1 & H11

9.00 (d, 2H)

H1 & H11

8.91 (d, 2H)

H1 & H11

9.00 (d, 2H)

H1 & H11

8.99 (d, 2H)

H3 & H9

8.81 (d, 2H)

H3 & H9

8.90 (d, 2H)

H3 & H9

8.89 (d, 2H)

H3 & H9

8.89 (d, 2H)

8.40 (m, 4H)

H6 & H7

8.42 (d, 2H)

H2 & H10

8.27 (d, 2H)

H5 & H8

7.98 (d, 2H)

H5 & H8

8.33 (d, 2H)

H5 & H8

7.79 (d, 2H)

H2 & H10

7.82 (d, 2H)

H6 & H7

7.59 (d, 2H)

H6 & H7

6.74 (d, 2H)

H2 & H10

7.76 (dd, 2H)
H9

7.50 (t, 1H)

NH2

5.63 (s, 2H)

H5 & H6
H7 & H8

H2 & H10

7.79 (d, 2H)
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D.4.5

The N-Boc protection of diamine linkers {Step 3}

Di-tert-butyl dicarbonate (Boc) is a commonly used protecting group used in organic
synthesis315,316. The general route for N-Boc protection of diamines is shown in
Scheme 10. The diamines ethylenediamine and 2,2′-(ethylenedioxy)bis(ethylamine)
were N-Boc-protected in a similar fashion, following methods previously published to
produce 16 and 17, respectively (Figure 63). A ten-fold excess of the diamine was
reacted against Boc to reduce di-Boc product formation. Reactions were clean and
high-yielding (> 88%), producing a stable colourless oil. The N-Boc protection of
cystamine (18) (Figure 63) proved slightly less advantageous, producing a product in
moderate yield (approx. 40%). Published data are quite similar, with yields of 43-45%
obtained317–319.

This particular synthetic step proved to be a key limiting factor in the overall synthesis
of FIMP-2 ligands. The excess of diamine required proved problematic (particularly
in the case of compounds 17 and 18) and attempts to reduce the ratio of Boc:diamine
resulted in the increased formation of the undesirable di-Boc protected products and a
decrease in N-boc-protected diamines. Furthermore, attempts to scale-up reactions
resulted in reduced product yields. These limitations resulted in a knock-on effect
throughout the synthesis of FIMP-2 ligands, particularly those incorporating the 2,2′(ethylenedioxy)bis(ethylamine) and the cystamine as linkers.
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Figure 63: N-Boc protected diamines 16 - 18.

Scheme 10: The N-Boc protection of diamines where R = (CH2)2NH2,
(CH2)2O(CH2)2O(CH2)2NH2 and (CH2)2SS(CH2)2NH2320

N-Boc diamines 16 - 18 were characterised primarily by NMR (1HNMR and 13CNMR)
and mass spectrometry. In 1HNMR spectra, the shielded Boc group, consisting of three
methyl branches, is the furthest upfield in all spectra, appearing from 1.08 – 1.47 ppm
respectively (Table 11). In the spectrum of 17, the singlet peak representing the
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unprotected NH2 appears to merge with that of the Boc group, increasing integration
from nine to eleven. In 1HNMR spectra of 16 and 18 (Appendices 12 and 14), the NH2
peak can be observed as a singlet at 1.22 ppm and 1.49 ppm. In all N-Boc protected
diamines, the NH group is observed as a singlet between 5.39 and 5.84 ppm,
respectively. The remaining peaks are associated with the aliphatic CH 2 groups.
Similar results have been published elsewhere 316,318,321.

Table 11: 1HNMR resonances for N-Boc protected diamines 16 - 18. The integration
and peak splitting are shown in brackets.
Chemical Shifts (ppm)
Compound
Boc group

NH

NH2

CH2 groups
3.07 (d, 2H)

16

1.36 (s, 9H)

5.84 (s, 1H)

1.22 (s, 2H)

2.70 (d, 2H)

3.37 (s, 4H)
*Peak hidden
3.27 (dd, 4H)
17

1.19 (s, 11H)*

5.39 (s, 1H)

under Boc peak
3.04 (d, 2H)
at 1.19 ppm
2.61 (t, 2H)
3.43 (d, 2H)

18

1.44 (s, 9H)

5.57 (s, 1H)

1.49 (s, 2H)

3.00 (t, 2H)
2.78 (dd, 4H)
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D.4.6

Conjugation of N-Boc-diamine linkers with folic acid {Step 4 (a)}

The conjugation of N-Boc protected diamine(s) 16 - 18 with folic acid was undertaken
with a view to generating compounds 19 - 21 (Figure 64). The method described by
Trindade et al is the basis for the folate-amine conjugation used in this project (Scheme
11)322. This involves the generation of an activated-folate ester via Nhydroxysuccinimide (NHS) and the coupling agent, N,N’-dicyclohexylcarbodiimide
(DCC). The newly formed activated ester cleanly reacts with amines under mild
conditions allowing for simple amide formation. The by-product of the DCC mediated
coupling, dicyclohexylurea (DCU) is highly insoluble in all organic solvents, allowing
for easy removal via filtration.

In the same paper, Trindade et al reported that only γ conjugates have medicinal
relevance due to their higher affinity towards the FR 322. Within the FR structure, the
glutamate residue is stabilized by six hydrogen bonds, four of which interact with the
α carboxylic acid. Therefore, it is apparent that only γ folate conjugates may retain the
fully effective affinity toward the receptor, 322 although this is a controversial subject
in the literature. Previous publications have proven that γ conjugates are inherently
obtained as the major product (from 55 to 90% selectivity) 62,172,322–325 using
carbodiimide chemistry. Furthermore, the markedly different pKa values of the
carboxylate groups contribute to their different reactivities 25,326.
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Figure 64: The proposed structures of N-Boc amine-folate conjugates 19 – 21
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Scheme 11: The conjugation of N-Boc protected diamine(s) to folic acid322.

The primary methods used to elucidate the structures of folate conjugates 19 - 21
(Figure 65) were mass spectrometry and NMR spectroscopy (1HNMR and 13CNMR).
However, characterisation did prove difficult due to the poor solubility of compounds
(hot DMF and hot DMSO only); and the presence of broad solvent peaks in the NMR
spectra.
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In order to determine if conjugation was successful, 1HNMR spectra were analysed to
identify peaks associated with folic acid as well as the characteristic peak associated
with the Boc protection group. In all spectra (Appendices 15 - 17), peaks related to
methylene groups of the diamine linkers were observed but could not be adequately
integrated due to distortion by the broad solvent peaks at 2.50 and 3.30 ppm 327. Peaks
corresponding to aromatic CH groups (Figure 65: H1, H4, and H5) and NH groups
appeared within the region of 6 – 9 ppm. The peaks corresponding to the hydrogen
bound to a carbonyl carbon (H7; Figure 65) was typically observed at 4.35 ppm, while
its neighbouring peak at 4.50 ppm was identified as a CH2 (H2). Two aliphatic
methylene groups (H8 and H9; Figure 65) appeared as three peaks between 1.90 – 2.30
ppm respectively. The peak which corresponds to H8 appears to be split into two, due
to the neighbouring hydrogen bound to the carbonyl carbon. Finally, the large peak at
approximately 1.35 ppm relates to the Boc protection group (H12).

Figure 65: N-Boc-amine-folate conjugate illustrating numbering scheme for 1H-NMR
analysis.

Mass spectra were also recorded for compounds 19 - 21 in addition to NMR
spectroscopy (Table 12). Results for both 19 and 20 were as expected and complement
structural data determined through NMR analysis. However, the data derived through
mass spectrometric analysis of compound 21 do not support the structure assumed on
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the basis of the NMR analysis, instead pointing towards a molecule in which two NBoc cystamine linkers were conjugated to folic acid (Figure 66). In 2011, Omran et al
published a paper detailing the synthesis of a folate-prodrug of cystamine in which the
final product contained two cystamine chains bound to both the α and γ carboxylate
groups of folic acid. The 1HNMR results published by the group are similar to those
obtained in this project, however, no mass spectrometric data were presented in their
paper328. Further investigation is required to understand how and why the α
carboxylate group is involved in this reaction. This problem coupled with the relatively
poor solubility of compounds 19 and 20 (leading to difficulties in their
characterisation) presented as significant problems for this approach to synthesising
the FIMP-2-type ligands and it was decided to approach the challenge from a different
direction.

Table 12: Mass spectrometry results of folate-amine conjugates 19 - 21
Folate-Amine Conjugate

[M+H]+ Calc

[M+H]+ Found

19

584.2576

584.2601

20

672.3100

672.3098

21

676.2336

910.3257

160

Figure 66: The possible structure of 21 reported by Omran et al328 and supported by
mass spectrometric data from the current study.

D.4.7

Conjugation of N-Boc-diamines linkers with IMP-COOH {Step 4

(b)}

Given the problematic solubility of the folate-amine conjugates 19 and 20 and the
potential amide formation at both α and γ carboxylate groups encountered with the
synthesis of 21, it was decided to approach the generation of the FIMP-2 ligands
differently. The N-Boc protected diamines were reacted with IMP-COOH to produce
the alternative diamine-IMP conjugated compounds 22 - 24 (Figure 67).

The synthetic path to compounds 22 - 24 is shown in Scheme 12. It has been reported
that activated esters such as aromatic esters are usually easier to hydrolyse than alkyl
esters and that they are prone to react with a wide range of nucleophiles due to the
increased electrophilicity of the carbonyl centre. However, all attempts to activate
IMP-COOH (13) via the DCC/NHS method described in Scheme 11 were
unsuccessful. This may be due to the undesirable formation of the unreactive N161

acylurea. To correct this issue, the fast reacting nucleophile, hydroxybenzotriazole
(HOBt), was added (Scheme 12). HOBt reduced this side reaction by reacting faster
than competing acyl transfers and generating an active intermediate capable of
coupling with the amine329. The protocol was adjusted further by replacing the
coupling agent DCC with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and
ensuring its addition was performed at 0 oC (Scheme 13).

Using this method, the N-boc-ethylenediamine-IMP (22) was isolated in high yield,
while both the N-boc-(ethylenedioxy)bis(ethylamine)-IMP (23) and the N-boccystamine-IMP (24) were only recovered in low to moderate yield. Table 13 presents
the resonances and shifts of 22 - 24 and the relevant proton numbering scheme is
shown in Figure 68. The peaks showing the greatest downfield shift correspond to H1
in all compounds, appearing at 9.04 – 9.02 ppm; this is due to the deshielding
properties of the adjacent nitrogen atoms. H6 in all conjugates are neighbours to a
carbonyl carbon which again has a deshielding effect, forcing the peaks corresponding
to H6 downfield to 8.92 ppm respectively. H7 and H8 represent NH groups; H8 is bound
to an ester functional group and is forced further downfield because of this. H7 exhibits
a similar effect although to a lesser extent. H2 as well as H5 exhibit little or no
deshielding and sit in the aromatic region of 7.80 – 8.08 ppm. H9 are situated on the
Boc protection group and appear in spectra as a singlet at 1.35 to 1.39 ppm. Methylene
groups along the alkyl chains of the diamine linkers appear within the region of 2.80
– 3.40 ppm, although the methylene groups of compound 23 experience greater
deshielding due to the ethereal oxygens present in the chain. Mass spectrometric
results are in agreement with structures elucidated through the NMR analysis.
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Figure 67: Structure of the N-Boc protected diamine-IMP conjugates 22 – 24.
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Scheme 12: Synthetic route to the N-Boc protected diamine-IMP conjugates 22 – 24.
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Scheme 13: Use of HOBt to minimise the formation of unreactive N-acylurea329.

Figure 68: N-Boc diamine-IMP conjugate illustrating numbering scheme for 1H-NMR
analysis.
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Table 13: 1HNMR resonances for compounds 22 - 24, carried out in DMSO-d6. The
integration and peak splitting are shown in brackets.
Proton

22 (ppm)

Proton

23 (ppm)

Proton

24 (ppm)

H1

9.04 (dd,2H)

H1

9.02 (d, 2H)

H1

9.02 (d, 2H)

H6

8.91 (d, 2H)

H6

8.92 (d, 2H)

8.92 (dd,
H6
2H)
H8

8.60 (s, 1H)

H8

8.81 (s, 1H)

H8

8.67 (s, 1H)

H3

8.34 (d, 2H)

H3

8.35 (d, 2H)

H3

8.35 (d, 2H)

H5

8.05 (d, 2H)

H5

8.07 (d, 2H)

H5

8.08 (d, 2H)

H2

7.83 (d, 2H)

7.87 – 7.78

7.83 (dd,
H2

H2
2H)

(m, 2H)

H7

6.97 (s, 1H)

H7

6.99 (s, 1H)

H7

6.74 (s, 1H)

H4

4.11 (s, 1H)

H4

-

H4

-

3.61 (dd,2H)
Methylene
groups

Methylene 3.24 (dd, 2H) Methylene
3.16 (d, 4H)

groups

2.96 (t, 2H)

groups

2.80 (t, 2H)

H9

D.4.8

1.39 (s, 9H)

H9

1.37 (s, 9H)

3.40 – 3.27
(m, 10H)
3.07 (d, 2H)

H9

1.35 (s, 9H)

Deprotection of N-Boc ethylenediamine-IMP {Stage 5}

As previously mentioned in section D.4.5, the problem of low yield when undertaking
the N-Boc protection of the diamines 2,2′-(ethylenedioxy)bis(ethylamine) and
cystamine to form compounds 17 and 18 proved to be a key limiting factor in achieving
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the synthesis of their corresponding FIMP-2 ligands. Furthermore, subsequent
difficulties experienced when attempting to conjugate 17 and 18 with folic acid further
compromised progression towards the end-state FIMP-2 compounds (see section
D.4.6) and unfortunately consumed scarce supplies of both of these N-Boc protected
compounds. The limited quantities of 17 and 18 that remained could only be used to
synthesise enough of the novel N-Boc-(ethylenedioxy)bis(ethylamine)-IMP (23) and
the novel N-Boc-cystamine-IMP (24) compounds for their characterisation. The
synthesis of N-Boc-ethylenediamine (16), on the other hand, was much more
successful enabling access to the N-Boc-ethylenediamine-IMP (22) in high enough
yield to facilitate its deprotection and subsequently conjugation with folic acid to yield
the final ‘second generation’ folate-ethylenediamine-IMP (FIMP-et) ligand.

N-Boc-ethylenediamine-IMP (22) was deprotected to yield the relatively soluble
compound 25 (Figure 69). This involved the deprotonation of the Boc group with
trifluoroacetic acid (TFA), resulting in the loss of the tert-butyl cation (this will either
be deprotonated to form isobutylene gas, or it will polymerize to form isobutylene
oligomers). The remaining carbamic acid is quickly decarboxylated to produce a free
amine. In the presence of excess TFA, the product may be present as a TFA salt which
can be neutralised with a base such as triethylamine to give the free amine as a stable
product (Scheme 14)320.
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Figure 69: The structure of N-Boc Ethylenediamine-IMP (25)

Scheme 14: The Boc deprotection of an amine

Analysis of the 1HNMR spectrum of 25 (Appendix 22) indicates the successful
removal of the N-Boc protection group which is typically observed as a singlet at 1.35
ppm. Peaks in the aromatic region of 7 – 9 ppm represent CH groups present in the
phenanthroline and benzene ring of the compound. A singlet at 8.25 represents the NH
group involved in the amide bond between IMP-COOH and ethylenediamine. As
discussed previously, a peak representing the imidazole proton is not observed due to
its tendency to readily exchange between the two nitrogens of the imidazole ring in
solution313. Peaks which represent the methylene groups of ethylenediamine can be
observed at 3.22 and 3.60 ppm. Mass spectrometric data confirms the proposed
structure of 25 depicted in Figure 69.
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D.4.9

Conjugation of ethylenediamine-IMP with folic acid {Stage 6}

The final step of this FIMP-2 ligand synthesis involved the conjugation of
ethylenediamine-IMP (25) with folic acid to attempt the generation of the novel γconjugate of the FIMP-ethylenediamine ligand (26) (FIMP-et; Figure 70). The
conjugation was undertaken using the method described by Trindade et al (Scheme
15) and involves the generation of an activated-folate ester via N-hydroxysuccinimide
(NHS) and the coupling agent, N,N’-dicyclohexylcarbodiimide (DCC) as described in
Section D.4.6322. Compound 26 was obtained as a yellow powder in good yield (>
70%) and it was soluble only in warm DMSO and warm DMF.

Scheme 15: The amide conjugation of imidazole-phenanthroline-ethylenediamine and
acid322.

The conjugation of ethylenediamine-IMP (25) with folic acid to generate the novel
FIMP-ethylenediamine ligand (26) has the potential to yield three possible isomers
(Figure 70). The current literature suggests that γ conjugates (Figure 70) are inherently
obtained as the major product (from 55 to 90% selectivity) of folate-based
carbodiimide conjugations, based on results obtained from reverse phase high pressure
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liquid chromatography (RP-HPLC)62,172,322–325. Furthermore, Trindade et al reported
that folic acid was conjugated with N‐Boc-ethylenediamine almost exclusively at the
terminal γ carboxylic acid as confirmed by RP‐HPLC (95% selectivity) 322. Similar
results have been reported elsewhere 330,331. It has also been suggested that this may be
due to hydrogen bonding of the α-carboxylic group to the neighbouring amide group,
resulting in limited access to bulky conjugates to the α-position332.

To throw light on the isomeric from of compound 26 it was analysed using infrared
spectroscopy, mass spectrometry, NMR spectroscopy (1HNMR and
reverse phase high pressure liquid chromatography (RP-HPLC).

Figure 70: Possible isomeric structures of FIMP-et (26)
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13

CNMR) and

The relevant proton numbering scheme of compound 26 is shown in Figure 71 and the
1

H NMR spectrum is shown in Figure 72. Due to poor solubility, NMR spectra were

obtained using 24000 scans. Additionally, a water-suppression protocol was
implemented to remove the broad water peak at 3.33 ppm associated with d 6-DMSO
which can be seen in Appendix 24.

The 1HNMR (Figure 72 and Appendix 24) and 13CNMR (Appendix 24) spectra of 26
were analysed to identify peaks associated with folic acid as well as the characteristic
peaks associated with the imidazole phenanthroline moiety. Peaks corresponding to
the aromatic CH groups of folic acid were observed at 6.66 and 7.70 ppm (H6 & H7;
para-aminobenzoic acid; Figure 70) and 8.67 ppm (H3) while peaks related to the
amide NH groups in folic acid (H5 & H8) were observed at 6.89 and 8.34 ppm. Peaks
corresponding to H4 and H9 were found at 4.36 – 4.56 ppm. The peaks which
correspond to the aromatic CH groups of imidazole-phenanthroline were observed at
7.83, 8.34, 8.92, and 9.03 (H17, H19, H18, H16 and H20; benzoic acid and
phenanthroline). Additionally, peaks relating to methylene groups of glutamic acid and
ethylenediamine were found in the aliphatic region of 1.90 – 2.95 ppm. The presence
of the methylene groups was further supported by the 13C NMR DEPT 135 spectrum
(Appendix 24). A small broad peak at 11.5 ppm indicated the presence of a free
carboxyl OH group. Additional spectral evidence of successful conjugation was found
in the IR spectrum of 26 where prominent peaks corresponding to C=O groups (1604
and 1641 cm-1) of folic acid and C-H bending of phenanthroline (740 and 836 cm-1)
were observed.
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Figure 71: FIMP-et ligand 26 illustrating numbering scheme for 1H-NMR analysis.

Figure 72: 1HNMR spectra of 26

Mass spectrometric analysis was also performed on 26 in addition to NMR and IR
spectroscopy. The mass spectrum of 26 (Appendix 23) contains a [M+H]+ peak at
806.29 (expected m/z 806.28) in low abundance (10% approximately). A peak at
776.27 m/z may be due to α-cleavage of the α-carboxyl group (m/z 776.31). It has
previously been reported that folic acid fragments readily to release the glutamate tail,
resulting in a peak at m/z 295 [M+H-Glu]+333. A similar trend is observed in the mass
spectrum of 26 where a peak at 295.10 m/z is observed, which may correspond to
[M+H– C27H26N7O2]. A subsequent peak at 416.10 m/z may correspond to this
fragment with solvent adducts [M – C27H26N7O2 + DMSO + acetonitrile + H]+ (m/z
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416.15). The remaining fragment (Glu-et-IMP) may correspond to the peak at m/z
465.16 ([M+H–C14H12N7O2]; m/z 465.20). The peak with highest abundance (m/z
585.71) may relate to [M – C14H12N7O2 + DMSO + acetonitrile + H]+ (m/z 585.71),
indicating solvent adducts.

In an attempt to establish the purity of 26, RP-HPLC was performed using a Waters
2998 HPLC and Photodiode Array Detector using a Poroshell 120, EC-C8 column. A
gradient solvent system of 95% TFA/water (solvent A) and 5% TFA/acetonitrile
(solvent B) to 100% TFA/acetonitrile was used. However, various mobile phases were
trialled but were found to be inappropriate due to elution capabilities and poor
solubility of compound 26, these included: pet ether/ethyl acetate/acetone (82:18:1),
water/acetonitrile (1:1), methanol/acetonitrile (1:1), ethanol:acetonitrile (1:1), 0.1%
TFA in water and 0.1% TFA in acetonitrile). A similar gradient solvent system
including TFA/H2O and TFA/ACN has been used successfully to separate folateconjugates previously172,181. An initial elution timeframe of 20 minutes was used
without success, with only the DMSO solvent peak observed {elution time: 2 min; 2.6
absorption units (AU)}. Upon extension of the runtime to 45 min, a very small peak
with low absorbance could be seen (elution time 33 minutes; 0.5 AU) (Figure 73). It
would appear that compound 26 is a highly non-polar molecule which may be
adsorbed onto the C-18 column. However, it is noteworthy that no impurities such as
unreacted folic acid were observed in the chromatogram. Furthermore, given the
presence of a peak at 11.5 ppm in the 1H NMR spectrum of 26 which indicates the
presence a free OH group (COOH functionality) and the relatively good C,H and N
elemental analysis values (available in section E.3.8.), it is believed that the γconjugate of the FIMP-et ligand has been obtained with good purity.
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Figure 73: The chromatogram of compound 26

D.4.10

Copper(II) and manganese(II) complexes incorporating the novel

second generation FIMP-ethylenediamine ligand

The FIMP-ethylenediamine ligand (FIMP-et) (26) reacted with Cu(ClO4)2.6H2O and
Mn(ClO4)2.6H2O to yield complexes 27 and 28, respectively. The synthetic route to
the FIMP-et complexes 27 and 28 is shown in Scheme 16. The complexes were
obtained as green/brown (27) and yellow (28) powders, were soluble in DMSO and
DMF, and they formulated on the basis of elemental analysis (Table 14) as [Cu(FIMPet)2(H2O)2].(ClO4)2.4.5H2O (27) [Mn(FIMP-et)3].(ClO4)2.9H2O (28), respectively.

Scheme 16: The synthetic route for complexes 27 and 28

The IR spectra for the FIMP-et ligand and complexes 27 – 28 are shown in and
Appendix 25. Complexes 27 and 28 have very similar spectra which reflect similar
structural characteristics for the two complexes. As well as the expected features
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associated with the FIMP-et ligand the spectra of the two complexes both have strong
broad peaks at 1084 – 1100 cm-1 characteristic of the presence of the perchlorate
anions229. Both complexes exhibit similar UV-Vis spectra (Appendix 25), with
absorbance bands from 254 – 258, 330 – 335, and 400 - 402 nm, respectively. In
comparison to the UV-Vis spectrum of the free FIMP-et ligand (26) which contains a
small shoulder at 272 nm, the UV-Vis spectra of complexes 27 and 28 contain much
more pronounced peaks from 254 – 258 nm which may suggest coordination to the
phenanthroline moiety of FIMP-et (Appendix 25). Structures that fit the physicochemical data for complexes 27 and 28 are shown in Figure 74 and they are believed
to have structures similar to those of their FIMP-1 analogues (Figure 57).

Table 14: The formulation, yields and elemental analytical data for complexes 27 and
28.
Mw

Yield

(g/mol)

(%)

1991.2

75

Found (Calc) %

Complex

[Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O
(27)

[Mn(FIMP-et)3].(ClO4)2.9H2O (28)

2833.8
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C

H

N

M

49.14

3.78

18.23

4.16

(49.46)

(4.20)

(17.73)

(3.39)

52.52

3.98

19.47

1.00

(52.14)

(4.38)

(19.28)

(1.94)

77

Figure 74: The proposed structures of complex 27 and 28

Attempts were also made to generate mixed-ligand complexes containing FIMP-et and
1,10-phenanthroline (proposed structure shown in Figure 75). Following a method
previously reported for similar mixed-ligand reactions copper(II) perchlorate,
phenanthroline, and FIMP-et (ratio of 1:1:1) were reacted in one-pot334,335. This
approach yielded only impure [Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O (27) as a
precipitate along with [Cu(phen)2].(ClO4)2 which was isolated from the filtrate. A
similar outcome was achieved for the manganese reaction.
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Figure 75: The intended structure of the mixed FIMP-et/phen metal complexes.

D.4.10

Conclusion

To date, one of three novel “second generation” FIMP-2 ligands (Figure 63) has been
successfully synthesised and characterised. For all ligands, stages 1 and 2 proceeded
without difficulties. Stage 3 proved to be a limiting step in the overall synthesis, due
to large ratios required and poor scalability, particularly regarding N-Boc-2,2′(ethylenedioxy)bis(ethylamine) (17) and N-Boc-cystamine (18). Issues regarding
conjugation of N-Boc-diamines with folic acid, experienced in Stage 4(a), were
overcome through the conjugation of the N-boc diamine linkers with IMP-COOH
{Stage 4(b)}, thus allowing for the isolation of all three desired compounds and better
solubility with easier characterisation. However, due to issues encountered in stage 3
and 4(a), only small quantities of N-Boc-2,2′-(ethylenedioxy)bis(ethylamine)-IMP
(23) and N-Boc-cystamine-IMP (24) could be synthesised and characterised but could
not be further deprotected or conjugated to folic acid. Nonetheless, the N-Bocethylenediamine-IMP product 22 was successfully deprotected to generate the
corresponding ethylenediamine-IMP derivative 25 {Stage 5} and subsequently
conjugated to folic acid using the DCC/NHS method to produce the novel “second
generation” FIMP-et ligand 26 {Stage 6}. The reaction of the FIMP-et ligand (26) with
copper(II) and manganese(II) perchlorate yielded the novel mononuclear complexes
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[Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O (27) and [Mn(FIMP-et)3].(ClO4)2.9H2O (28) in
good yield (> 75%). Attempts to generate mononuclear mixed phenanthroline complex
{[M(FIMP)(phen)x] (M= Cu2+ and Mn2+)} via a reaction between metal(II)
perchlorate, 1,10-phenanthroline, and (26) (1:1:1) yielded only an impure metal-FIMP
complex and [M2+(phen)X](ClO4)2.
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CONCLUSION & FUTURE
PERSPECTIVES
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C.1

Conclusion

This work focused on interdisciplinary research in chemistry and biology with a view
to generating novel folate complexes with 1,10-phenanthroline ligation and novel
folate-phenanthroline conjugates and to elucidate their targeting capabilities and
mechanisms of action in-vitro. The synthesis work in this thesis, particularly in
generating the FIMP-2 was complex and challenging. However, despite the difficulties
encountered, the work resulted in the generation of one novel second generation FIMP2 ligand, two novel metal complexes with FIMP-2 ligation and eight novel simple
metal-folate complexes. Subsequent biological testing could be performed on four of
the simple metal folate complexes generated in this project, in addition to some basic
cytotoxicity studies performed on first generation FIMP-1 complexes.

All attempts to generate a series of simple binuclear metal folate complexes (where M
= Cu2+, Mn2+, Fe3+, and Zn2+), using methods previously published, did not yield the
expected products. Instead the di-sodium salt of folic acid reacted with the relevant
metal chlorides to yield the novel mononuclear complexes [Cu(fol)(H2O)3].H2O (1),
[Mn(fol)(H2O)3].3H2O (2), [Fe(fol)(H2O)2(Cl)].4H2O (3) and [Zn(fol)(H2O)3].3H2O
(4). Complexes 1 – 4 (Figure 28) were characterised using IR, solid-state UV
spectroscopy, thermogravimetric analysis, magnetic susceptibility measurements and
elemental analysis. 13C NMR evidence in conjunction with the IR data, indicate that
the folate ligand is present in the complexes in a tridentate ONO {α-COO-, γ-COO-, and
Namide} binding mode.
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Regardless of the amount of 1,10-phenanthroline employed (up to four equivalents)
all reactions with complex 1 yielded only [Cu(fol)(phen)(H2O)].3H2O (5). All attempts
to react 1,10-phenanthroline with complexes 2 – 4 were unsuccessful. Attempts to
generate the binuclear metal complexes [{M(phen) 2}2(folate)] (M = Cu2+, Mn2+, Fe3+
and Zn2+) via a reaction between the chlorides of [Cu(phen) 2]2+, [Mn(phen)2]2+,
[Fe(phen)3]3+, and [Zn(phen)]2+ and disodium folate yielded the novel mononuclear
complexes

[Cu(fol)(phen)(H2O)].3H2O

(5),

[Mn(fol)(phen)(H2O)].4H2O

(6),

[Fe(fol)(phen)(Cl)].5H2O (7), [Zn(fol)(phen)(H2O)].4H2O (8), in good to high yield.
Complexes 5 – 8 were characterised using IR, solid-state UV spectroscopy,
thermogravimetric analysis, magnetic susceptibility measurements and again all of the
products formulate as having just one phen ligand present in their structure and it is
believed that the folate is again acting as a tridentate ONO ligand.

The successful synthesis of complexes 1 - 8 allowed the biological effects to be
investigated in cellular models. The solubility of these complexes proved challenging
and most were only partly soluble in hot DMSO. This highlights some of the
challenges that face medicinal chemists in developing novel complexes with
therapeutic potential and their suitability for in-vitro testing. A further challenge is
identifying a suitable cellular model for these studies. There are conflicting results in
the literature regarding folate receptor expression in cell lines and to overcome this
challenge, we investigated folate receptor expression directly using western blot
analysis. It was concluded that SKOV-3 (FR-overexpressing) and A549 (FR
underexpressing) were suitable models for further work. Studies conducted using
complexes

1,

2,

5

and

6

showed
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that

[Cu(fol)(H2O)3].H2O

(1)

and

[Mn(fol)(H2O)3].3H2O (2) were not cytotoxic against either cell line up to 50 µM and
these were not further investigated.
The copper-phen complex [Cu(fol)(phen)(H2O)].3H2O (5) was found to be cytotoxic
within 24 hours in both FR-overexpressing SKOV-3 and FR-underexpressing A549
cells, with EC50 values of 3.13 µM (SKOV-3) and 3.79 µM (A549). Saturation studies
with folic acid (100 µM) allowed us to conclude that the cytotoxic effect was not FRmediated, suggesting complex 5 enters cells via a different mechanism. Complex 5
was an attractive complex for further investigation given its activity in the low
micromolar range. Complex 5 (5 µM) induced proteasome inhibition within 18 hours
in MelJuso-UbG76V-YFP cells, evident by live cell analysis and western blot analysis,
with key proteins upregulated and an accumulation of ubiquinated proteins evident. It
was concluded that the copper phenanthroline moiety may be responsible for the
inhibitory effects on the proteasome as neither complex 1, the free phen ligand or
[Mn(phen)2]2+ induced the effect. Attempts to elucidate the precise region of complex
5 interaction with the proteasome was unsuccessful and needs to be revisited.

As mentioned previously, current proteasome inhibitors such as Bortezomib are
ineffective against solid tumours. Given that copper phenanthroline complexes were
effective proteasome inhibitors, their effects against 3D tumour spheroids were
investigated. Our results identified that copper(II) phenanthroline complexes induced
significant disaggregation of SKOV-3 spheroids at 10 µM within 72 hours. This is the
first report on the effects of metal-based proteasome inhibitors against 3D tumour
spheroids which show promising results and warrants further research. Taken together,
these results suggest that complex 5 is a novel cell permeable proteasome inhibitor
which is active against spheroids which holds promise for future investigations.
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Interestingly, the manganese folate phen [Mn(fol)(phen)(H2O)].4H2O (6), although
cytotoxic in SKOV-3 and A549 cells, was not a proteasome inhibitor. Again, the EC50
values calculated for complex 6 in SKOV-3 and A549 cell lines were in the low
micromolar range (4.92 µM (SKOV-3) and 7.63 µM (A549) at 48 hours, and 4.50 µM
(SKOV-3) and 4.64 µM (A549) at 72 hours. A novel finding of this study was that
complex 6 can inhibit/halt migration of MelJuso melanoma cells in-vitro.
Morphological changes in treated MelJuso-UbG76V-YFP cells were apparent at 48 – 72
hr (chromatin condensation, enlarged nuclei, and increased cell granularity), as
confirmed by flow cytometry. Additional experimental evidence gained suggests that
complex 6 induces cell death via ROS induced autophagy which is an exciting new
possibility for metal complexes.

Novel first generation FIMP-1 ligands were synthesized outside the scope of this
project but formed the basis for the development of FIMP-2 ligands, which was a
major part of the chemistry undertaken in this PhD. Basic cytotoxicity studies were
undertaken on the FIMP-1 ligand, [Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP1)3](ClO4)2.2H2O (10). It was found that the free ligand induced a 50% reduction in
SKOV-3 cell viability at 50 and 100 μM and exerted a significant effect on the viability
of A549, particularly at the higher concentration of 100 μM. Cells treated with
[Cu(FIMP-1)2](ClO4)2.2H2O (9) caused a greater reduction in the cell population of
FR-ve A549 than FR+ve SKOV-3. [Mn(FIMP-1)3](ClO4)2.2H2O (10; 50 and 100 µM)
induced a far greater cytotoxic effect against FR+ve SKOV-3 at 48 hr (with reductions
in viability from 23% to 14%) in comparison to FR-ve A549 cells (49% to 45%,
respectively). Further investigation is required into the role of the FR in these effects.
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In order to overcome issues associated with solubility and potential steric hinderance
encountered with complexes 1, 2, 5, 6, 9 and 10, the synthesis of novel second
generation FIMP-2 ligands with functional linkers was attempted. The synthesis of
FIMP-2 ligands was multistep, beginning with the large-scale synthesis of phendione
(11) which was generated in high yields and high purity. Step two involved the novel
microwave synthesis of imidazole-phenanthroline compounds 12 – 14, which again
were generated in high yield and purity. IMP-NO2 (12) was further reacted to generate
IMP-NH2 (15), which is required for the synthesis of the FIMP-1 ligand. Step three
involved the N-Boc protection of diamine linkers ethylenediamine, 2,2'(ethylenedioxy)bis(ethylamine), and cystamine to yield compounds 16 – 18. This step
proved limiting due to the excess of diamine required, and the inability to scale up the
reaction. Step four (a) was the amide conjugation of compounds 16 – 18 to folic acid
using DCC/NHS to yield compounds 19 – 21. N-Boc-ethylenediamine-folate (19) and
N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)-folate (20) were isolated in moderate
yields, and were characterised using IR, 1H NMR, 13C NMR, elemental analysis and
mass spectrometry. However, due to poor solubility and complexity of the molecules,
NMR spectra were difficult to accurately integrate. The reaction of folic acid with
compound 18 resulted in the a,γ folate conjugate, N-Boc-cystamine-folate (21), which
is undesirable. Given the issues encountered in step 4 (a), conjugation of compounds
16 – 18 with IMP-COOH (13) was performed to yield N-Boc-diamine-IMP
compounds 22 - 24 {step 4 (b)}. 22 – 24 were obtained in good yield and purity and
allowed for easy characterisation due to improved solubility and decreased molecular
complexity. Due to issues encountered in steps 3 an 4(a), only compound N-Bocethylenediamine-IMP (22) was generated in high enough quantities to allow
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subsequent deprotection and conjugation with folic acid. However, N-Boc-2,2'(ethylenedioxy)bis(ethylamine)-IMP (23) and N-Boc-cystamine-IMP (24) are novel
and they were characterised by IR and NMR spectroscopy, mass-spectrometry and
elemental analysis. In light of this, compound 22 was deprotected using trifluoroacetic
acid (step 5) to yield compound IMP-ethylenediamine (25) in good yield and purity.
The final synthetic step (step 6) involved the conjugation of folic acid and compound
25 to yield the novel second generation, folate-ethylenediamine-imidazolephenanthroline ligand (FIMP-et; 26). The ligand was characterised using IR, UV, mass
spectrometry, elemental analysis and NMR.

Novel

FIMP-et

complexes

[Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O

(27)

and

[Mn(FIMP-et)3].(ClO4)2.9H2O (28) were generated by reacting FIMP-et (26) with the
relevant metal perchlorates. Both complexes were obtained in good yield and purity.
Physico-chemical data suggests that complex 27 is a mononuclear copper(II) complex
with two FIMP-et ligands, while complex 28 is a mononuclear complex with three
FIMP-et ligands.

In conclusion, this study has established that folic acid does not act as a traditional
dicarboxylate ligand, precluding the generation of binuclear metal-phen complexes
analogous to those previously generated using simple dicarboxylic acids. However,
the novel mononuclear complexes 1 – 8 are extremely interesting in their own right,
shedding light on the coordination chemistry of the folate ligand. The biological
studies carried out on the copper (1 and 5) and manganese (2 and 6) complexes
revealed that the phen-based complexes (5 and 6) exhibit cytotoxicity at in-vivo
relevant concentrations in the low micromolar range and that they do not require a
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folate receptor mediated transport for efficacy. The copper-phen complex 5 has a
notably different mechanism of action compared to that of its manganese analogue
complex 6. These differences are highlighted in Table 15.

The preliminary biological studies on the copper and manganese complexes of the first
generation folate-imidazole-phen (FIMP-1) ligands ([Cu(FIMP-1)2](ClO4)2.2H2O (9)
and [Mn(FIMP-1)3](ClO4)2.2H2O (10)) revealed that, whereas both complexes
displayed a cytotoxic profile, only the manganese-FIMP-1 complex [Mn(FIMP1)3](ClO4)2.2H2O (10) may be acting via a folate receptor mediated uptake. A synthetic
route to the second-generation folate-imidazole-phen (FIMP-2) ligands has been
developed via a challenging multi-step approach. The synthesis of the FIMP-et ligand,
which contains an ethylenediamine spacer between the imidazole-phen and the folate
moieties has been successful. Although attempts to make the mixed ligand FIMPet/phen complexes were not successful, the novel complexes [Cu(FIMPet)2(H2O)2].(ClO4)2.4.5H2O (27) and [Mn(FIMP-et)3].(ClO4)2.9H2O (28) were isolated
and characterised.
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Table 15: Comparison of the effects of copper(II) or manganese(II) containing complexes on SKOV-3, A549 or MelJuSo-UbG76V-YFP cells
Complex

Folate
Targeting

[Cu(fol)(H2O)3].H2O
(1)

Not targeted via
the FR

[Mn(fol)(H2O)3].3H2O
(2)

Not targeted via
the FR

Cytotoxicity
Cytotoxic at 100
µM in both SKOV3 and A549 cells
(24 hr)
Not cytotoxic in
SKOV-3 or A549
cells up to 100 µM
(48 hr)

Proteasome
Activity

Effect on 3D
Spheroids

Mitochondrial
Depolarisation

Cell Cycle
Activity

Wound
Scratch
Assay

Proposed
mechanism
of action

No
proteasomal
activity

Ineffective
against 3D
spheroids

Not tested

Not tested

Not tested

-

No
proteasomal
activity

Ineffective
against 3D
spheroids

Not tested

Not tested

Not tested

-

Proteasome
inhibitor

Causes
disaggregation
of spheroids
within 72 hr (10
µM)

Not tested

Not tested

Not tested

Cell
permeable
DUB
inhibitor

No
proteasomal
activity

Ineffective
against 3D
spheroids

No
mitochondrial
depolarisation

Causes
arrest in S
phase

Inhibits cell
proliferation
and migration

ROS induced
autophagy

Not tested

Not tested

Not tested

Cell
permeable
DUB
inhibitor

Not tested

Not tested

Not tested

ROS induced
autophagy

[Cu(fol)(phen)(H2O)].3H2O
(5)

Not targeted via
the FR

Cytotoxic below 5
µM in both SKOV3 and A549 cells
(24 hr)

[Mn(fol)(phen)(H2O)].3H2O
(6)

Not targeted via
the FR

Cytotoxic below 8
µM in both SKOV3 and A549 cells
(48 hr)

-

Cytotoxic below 5
µM in both SKOV3 and A549 cells
(24 hr)

Proteasome
inhibitor

Causes
disaggregation
of spheroids
within 72 hr (10
µM)

-

Cytotoxic below 8
µM in both SKOV3 and A549 cells
(48 hr)

No
proteasomal
activity

Ineffective
against 3D
spheroids

[Cu(phen)2

]2+

[Mn(phen)2

]2+
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C.2

Future work

This body of work has identified exciting potential for the development of novel
cytotoxic agents. While the use of folic acid as a means of targeting complexes to cells
via the FR does not appear to function in simple metal complexes, this did not prevent
these complexes exhibiting cytotoxic effects in the low micromolar range, at
concentrations that would be considered relevant in-vivo. Future proposed work is
detailed below and provides useful information to assist chemists in the search for
folate targeted metal complexes:

•

The potential of [Cu(fol)(phen)(H2O)].3H2O (5) to inhibit the proteasome is
novel. There are a number of deubiquitinating enzymes (DUBs) associated
with the proteasome located at the 19S cap. To identify which deubiquitinases
are inhibited by complex 5, a competitive labelling experiment using
hemagglutinin-tagged ubiquitin vinylsulphonone (HA-UbVS), an active-site
directed probe that irreversibly reacts with cysteine deubiquitinases, should be
performed. Using this labelling process, cysteine proteases such as UCHL5 and
USP14, which form part of the 19S cap, will be labelled. By a process of
elimination, these experiments would clarify if complex 5 can directly interact
with the 19S cap of the proteasome and which DUB enzyme it can interact
with.

•

The effect of complex 5 in the disaggregation of 3D spheroids warrants further
investigation. 3D spheroids contain a hypoxic centre and the clinical drug
Bortezomib is ineffective in 3D spheroids and solid tumours. 3D spheroids
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more closely represent in-vivo tissues and the microenvironment. Does
complex 5 inhibit cell aggregation by affecting the extracellular matrix or cause
disaggregation through cell death?

•

Further investigation into the relationship between manganese(II) complex
[Mn(fol)(phen)(H2O)].4H2O (6) and ROS-induced autophagy is required. To
confirm that complex 6 does induce ROS generation, ROS levels should be
measured in treated cells.

•

The potential for manganese containing complex 6 to induce autophagy can be
confirmed using markers of autophagy and confocal microscopy e.g.
quantitation of LC3B protein on autophagic vesicles using commercially
available autophagy assays. Known autophagic inducers {e.g. rapamycin
(Rapa) and suberoyanilide hydroxamic acid (SAHA)} and autophagic
inhibitors {e.g. 3-methyladenine (3-MA) and chloroquine (CQ)} could also be
used experimentally.

•

Studies using animal models could be considered to determine the efficacy of
complexes 5 and 6 in vivo. Mouse or guinea pig models could be suitable for
studies on absorption, metabolism, distribution, and excretion of the
complexes. Furthermore, such studies allow for safety aspects such as adverse
effects and drug-drug interactions to be evaluated336. Given the poor solubility
of both complexes, administration of the complexes to animals would be
challenging and oral administration would be the most suitable route of
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administration. Improvement in solubility is a key priority to advance the
research to in vivo models.

•

Deprotection and conjugation of N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)
and

N-Boc-cystamine

with folic

acid

to

yield

novel

FIMP-2,2'-

(ethylenedioxy)bis(ethylamine) and FIMP-cystamine ligands remains. The
proposed improved solubility of FIMP-2,2'-(ethylenedioxy)bis(ethylamine)
may allow for analysis by RP-HPLC. Furthermore, these ligands with
functional linkers (improved solubility and cleavage in the acidic endosome)
may offer advantageous biological activity and improved FR selectivity.

•

Although the novel FIMP-1 ligands showed promise, investigation of the
cytotoxicity, cytoselectivity, and mechanism of action of the novel FIMP-et
ligand and its copper(II) and manganese(II) complexes in FR cell models is
required.
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EXPERIMENTAL

191

E.1

Experimental Methods and Instrumentation

Chemicals and reagents were purchased from Sigma Aldrich Ireland, ACROS Ireland
and Fluorochem and used without further purification.

Infrared (IR) spectra were recorded in the region 4000 – 600 cm-1 on a Perkin Elmer
Spectrum GX FT-IR Microscope using Attenuated total reflectance (ATR)

UV-Vis spectra were recorded on a Unicam UV-500 spectrometer. Soluble samples
were analysed in a 1 cm-1 quartz cuvette with a path length of 1 cm with a spectral
range of 200 – 800 nm unless otherwise specified. The background was corrected for
blank solvent absorbance prior to each measurement and was collected at room
temperature. Samples with poor solubility were analysed as solids using an integrating
sphere attachment and a quartz slide. The background was corrected for blank quartz
slide absorbance prior to each measurement and was collected at room temperature

All Nuclear magnetic resonance (NMR) characterisation was performed on a Bruker
Ascend 500 MHz or a Bruker Avance 400MHz spectrometer using deuterated DMSOd6, deuterated chloroform or deuterium oxide unless otherwise stated. Peak positions
are relative to trimethylsilane (TMS; 0 ppm chemical shift). All NMR spectra were
processed and analysed using MestReNova NMR software.

1

H NMR and 13C NMR of folic acid/copper chloride mixtures were performed on a

Bruker Avance 400MHz spectrometer. Samples were prepared in 1 ml D2O (99.95 %)
and the final concentration was 40 mM for proton and carbon spectra. NMR spectra
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were recorded for folate and Cu(II)–folate system at pH 7 by adding a small volume
of 1M NaOH. Measurements were made for Cu(II)–folate at a molar ratio of 1:100
(Metal:Ligand).

Inductively coupled plasma - optical emission spectrometry (ICP-OES) was performed
on a Varian Liberty 150 ICP-Emission spectrometer. Standard curves were generated
using 1 – 10 mg/L solutions of Centipur ICP-multi-element standard solution (contains
1000 mg/L Cu2+, Mn2+, and Fe3+)

Magnetic susceptibility measurements were performed using a Johnson Matthey
magnetic susceptibility balance. Hg[Co(SCN)4] was used as a reference standard.

Mass Spectroscopy were carried out by the Analytical Chemistry Laboratory,
Maynooth University, Kildare, Ireland and University of Southern Denmark, Odense,
Denmark.

Elemental analyses were performed by the Microanalytical Laboratory, University
College Dublin. Ireland and the Analytical Chemistry Laboratory, Maynooth
University, Kildare, Ireland.

Thermogravimetric analysis (TGA) was carried out using a TGA – Q50 TA Instrument
by the Technological University Dublin (TU Dublin), Tallaght Campus. Scanning was
performed from ambient temperature to 800oC in the presence of nitrogen gas with the
sample purge flow of 30 ml min-1. The sample was loaded in a platinum pan and
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analysis was carried out at a heating rate of 10 oC min-1. The percentage of weight loss
versus temperature was examined.

RP-HPLC analysis was performed on a Waters 2998 HPLC and Photodiode Array
Detector, (Waters, USA), using a Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7
μm, (Agilent Technologies, UK). Gradient elution was carried out at a flow rate of 1
mL/min, column temperature 25 ± 5.0 °C. The gradient running was 5% A/95% B to
100% A over 45 min where A is 0.1% TFA in acetonitrile and B is 0.1% TFA in water.
Samples were monitored according to their UV absorbance at 280 nm.

Microscopy and cell imaging were performed using an Olympus IX73 inverted
microscope in Linkoping University.

Live cell analysis was performed using an IncuCyte S3 live cell analysis system in
Linkoping University. A 10X objective was used for spheroid cultures and a 20X
objective was used for monolayer cultures.

Fluorescence was measured using a Perkin Elmer Victor 3V 1420 Multilabel Plate
Counter from 560 – 590 nm in Linkoping University.

Absorbance was measured using a Molecular Devices Versa Max Microplate
Spectrophotometer at 570 nm in Linkoping University.
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E.2

The synthesis of simple metal folates and their 1,10-phenanthroline

derivatives

E.2.1

The general procedure for the synthesis of simple metal folate

complexes.

Simple metal folate complexes were synthesised according to El-Wahed et al147. A
methanolic suspension of folic acid (0.441 g, 1.0 mmol, 50 ml) was neutralised using
a sodium hydroxide solution (0.1 M). To this, a 10 ml solution of metal chloride was
added (1.0 mmol). The mixture was heated to approximately 80 oC and refluxed for
two hours. The coloured suspension cooled and centrifuged at 3000 rpm for 5 min.
The coloured pellet was washed with excess amounts of distilled water to remove
residual chloride ions and centrifugation was repeated in methanol and diethyl ether.
The product was dried overnight at 50oC.

[Cu(fol)(H2O)3].H2O (1)
Yield: 0.38 g (68%); Appearance: Brown solid; Solubility: Insoluble in all solvents;
µeff: 1.78 B.M.; ƛmax (nm): 235, 335, 417 nm; Elemental Analysis (Calc): C, 39.76;
H, 4.21; N, 17.38; Cu, 11.07; Elemental Analysis (Found): C, 39.65; H, 3.80; N, 17.42;
Cu, 11.29; TG Analysis: 9.36 % (calculated: 9.71 %; 4 H2O); IR: 3252, 3164, 2790,
2102, 2047, 1686, 1603, 1568, 1510, 1450, 1404, 1334, 1299, 1259, 1125, 1105, 991,
969, 838, 818, 766, 736, 675 cm-1.
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[Mn(fol)(H2O)3].3H2O (2)
Yield: 0.35 g (63 %); Appearance: Yellow solid; Solubility: Insoluble in all solvents:
µeff: 6.11 B.M; λmax (nm): 292, 397; Elemental Analysis (Calc): C, 37.95; H, 4.69; N,
16.30; Mn, 9.13; Elemental Analysis (Found): C, 37.85; H, 4.20; N, 16.08; Mn, 9.37;
TG Analysis: 17.36 % (calculated: 17.97 %; 6 H2O); IR: 3250, 3166, 3126, 2783,
1691, 1603, 1561, 1526, 1507, 1501, 1408, 1335, 1298, 1188, 1124, 1055, 986, 970,
952, 855, 821, 768, 734, 697, 670 cm-1.

[Fe(fol)(H2O)2(Cl)].4H2O (3)
Yield: 0.38 g (61.29 %); Appearance: Red-brown solid; Solubility: Insoluble in all
organic solvents; λmax: 287, 393 nm; µeff: 2.71 B.M.; Elemental Analysis (Found): C,
35.99; H, 4.42; N, 15.45; Fe; 9.05; Elemental Analysis (Calc): C, 35.78; H, 4.43; N,
15.37; Fe, 8.76; TG Analysis: 16.54 & (calculated: 16.93 %; 6 H2O); IR: 3340, 1687,
1641, 1607, 1511, 1448, 1408, 1337, 1303, 1191, 1130, 1105, 946, 840, 823, 768, 736,
584, 516 cm-1.

[Zn(fol)(H2O)3].3H2O (4)
Yield: 0.38 g (62.20 %); Appearance: Yellow solid; Solubility: Insoluble in all organic
solvents; Elemental Analysis (Found): C, 38.10; H, 4.99; N, 16.42; Zn, 10.69;
Elemental Analysis (Calc): C, 37.70; H, 4.61; N, 16.02; Zn, 9.74; TG Analysis: 16.15
% (calculated: 17.68 %; 6 H2O); IR: 3320, 3178, 2942, 2859, 2788, 1601, 1547, 1509,
1449, 1398, 1341, 1309, 1274, 1184, 1133, 1106, 838, 822, 770 cm-1.
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E.2.2

The Synthesis of 1,10-Phenanthroline derivatives of simple metal

folate complexes

E.2.2.1

The coordination of 1,10-phenanthroline and simple metal folates

1,10-phenanthroline (0.15 g, 0.8 mmol) was added to a stirred suspension of metal
folate (0.3 g, 0.4 mmol) in 40 ml methanol. The suspension was refluxed for 4 hr. The
resulting precipitate was centrifuged at 3000 rpm for 5 min and the pellet was washed
with methanol and diethyl ether. The green powder was dried overnight at room
temperature.

[Cu(fol)(phen)(H2O)].3H2O (5)
Yield: 0.27 g (87.10 %); Appearance: Green solid; Solubility: Partially soluble in hot
DMF and DMSO; µeff: 1.82 B.M.; λmax: 259, 386, 712 nm; Elemental Analysis
(Calc): C, 49.37; H, 4.28; N, 16.71; Cu, 8.43; Elemental Analysis (Found): C, 49.45;
H, 3.78; N, 17.70; Cu, 7.35; TG Analysis: 9.94 % (calculated: 9.54 %, 4 H2O); IR:
3255, 3081, 2973, 2795, 1724, 1687, 1605, 1561, 1517, 1450, 1427, 1400, 1341, 1299,
1254, 1192, 1147, 1127, 1107, 1053, 970, 850, 769, 723, 675 cm-1.

E.2.2.2

The coordination of folic acid with metal bis phenanthroline

complexes

To a neutralised solution of folic acid (0.44 g, 1 mmol) in methanol, two molar
equivalents of the metal-bis phenanthroline was added. The resulting coloured mixture
was refluxed for 4 hr. The suspension was centrifuged at 3000 rpm for 5 min and the

197

pellet was washed with methanol and diethyl ether. The yellow powder was dried
overnight at room temperature.

[Mn(fol)(phen)(H2O)].4H2O (6)
Yield: 0.74 g (97.56 %); Appearance: Yellow solid; Solubility: Partially soluble in hot
DMF and DMSO; µeff; 5.32 B.M; λmax (nm): 258, 291, 389; Elemental Analysis
(Calc): C, 48.76; H, 3.92; N, 16.51; Mn, 7.19; Elemental Analysis (Found): C, 48.49;
H, 3.65; N, 16.66; Mn, 8.15; TG Analysis: 10.31 % (calculated: 11.79 %, 5 H2O); IR:
3302, 3062, 2971, 2845, 2796, 1725, 1688, 1604, 1514, 1449, 1424, 1409, 1341, 1302,
1189, 1145, 1120, 1106, 1050, 969, 951, 865, 847, 822, 767, 730, 670 cm-1.

[Fe(fol)(phen)(Cl)].5H2O (7)
Yield: 0.35 g (44.31 %); Appearance: Red solid; Solubility: Partially soluble in hot
DMF and DMSO; µeff: 2.71 B.M.; Elemental Analysis (Calc): C, 46.54; H, 4.28; N,
15.76; Fe, 6.98; Elemental Analysis (Found): C, 46.42; H, 4.31; N, 16.73; Fe, 7.15;
TG Analysis: 10.74 % (calculated: 11.25 %, 5 H2O); IR: 3329, 3107, 1690, 1602, 1515,
1454, 1426, 1406, 1335, 1299, 1262, 1185, 1130, 1106, 845, 725 cm-1.

[Zn(fol)(phen)(H2O)].4H2O (8)
Yield: 0.65 g (84.42 %); Appearance: Yellow solid; Solubility: Partially soluble in hot
DMF and DMSO; Elemental Analysis (Calc): C, 48.10; H, 4.43; N, 16.29; Zn, 8.45;
Elemental Analysis (Found): C, 48.38; H, 3.97; N, 16.59; Zn, 7.95; TG Analysis: 9.94
% (calculated: 7.14 %, 5 H2O); IR: 3318, 3070, 2942, 2837, 1690, 1606, 1544, 1509,
1452, 1428, 1393, 1338, 1306, 1274, 1190, 1127, 1110, 852, 822, 770, 730 cm-1.
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E.2.2.3

The general method for the synthesis of metal phenanthroline

chloride complexes

The method described by McCann et al was used to synthesise metal phenanthroline
chloride complexes225. To a solution of the relevant metal chloride (1 gram) in
methanol (20 ml) was added a solution of 1,10-phenanthroline in methanol (2 molar
equivalent; 20 ml). The resulting suspension was stirred for 2 hr at room temperature.
The coloured solid was filtered off, washed with methanol and dried in vacuo.
Recrystallisation was performed in minimal amounts of methanol and crystals
developed over the period of weeks.

[Cu(phen)2Cl2].CH3OH.4.5H2O
Yield: 2.90 g (81.46 %); Appearance: Blue crystal; Solubility: Soluble in hot methanol,
ethanol, DMSO, and DMF; µ eff: 1.78 B.M; Elemental Analysis (Calc): C, 49.28; H,
4.48; N, 9.58; Elemental Analysis (Found): C, 49.69; H, 4.30; N, 9.49; IR: 3360, 3059,
1628, 1586, 1519, 1427, 1341, 1228, 1145, 1039, 852, 784, 721 cm-1.

[Mn(phen)2Cl2]
Yield: 1.80 g (73.47 %); Appearance: Yellow crystal; Solubility: Soluble in hot
methanol, ethanol, DMSO, and DMF; µ eff: 5.75 B.M; Elemental Analysis (Calc): C,
59.28; H, 3.32; N, 11.52; Elemental Analysis (Found): C, 59.07; H, 3.24; N, 11.26;
IR: 3048, 2994, 1623, 1578, 1515, 1426, 1224, 1144, 1093, 1028, 988, 845, 779, 722
cm-1.
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[Fe(phen)3]Cl3.CH3OH.5.5H2O
Yield: 1.77 g (57.28 %); Appearance: Red crystal; Solubility: Soluble in hot methanol,
ethanol, DMSO, and DMF; µ eff: 2.41 B.M; Elemental Analysis (Calc): C, 53.29; H,
4.71; N, 10.08; Elemental Analysis (Found): C, 52.82; H, 3.23; N, 10.09; IR: 3436,
,3057, 1619, 1582, 1515, 1421, 1340, 1305, 1216, 1144, 1102, 847, 776, 720, 640 cm1

.

[Zn(phen)Cl2]
Yield: 1.36 g (58.62 %); Appearance: Colourless solid; Solubility: Soluble in hot
methanol, ethanol, DMSO, and DMF; Elemental Analysis (Calc): C, 45.54; H, 2.55;
N, 8.58; Elemental Analysis (Found): C, 46.03; H, 2.07; N, 3.69; IR: 3050, 1584, 1519,
1425, 1342, 1224, 1105, 1035, 979, 851, 780, 723 cm-1.
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E.3

The synthesis of novel second generation folate-imidazole ligands

E.3.1

Synthesis of 1,10-phenanthroline-5,6-dione (phendione; 11)

Phendione was synthesised as previously described 310. 10 g (55.49 mmol) of 1,10phenathroline was dissolved in 130 ml 60% H2SO4 in a 500 ml round bottom flask.
Over a period of 1 hr, 10.19 g (61.04 mmol) KBrO3 was added in small quantities. A
colour change ranging from red to orange to yellow was observed upon increasing
concentrations of KBrO3. The solution was left uncovered for 1 hr to facilitate the
removal of bromine gas before the yellow solution was gently stoppered and left to stir
for 20 – 24 hr. The solution was poured over 400 ml of ice and the pH recorded as pH
1. To raise the pH to pH 7, approximately 100 ml of saturated NaOH solution was
added, inducing a colour change from yellow solution to tan suspension. The product
was extracted with three 100 ml aliquots of dichloromethane (DCM) and the combined
organic layers removed in vacuo. The yellow product was recrystallized in minimal
quantities of methanol, filtered, washed with cold methanol and air-dried. Yield: 9.70
g (83.19 %); Appearance: yellow crystalline solid; Solubility: MeOH, acetone,
DMSO, DMF, ACN, DCM, THF and CHCl3; λmax: 258 and 299 nm; LC-MS (ESI)
calcd for C12H6N2O2 211.0502 [M+H]+, found 211.0500; Elemental Analysis (Found)
C, 68.52; H, 2.74; N, 13.48; Elemental Analysis (Calc): C, 68.57; H, 2.88; N, 13.33;
1

H NMR (500 MHz, CDCl3) δ 9.09 (dd, J = 4.6 Hz, 2H), 8.48 (dd, J = 7.9 Hz, 2H),

7.57 (dd, J = 7.8 Hz, 2H);

C NMR (126 MHz) δ 178.72, 156.51, 153.02, 137.40,

13

128.19, 125.64; IR: 3350, 3061, 2914, 2849, 1995, 1704, 1685, 1577, 1561, 1463,
1458, 1414, 1317, 1293, 1205, 1184, 1115, 1060, 1011, 925, 817, 817, 740, 735, 668
cm-1.
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E.3.2 The general procedure for the synthesis of imidazo-phenanthrolines
(IMP) compounds

To 0.30 g of phendione (1.43 mmol) in 10 ml methanol, was added a 10 ml methanolic
solution of ceric ammonium nitrate (0.04 g, 0.07 mmol). An excess of ammonium
acetate (1.10 g, 143 mmol) was added and the suspension was heated until soluble.
1.43 mmol of the chosen aldehyde was added and the reaction vessel was sealed. The
reaction continued in a microwave synthesiser, with parameters set as follows: 15 min
at 70 oC/3 bar/300 watt with constant stirring. The product was submerged in 150 ml
distilled water and stirred for an additional 30 min. The mixture was filtered, washed
with acetone or diethyl ether and allowed to dry at 70 oC overnight.

IMP-NO2 (12)
Yield: 0.39 g (72.91%); Appearance: Orange solid; Solubility: DMF and DMSO,
partially soluble in acetone, hot MeOH & EtOH; LC-MS (ESI) calcd for C19H12N5O2
342.0986 [M+H]+, found 342.1009; Elemental Analysis (Found) C, 60.52; H, 4.34; N,
18.48; Elemental Analysis (Calc): C, 60.47; H, 4.01; N, 18.56; 1H NMR (500 MHz,
DMSO) δ 9.05 (dd, J = 4.2, 1.5 Hz, 2H), 8.91 (d, J = 8.0 Hz, 2H), 8.49 (q, J = 9.0 Hz,
4H), 7.85 (dd, J = 7.9, 4.2 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 149.93, 148.33,
143.97, 132.48, 130.14, 129.59, 128.54, 123.41; IR: 3385, 3176, 3097, 3076, 3037,
1603, 1567, 1515, 1454, 1399, 1343, 1299, 1108, 1072, 854, 805, 738, 708 cm-1
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IMP-COOH (13)
Yield: 0.46 g (94.05%); Appearance: Yellow solid; Solubility: Partially soluble in hot
DMSO and DMF; λmax: 282, 337 nm; LC-MS (ESI) calcd for C20H13N4O2 341.1033
[M+H]+, found 341.10.35; Elemental Analysis (Found) C, 63.91; H, 4.51; N, 14.87;
Elemental Analysis (Calc): C, 63.82; H, 4.28; N, 14.89; 1H NMR (500 MHz, DMSO)
δ 8.91 (d, J = 1.2 Hz, 2H), 8.90 (d, J = 1.1 Hz, 2H), 8.42 (d, J = 8.2 Hz, 2H), 8.33 (d, J
= 23.7 Hz, 2H), 7.76 (dd, J = 8.0, 4.3 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 172.42,
168.24, 166.57, 159.16, 157.50, 151.56, 150.21, 149.21, 148.17, 144.12, 137.62,
136.59, 133.93, 130.53, 130.13, 129.76, 126.68, 125.32, 123.66, 123.23; IR: 3374,
3060, 1931, 1679, 1602, 1536, 1479, 1380, 1317, 1254, 1182, 1114, 1070, 1015, 958,
862, 807, 735, 711 cm-1

IMP-Phenyl (14)
Yield: 0.37 g (87.08 %); Appearance: Pale yellow solid; Solubility: MeOH, DMSO,
DMF and CHCl3; LC-MS (ESI) calcd for C19H13N4 297.1135 [M+H]+, found
297.1144; Elemental Analysis (Found) C, 72.32; H, 4.27; N, 17.88; Elemental
Analysis (Calc): C, 72.60; H, 4.49; N, 17.82; 1H NMR (500 MHz, DMSO) δ 9.00 (s,
2H), 8.89 (d, J = 7.8 Hz, 2H), 8.27 (d, J = 7.6 Hz, 2H), 7.79 (s, 2H), 7.59 (t, J = 7.6
Hz, 2H), 7.50 (t, J = 7.3 Hz, 1H);

C NMR (126 MHz) δ 150.54, 147.76, 143.63,
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130.03, 129.64, 129.02, 126.20, 123.27; IR: 3062, 1950, 1882, 1603, 1562, 1546,
1505, 1514, 1476, 1458, 1428, 1398, 1351, 1297, 1190, 1158, 1134, 1105, 1069, 1030,
969, 952, 918, 803, 775, 739, 694, 666, 643, 621 cm-1
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E.3.3

Synthesis of IMP-NH2 (15)

IMP-NH2 was synthesised as previously described314. To a 300 ml solution of 12 (0.80
g, 2.34 mmol), 0.2 g of 10% Palladium/Carbon catalyst was added. The mixture was
refluxed for 2 hr in the absence of light before 1.25 ml (0.026 mmol) hydrazine
monohydrate was added in one portion and the mixture was refluxed for 3 hr. The
resulting dark mixture was allowed to cool to room temperature and filtered through a
bed of celite to product a yellow filtrate. The solvent was removed under reduced
pressure to yield an orange solid. Yield: 1.53 g (74.88 %); Appearance: Orange solid;
Solubility: H2O, EtOH, MeOH, DMSO, DMF; LC-MS (ESI) calcd for C19H14N5
312.1244 [M+H]+, found 312.1252; Elemental Analysis (Found) C, 65.11; H, 4.26; N,
20.66; Elemental Analysis (Calc): C, 65.69; H, 4.93; N, 20.16; 1H NMR (500 MHz,
DMSO) δ 8.99 (s, 2H), 8.89 (d, J = 3.1 Hz, 1H), 7.98 (d, J = 5.4 Hz, 2H), 7.82 (d, J =
20.0 Hz, 2H), 6.74 (d, J = 7.9 Hz, 2H), 5.63 (s, 2H); 13C NMR (126 MHz, DMSO) δ
151.59, 149.95, 146.82, 142.66, 128.96, 128.33 , 127.12, 122.69, 116.84, 113.17; IR:
3324, 3198, 1608, 1561, 1523, 1482, 1451, 1427, 1350, 1295, 1180, 1067, 1029, 834,
798, 735, 694, 645, 620 cm-1
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E.3.4

The N-Boc protection of diamines

E.3.4.1

The N-Boc protection of ethylenediamine (16)

Ethylenediamine was protected as previously described 316. To a cooled solution of
ethylenediamine (9.359 ml, 140 mmol) in anhydrous DCM (20 ml), a solution of ditert-butyl dicarbonate (3.055 g, 14 mmol) in 50 ml anhydrous DCM was added dropwise over a period of 2 hours. The reaction was stirred for 24 hr at room temperature
under nitrogen. The solvent was removed under reduced pressure and replaced with
water. The aqueous suspension was filtered to remove the di-boc protected by-product
and the filtrate was washed with three portions of DCM (50 ml). The combined organic
layers were dried over Na2SO4 and evaporated to yield a viscous oil. Yield: 3.96 g
(88.19%); Appearance: Viscous oil, ranging in colour from colourless to pale yellow;
Solubility: H2O, MeOH, EtOH, Et2O, Acetone, EtOAc, DCM, ACN, CHCl3, DMF and
DMSO; λmax: 216 nm; LC-MS (ESI) calcd for C7H17N2O2 161.1285 [M+H]+, found
161.1297; 1H NMR (500 MHz, CDCl3) δ 5.84 (s, 1H), 3.07 (d, J = 5.3 Hz, 2H), 2.70
(t, J = 5.9 Hz, 2H), 1.36 (s, 9H), 1.22 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 156.30,
78.63, 43.38, 41.78, 28.30; IR: 3368, 2866, 1702, 1522, 1454, 1390, 1364, 1275, 1250,
1170, 1105, 1042, 999, 967, 916, 864, 815, 781 cm-1.
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E.3.4.2

The N-Boc protection of 2,2'-(ethylenedioxy)bis(ethylamine) (17)

2,2'-(ethylenedioxy)bis(ethylamine) was protected as previously described 321. To a
cooled solution of 2,2-(ethylenedioxy)bis(ethylamine) (20.44 ml, 140 mmol) in 20 ml
anhydrous chloroform, a solution of di-tert-butyl dicarbonate (3.06 g, 14 mmol) in 50
ml anhydrous chloroform was added drop-wise over a period of 2 hours. The reaction
was stirred for 24 hr at room temperature under nitrogen. The solvent was removed
under reduced pressure and the residue dissolved in DCM (50 ml), washed with three
50 ml portions of distilled water, dried over Na 2SO4 and evaporated to yield a
colourless, viscous oil. Yield: 3.22 g (92.72 %); Appearance: Colourless viscous oil;
Solubility: H2O, MeOH, EtOH, Acetone, EtOAc, DCM, ACN, CHCl3, DMF and
DMSO. LC-MS (ESI) calcd for C11H25N2O4 249.3272 [M+H]+, found 249.1815; 1H
NMR (500 MHz, CDCl3) δ 5.52 (s, 1H), 3.26 (s, 4H), 3.16 (d, J = 15.1 Hz, 4H), 2.92
(s, 2H), 2.50 (s, 2H), 1.08 (s,11H); 13C NMR (126 MHz) δ 155.42, 77.96, 72.81, 69.51,
41.08, 39.64, 27.77. IR: 3354, 2975, 2932, 2869, 1686, 1518, 1543, 1391, 1364, 1272,
1248, 1165, 1041, 953, 870, 779 cm-1

206

E.3.4.3

The N-Boc protection of cystamine dihydrochloride (18)

Cystamine bis-hydrochloride was N-Boc protected as previously described319. To a
cooled solution of cystamine bis-hydrochloride (8.0 g, 36 mmol) in methanol (200 ml),
14.9 ml (107 mmol) of triethylamine was added. A solution of di-tert-butyl dicarbonate
(7.70 g, 36 mmol) in 100 ml methanol was added drop wise over a period of 2 hours.
The reaction was stirred for 24 hr at room temperature. The solvent was removed under
reduced pressure and the white residue dissolved in 80 ml of 1 M aqueous NaH2PO4.
The aqueous solution was extracted twice with diethyl ether to remove di-Boccystamine and subsequently basified to pH 10 with 1 M NaOH. The aqueous layer was
then extracted three times with ethyl acetate. The combined ethyl acetate layers were
washed twice with distilled water, dried with Na 2SO4 and evaporated in vacuo to yield
a yellow, viscous oil. Yield: 3.56 g (39.99 %); Appearance: Yellow viscous oil;
Solubility: MeOH, EtOH, Acetone, Et 2O, EtOAc, DCM, CHCl3, DMF, DMSO &
ACN; LC-MS (ESI) calcd for C9H21N2O2S2 253.1044 [M+H]+, found 253.1050; 1H
NMR (500 MHz, CDCl3) δ 5.57 (s, 1H), 3.42 (s, 2H), 3.00 (t, J = 5.9 Hz, 2H), 2.78
(dd, J = 13.5, 6.7 Hz, 4H), 1.47 (d, J = 24.0 Hz, 11H); 13C NMR (126 MHz, CDCl3) δ
155.41, 78.73, 41.93, 40.19, 38.92, 37.90, 27.95; IR: 3357, 2974, 2928, 2865, 1691,
1513, 1453, 1390, 1364, 1270, 1299, 1163, 1043, 1006, 947, 919, 865, 777 cm-1
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E.3.5

The general procedure for the conjugation of N-Boc protected

diamines with folic acid

The method for amide conjugation described by Trindade et al was used322. To a
solution of folic acid (0.893 g, 2 mmol) dissolved in 60 ml anhydrous dimethyl
sulfoxide (DMSO), N,N′-dicyclohexylcarbodiimide (DCC; 0.826 g; 4 mmol) and Nhydroxysuccinamide (NHS; 0.465 g; 4 mmol) were added successively. The reaction
mixture was stirred in the absence of light for 24 hr at room temperature, after which
time a colourless precipitate, dicyclohexylurea, was removed by vacuum filtration. To
the orange filtrate, 0.523 ml (3.8 mmol) of triethylamine and 0.784 g (3.8 mmol) DCC
were added, followed by 3.8 mmol of the selected N-Boc protected diamine dissolved
in 5 ml DMSO. The mixture was stirred overnight at room temperature, in the absence
of light before a mixture of 20% acetone in diethyl ether was added (100 ml). The fine,
yellow precipitate was filtered and washed thoroughly with excess acetone/diethyl
ether mix (20% v/v) and dried in a 60oC oven overnight.

N-Boc-ethylenediamine-folate (19)
Yield: 0.981 g (84.06 %); Appearance: Yellow solid; Solubility: DMF, DMSO (hot); ;
LC-MS (ESI) calcd for C26H33N9O7 584.2576 [M+H]+, found 584.2601; Elemental
Analysis (Found) C, 50.88; H, 6.34; N, 19.81; Elemental Analysis (Calc): C, 50.40; H,
6.02; N, 20.34; 1H NMR (500 MHz, DMSO) δ 8.77 – 8.54 (m, 2H), 8.02 (d, J = 7.2
Hz, 1H), 7.94 – 7.58 (m, 4H), 7.42 (d, J = 8.7 Hz,1H), 7.21 (d, J = 5.9 Hz, 1H), 7.09 –
6.51 (m, 8H), 4.64 – 4.38 (m, 3H), 3.06 (dd, J = 10.7, 5.6 Hz, 2H), 3.01 – 2.91 (m,
2H), 2.36 (t, J = 6.8 Hz, 1H), 2.16 – 2.05 (m, 1H), 1.99 (d, J = 5.9 Hz, 1H), 1.87 (dd,
J = 26.0, 8.4 Hz, 1H), 1.45 – 1.23 (m, 11H). 13C NMR (126 MHz, DMSO) δ 172.38
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(s), 166.70 (s), 157.13 (s), 156.08 (s), 154.26 (s), 151.21 (s), 149.11 (s), 129.53 (s),
111.64 (s), 78.11 (s), 53.51 (s), 47.97 (s), 46.36 (s), 40.87 (s), 40.47 (s), 40.30 (s),
40.12 (s), 39.95 (s), 39.79 (s), 39.71 – 39.15 (m), 33.79 (s), 32.47 (s), 28.66 (s), 25.76
(s), 24.90 (s); IR: 3324, 2929, 2852, 2791, 2720, 1693, 1624, 1602, 1536, 1509, 1435,
1366, 1273, 1246, 1172, 1128, 1018, 952, 892, 818, 768, 730, 705, 639 cm-1

N-Boc-2 2'-(ethylenedioxy)bis(ethylamine)-folate (20)
Yield: 1.26 g (98.82 %); Appearance: Yellow solid; Solubility: DMF, DMSO (hot);
LC-MS (ESI) calcd for C30H42N9O9 672.3100 [M+H]+, found 672.3098; Elemental
Analysis (Found) C, 53.27; H, 6.62; N, 17.71; Elemental Analysis (Calc): C, 53.64; H,
6.15; N, 18.70; 1H NMR (500 MHz, DMSO) δ 8.66 (d, J = 14.4 Hz, 1H), 8.05 – 7.80
(m, 3H), 7.73 – 7.59 (m, 2H), 6.92 (d, J = 4.9 Hz, 2H), 6.72 (s, 1H), 6.64 (d, J = 8.7
Hz, 2H), 4.53 (dd, J = 37.6, 4.9 Hz, 2H), 4.32 (dd, J = 13.2, 8.3 Hz, 1H), 3.38 – 3.31
(m, 6H), 3.27 – 3.13 (m, 3H), 3.05 (d, J = 5.2 Hz, 3H), 2.25 – 2.07 (m, 2H), 1.97 (dd,
J = 13.3, 5.7 Hz, 1H), 1.91 – 1.79 (m, 1H), 1.35 (s, 11H);

C NMR (126 MHz) δ

13

171.98, 166.21, 155.64, 153.94, 150.78, 149.26 – 148.48, 148.34, 129.04, 127.95,
121.48, 111.23, 77.64, 69.33, 68.99, 53.17, 45.95, 32.04, 28.25, 27.68; IR: 3311, 3154,
2930, 2863, 2773, 1703, 1645, 1603, 1524, 1488, 1365, 1331, 1295, 1270, 1178, 1124,
1015, 948, 836, 822, 766, 643, 607, 509, 442 cm-1

N-Boc-cystamine-folate (21)
Yield: 1.54 g (60.01%); Appearance: Yellow solid; Solubility: DMF, DMSO (hot);
LC-MS (ESI) calcd for C28H38N9O7S2 676.2336 [M+H]+, found 910.3257; Elemental
Analysis (Found) C, 48.23; H, 5.39; N, 18.68; Elemental Analysis (Calc): C, 48.47; H,
5.67; N, 18.17; 1H NMR (500 MHz, DMSO) δ 8.64 (s, 1H), 8.01 (dd, J = 10.6, 6.6 Hz,
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2H), 7.66 (d, J = 8.6 Hz, 2H), 6.94 (s, 3H), 6.70 – 6.58 (m, 2H), 4.49 (d, J = 5.6 Hz,
2H), 4.32 (dd, J = 13.1, 8.5 Hz, 1H), 3.19 (dd, J = 12.2, 6.0 Hz, 2H), 2.73 (dd, J = 8.4,
5.0 Hz, 6H), 2.15 (dd, J = 14.4, 6.9 Hz, 2H), 1.99 (d, J = 6.4 Hz, 1H), 1.93 – 1.78 (m,
1H), 1.35 (s, 11H); 13C NMR (126 MHz) δ 171.60, 165.94, 155.29, 153.64, 150.45,
128.81, 127.62, 110.88, 77.59, 45.62, 39.69, 39.44, 39.19, 39.02, 38.77, 37.75, 37.32,
36.87, 31.75, 27.90, 27.23; IR: 3294, 3148, 3087, 2980, 2924, 1695, 1606, 1505, 1413,
1390, 1365, 1334, 1295, 1270, 1248, 1166, 1124, 1041, 1018, 945, 856, 817, 766, 733,
607, 509 cm-1

E.3.6 The general procedure for the conjugation of N-Boc protected diamines
with IMP-COOH

N-Boc protected diamines were conjugated with IMP-COOH using a similar method
to one previously described by Pu et al337 . To 25 ml dimethylformamide (DMF), IMPCOOH (11) (0.40 g, 1.17 mmol) and hydroxybenzotriazole (HOBt; 0.36 g; 2.34 mmol)
were

added.

The

suspension

was

cooled

to

0

o

C

and

1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC; 0.45 g; 2.34 mmol) was added and stirred
for 20 min. The final addition of N-Boc diamine (2.34 mmol) in 10 ml DMF was
performed at room temperature. The reaction was left to stir for 24 hr at room
temperature. To the orange solution, 100 ml distilled water was added to produce a
fine yellow precipitate. The crude product was washed well with water and
subsequently recrystallized in minimal quantities of methanol, filtered, washed with
cold diethyl ether and air-dried.
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N-Boc-ethylenediamine-IMP (22)
Yield: 0.50 g (89.05 %); Appearance: Pale yellow solid; Solubility: MeOH, DMF,
DMSO (hot); λmax: 227, 278, 325 nm; LC-MS (ESI) calcd for C27H27N6O3 483.2145
[M+H]+, found 483.2158; Elemental Analysis (Found): C, 60.35; H, 5.51; N, 15.92;
Elemental Analysis (Calc): C, 60.44; H, 6.01; N, 15.66; 1H NMR (500 MHz, DMSO)
δ 9.04 (d, J = 4.1 Hz, 2H), 8.94 (d, J = 8.1 Hz, 2H), 8.60 (s, 1H), 8.36 (d, J = 8.2 Hz,
2H), 8.06 (d, J = 8.1 Hz, 2H), 7.85 (dd, J = 8.0, 4.3 Hz, 2H), 6.95 (s, 1H), 4.11 (s, 1H),
3.17 (s, 4H), 1.39 (s, 9H);

C NMR (126 MHz) δ 166.02, 156.00, 150.00, 148.18,
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143.91, 135.19, 132.49, 129.88, 126.03, 123.57, 78.10, 48.73, 28.53; IR: 3648, 3363,
3314, 3078, 2978, 2944, 1693, 1638, 1544, 1528, 1480, 1448, 1395, 1367, 1351, 1330,
1303, 1278, 1250, 1235, 1171, 1032, 978, 856, 807, 740, 699, 676, 644, 623 cm-1

N-Boc-2 2'-(ethylenedioxy)bis(ethylamine)-IMP (23)
Yield: 0.29 g (44.93 %); Appearance; Yellow solid; Solubility: MeOH, DMSO, DMF;
LC-MS (ESI) calcd for C29H31N6O3S2, 575.1894 [M+H]+, found 575.1873; 1H NMR
(500 MHz, DMSO) δ 9.02 (d, J = 2.9 Hz, 2H), 8.91 (d, J = 7.7 Hz, 2H), 8.81 (s, 1H),
8.35 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.87 – 7.78 (m, 2H), 6.99 (s, 1H),
3.61 (dd, J = 12.6, 6.3 Hz, 2H), 3.24 (dd, J = 12.8, 6.3 Hz, 2H), 2.96 (t, J = 6.9 Hz,
2H), 2.80 (t, J = 6.9 Hz, 2H), 1.37 (s, 9H);

C NMR (126 MHz, DMSO) δ 155.29,

13

149.29, 147.68, 143.26, 134.53, 131.98, 129.52, 127.65, 125.70, 123.23, 123.03,
77.40, 37.39, 36.87, 27.93; IR: 3213, 2976, 2929, 1688, 1637, 1519, 1480, 1451, 1396,
1365, 1308, 1278, 1252, 1166, 1069, 1029, 953, 856, 805, 775, 741, 705, 644, 622 cm1
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N-Boc-cystamine-IMP (24)
Yield: 0.29 g (43.22 %); Appearance: Yellow solid; Solubility: EtOH, MeOH, CHCl 3,
DCM, DMSO, DMF; LC-MS (ESI) calcd for C31H35N6O5, 571.2663 [M+H]+, found
571.2637; 1H NMR (500 MHz, DMSO) δ 9.02 (d, J = 1.6 Hz, 2H), 8.92 (d, J = 7.7 Hz,
2H), 8.67 (s, 1H), 8.35 (d, J = 7.7 Hz, 2H), 8.08 (d, J = 7.7 Hz, 2H), 7.83 (d, J = 2.9
Hz, 2H), 6.74 (s, 1H), 3.40 – 3.27 (m, 10H), 3.07 (d, J = 5.3 Hz, 2H), 1.35 (s, 9H); 13C
NMR (126 MHz, DMSO) δ 166.03, 155.87, 149.92, 148.22, 143.88, 135.18, 132.47,
129.96, 128.19, 127.01, 126.20, 124.51, 123.62, 119.20, 110.03, 77.88, 69.77, 69.42,
69.14, 28.44. IR: 3310, 3071, 2974, 2868, 1691, 1639, 1518, 1480, 1452, 1396, 1365,
1281, 1250, 1169, 1100, 1031, 1017, 969, 952, 860, 806, 776, 741, 712, 675, 644, 621
cm-1.

E.3.7

The deprotection of N-Boc-ethylenediamine-IMP (25)

N-Boc-ethylenediamine-IMP was deprotected as described by Trindade et al322. NBoc-ethylenediamine-IMP (0.2 g, 0.4 mmol) was added to cooled trifluoroacetic acid
(TFA; 5 ml) and stirred at room temperature for two hours. The TFA was removed in
vacuo with the aid of DCM (50 ml) and a minimal volume of DMF was used to
dissolve the residue. The addition of 200 µl triethylamine (TEA) resulted in
precipitation of a yellow product. A 70:30 mixture of diethyl ether and acetone was
used to wash the product. The product was filtered and washed with an excess of
acetone and diethyl ether and dried at 60oC overnight. Yield: 0.108 g (71.05%);
Appearance: Yellow solid; Solubility: MeOH, DMF, DMSO; λmax: 225. 278, 327 nm;
LC-MS (ESI) calcd for C22H19N6O 383.1615 [M+H]+, found 383.1620; Elemental
Analysis (Found): C, 68.56; H, 4.26; N, 22.22; Elemental Analysis (Calc): C, 69.10;
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H, 4.74; N, 21.98; 1H NMR (500 MHz, DMSO) δ 9.01 (d, J = 5.6 Hz, 2H), 8.92 (d, J
= 7.6 Hz, 2H), 8.25 (s, 1H), 7.89 (dd, J = 12.8, 8.3 Hz, 4H), 7.36 (d, J = 7.0 Hz, 2H),
3.66 – 3.52 (m, 2H), 3.34 – 3.00 (m, 2H), 2.08 (s); 13C NMR (126 MHz, DMSO) δ
165.51, 158.34 – 158.18 (m), 149.64, 148.09, 143.32, 133.38, 131.93, 130.47 – 130.11
(m), 127.03, 125.17, 123.60, 121.82, 38.33; IR: 3373, 1677, 1553, 1520, 1481, 1454,
1399, 1309, 1203, 1134, 1073, 1034, 859, 837, 802, 739, 721, 674, 645, 625 cm-1

E.3.8 The conjugation of folic acid with IMP-ethylenediamine (26)

Folic acid was conjugated with IMP-ethylenediamine as previously described by
Trindade et al322. To a solution of folic acid (0.447 g, 1 mmol) dissolved in 30 ml
anhydrous DMSO, DCC (0.413 g, 2 mmol) and NHS (0.233 g, 2 mmol) were added
successively. The reaction mixture was stirred in the absence of light for 24 hr at room
temperature, after which time, a colourless precipitate, dicyclohexylurea, was removed
by vacuum filtration. To the orange filtrate, 0.279 ml (2 mmol) of triethylamine and
0.413 g (2 mmol) DCC were added, followed by compound 25 (0.57 g, 2 mmol)
dissolved in 5 ml DMSO. The mixture was stirred overnight at room temperature, in
the absence of light before a mixture of acetone in diethyl ether (20% v/v; 100 ml) was
added. The fine, yellow precipitate was centrifuged at 3000 RPM for 10 minutes.
Centrifugation was repeated in methanol, acetone and diethyl ether. The product was
dried in a 60oC oven overnight. Yield: 0.508 g (71.05%); Appearance: Yellow solid;
Solubility: DMSO (hot), DMF (hot); λmax: 283, 333 nm; LC-MS (ESI) calcd for
C41H35N13O6 806.28 [M+H]+, found 806.28; Elemental Analysis (Found): C, 54.52; H,
4.19; N, 20.00; Elemental Analysis (Calc): C, 54.97; H, 5.06; N, 20.33; 1H NMR (400
MHz, DMSO) δ 8.98 (d, J = 42.2 Hz, 23H), 8.77 – 8.51 (m, 12H), 8.34 (s, 12H), 8.05
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(s, 21H), 7.82 (s, 13H), 7.67 (td, J = 21.2, 10.5 Hz, 10H), 6.89 (d, J = 3.3 Hz, 11H),
6.76 – 6.52 (m, 11H), 4.46 (ddd, J = 33.4, 30.9, 15.1 Hz, 11H), 2.93 (s, 6H), 2.80 (s,
5H), 2.67 (s, 3H), 2.58 (d, J = 11.3 Hz, 5H), 2.33 (s, 6H), 2.20 (s, 8H), 2.08 (s, 7H),
1.93 (s, 6H). 13C NMR (101 MHz, DMSO) δ 176.36, 174.20, 172.22, 166.60, 166.42,
166.00, 165.91, 165.55, 161.00, 154.32, 153.93, 150.80, 149.68, 148.50, 147.99,
143.70, 135.04, 133.46, 132.24, 130.46, 129.74, 129.15, 127.98, 125.94, 123.39,
121.45, 118.42, 112.50, 111.20, 53.28, 45.90, 45.72, 45.54, 40.15, 39.94, 39.52, 39.52,
39.31, 39.10, 38.89, 32.72, 32.15, 30.72, 29.27, 27.55; IR: 3318, 3077, 2937, 1641,
1605, 1571, 1532, 1516, 1480, 1453, 1397, 1300, 1273, 1180, 1126, 1073, 1031, 1016,
995, 969, 953, 878, 858, 836, 821, 809, 768, 740, 713, 696, 676 cm-1

E.3.9

The coordination of copper(II) and manganese(II) to the folate-

ethylenediamine-imidazole-phenanthroline (FIMP-et) ligand

To a stirred solution of compound 26 (0.1 g, 0.1 mmol) in methanol (20 ml), a
methanolic solution of metal(II) perchlorate hexahydrate (0.03 mmol) was added. The
suspension was refluxed for four hours, after which the suspension was cooled and
centrifuged at 3000 rpm for five minutes. Centrifugation was repeated in deionised
water, methanol and diethyl ether. The product was dried at room temperature
overnight.

Special caution is advised when handling or working with metal perchlorates due to
their potentially oxidising and explosive nature.
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[Cu(FIMP-et)(H2O)2].(ClO4)2.4.5H2O (27)
Yield: 0.11 g (75.21 %); Appearance: Green-brown solid; Solubility; partially soluble
in DMSO and DMF; λmax: 212, 253, 401 nm; Elemental Analysis (Found): C, 49.14;
H, 3.78; N, 18.23; Cu. 3.39; Elemental Analysis (Calc.): C, 49.46; H, 4.20; N, 18.29;
Cu, 3.19; IR: 3330, 3078, 2939, 1641, 1604, 1566, 1553, 1532. 1481, 1457, 1403,
1360, 1304, 1278, 1186, 1100, 1079, 1023, 953, 862, 840, 813, 771, 738, 712 cm-1.

[Mn(FIMP-et)].(ClO4)2.9H2O (28)
Yield: 0.091 g (77.45 %); Appearance: Yellow solid; Solubility; partially soluble in
DMSO and DMF; λmax: 213, 254, 283, 399 nm; Elemental Analysis (Found): C,
52.52; H, 3.95; N, 19.47; Mn, 1.00; Elemental Analysis (Calc.): C, 52.14; H, 4.38; N,
19.28; Mn, 1.94; IR: 3265, 3083, 2939, 2808, 1688, 1637, 1606, 1561, 1524, 1478,
1453, 1399, 1305, 1277, 1180, 1101, 1076, 953, 859, 817, 811, 772, 737, 712 cm-1.
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E.4

The cytotoxicity and mechanism of action of simple copper(II)

and manganese(II) folate complexes and their 1,10-phenanthroline derivatives.

E.4.1

Cell culture

E.4.1.1

Cell culture conditions

SKOV-3 (human ovarian adenocarcinoma cells), A549 (human lung carcinoma cells)
and RPE-1 (non-malignant retinal epithelial cells) were purchased from American
Type Culture Collection. MelJuSo-UbG76V-YFP (human melanoma cells) were
generated as previously described338. Briefly, MelJuso cells were transfected with a
UbG76V‐GFP reporter plasmid for 48 hours and subsequently cultured in the presence
of G418 (Sigma) to select for stably transfected cells. SKOV-3, A549, RPE-1 and
MelJuSo-UbG76V-YFP were grown in folate-free RPMI 1640 medium (Gibco),
supplemented with 10% foetal bovine serum and 5% penicillin/streptomycin (Life
Technologies). Cells were cultured in 5% CO2 at 37oC.

E.4.1.2

Folate saturation experiments in SKOV-3

For folate saturation experiments, SKOV-3 cells were plated in two separate 25ml
flasks (Sarstedt) at 37oC in 5% CO2 and grown for 1 week before treatment. One flask
was then cultured in folate-free RPMI 1640 media, while the other was cultured in
RMPI-1640 media supplemented with 100 µM folic acid for one week. Cells were
harvested, and cell viability was measured using the Alamar Blue Assay as described
in section E.4.3
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E.4.2

Western blot analysis

E.4.2.1

Western blot analysis of folate receptor expression

SKOV-3 (human ovarian adenocarcinoma), A549 (human lung carcinoma), RPE-1
(retinal epithelial) and MelJuSo-UbG76V-YFP (human melanoma expressing UbG76VYFP and nuclear red) cells were seeded at 200,000 cells per well in folate-free RPMI
1640 medium and grown to 80% confluency. Cells were lysed in RIPA buffer (140
mM NaCl, 10 mM Tris-Cl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100,
0.1% sodium deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Sigma
Aldrich). Protein concentrations of cell lysates were determined using the detergent
compatible (DC) protein assay (Bio-Rad) at 570 nm. 15 µg/well total protein were
resolved on 4-12% Bis-Tris PAGE gels (Invitrogen) in MES buffer (pH 7.3) and
transferred onto a nitrocellulose membrane (Bio-Rad) for Western blotting. Equal
protein loading was confirmed using reversible Ponceau staining. Blots were
developed with enhanced chemiluminescence reagents (Bio-Rad) on a Chemi-DocTM
Imaging system (Bio-Rad). Primary antibody anti-FRα (Thermofisher Scientific) was
used at a 1:1000 dilution and secondary antibody, anti-rabbit-horseradish peroxidase
(HRP) (Thermofisher Scientific) was used at a 1:1000 dilution.

E.4.2.2

Western blot analysis of [Cu(fol)(phen)(H2O)].3H2O mechanism of
action

Western blots were prepared as described in Section E.4.2.1 with the following
deviations:
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MelJuSo-UbG76V-YFP cells were cultured as per section E.4.1 and treated with 1.57-5
µM of [Cu(fol)(phen)(H2O)].3H2O, and [Cu(phen)2]2+ in folate-free RPMI 1640
medium. Bortezomib (50 nM) was included as a positive control and DMSO-treated
(0.05%) cells were used as a negative control for [Cu(fol)(phen)(H2O)].3H2O and
ethanol-treated (0.05%) cells were used as a negative control for [Cu(phen)2]2+. Cells
were harvested following 6 hr and 18 hr treatments. 15 µg/well protein was resolved
for each sample. Proteins with molecular weight greater than 40 kDa (K48 Ub, GFP,
HSPA6, BIP, and p53) were resolved on 3-8% Tris-Acetate PAGE gels (Invitrogen)
in tris-acetate buffer (pH 8.3). Proteins with molecular weights less than 40 kDa
(HMOX-1, Casp-3, and p21) were resolved on 4-12% Bis-Tris PAGE gels (Invitrogen)
in MES buffer (pH 7.3).

Antibodies used in this study were as follows (Table 16): β actin (Sigma Aldrich),
HSPA6 (Sigma Aldrich); Ubiquitin K48 (Apu2) (Millipore); Green Fluorescence
Protein (Cell Signalling); GRP78/BiP (Cell Signalling); Tumour Suppressor p53
(Santa Cruz Bio); Heme Oxygenase 1 (BD Biosciences), Caspase 3 (BD Biosciences);
and CDK-interacting protein 1 (Cell Signalling). All primary antibodies were used at
a 1:5000 dilution. Secondary antibodies, mouse-IgG-HRP (Cell Signalling), and
rabbit-IgG-HRP (Cell Signalling) were used at a 1:1000 dilution. Blots were developed
on a Chemi-DocTM Imaging system (Bio-Rad).
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Table 16: Antibodies used, including molecular weight, target of interest and protein
function in the cell
Molecular Weight
(kDa)

Antibody

Protein Target

Function
Housekeeping
protein (loading
control)
Mitochondrial
chaperone

Anti-β-actin

42

Actin

Anti-heat shock
protein HSPA6

71

HSPA6

Anti-ubiquitin K48

Various

Ubiquitin

Protein degradation

Anti-green
fluorescent protein

27

GFP-linked
Ubiquitin

Protein degradation

Anti-GRP78/BiP

78

GRP78/BiP

Anti-p53

53

p53

Anti-Heme
Oxygenase 1

32

HMOX-1

Anti-caspase 3

32/17 (cleaved)

Caspase-3

Anti-CDKinteracting protein 1

21

p21

E.4.2.3

Chaperone Endoplasmic
reticular stress
Tumour suppressor
Apoptosis
Anti-oxidase
(Oxidative stress)
Death protease
Apoptosis
Kinase
Apoptosis

Western blot analysis of [Mn(fol)(phen)(H 2O)].4H2O mechanism of
action

Western blots were prepared as described in Section E.4.2.1 with the following
deviations:

MelJuSo-UbG76V-YFP-NR cells were cultured as per section E.4.1 and treated with 6
- 20 µM of [Mn(fol)(phen)(H2O)].4H2O, and [Mn(phen)2]2+ in folate-free RPMI 1640
medium. Bortezomib (50 nM) was included as a positive control and DMSO- and
ethanol-treated (0.1%) cells were used as negative controls. Cells were harvested
following 48 hr treatment. 10.5 µg/well protein was resolved for each sample. Proteins
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with molecular weight greater than 40 kDa (HSP60 and p62) were resolved on 3-8%
Tris-Acetate PAGE gels (Invitrogen) in tris-acetate buffer (pH 8.3). HMOX-1 protein
was resolved on 4-12% Bis-Tris PAGE gels (Invitrogen) in MES buffer (pH 7.3).

Antibodies used in this study were as follows (Table 17): Anti-α tubulin (Sigma
Aldrich), anti-heat shock protein HSP60 (Cell Signalling), anti-p62 (Cell Signalling),
anti-Heme Oxygenase 1 (BD Biosciences). All primary antibodies were used at a
1:5000 dilution. Secondary antibodies, mouse-IgG-HRP (Cell Signalling), and rabbitIgG-HRP (Cell Signalling) were used at a 1:1000 dilution.

Table 17: Antibodies used, including molecular weight, target of interest and protein
function in the cell
Antibody

Molecular Weight
(kDa)

Protein Target

Function
Housekeeping
protein (loading
control)
Mitochondrial
chaperone

Anti-α tubulin

51

Tubulin

Anti-heat shock
protein HSP60

60

HSP60

Anti-p62

62

p62

Autophagic flux

Anti-Heme
Oxygenase 1

32

HMOX-1

Anti-oxidase
(Oxidative stress)

E.4.3 Cell viability assay

The Alamar Blue assay encompasses a fluorometric/colorimetric growth indicator
based on the detection of metabolic activity. The system incorporates an oxidationreduction indicator that both fluoresces and changes colour in response to chemical
oxidation of growth medium as a result of cell death. A decrease in cell viability results
in a colour change from pink (reduced, fluorescent) to blue (oxidised, non-fluorescent).
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E.4.3.1

Effects of [Cu(fol)(H2O)3].H2O and [Cu(fol)(phen)(H2O)].3H2O

in 2D monolayer cell culture

The Alamar Blue assay (Invitrogen) was used to measure cell proliferation effects of
[Cu(fol)(H2O)3].H2O and [Cu(fol)(phen)(H2O)].3H2O against SKOV-3 and A549
cells. Cells were grown to 80% confluency and seeded at a density of 5000 cells per
well in triplicate in 96-well plates (Corning). Preliminary studies were conducted in
the range of 2.5 – 100 µM using [Cu(fol)(H2O)3].H2O and [Cu(fol)(phen)(H2O)].3H2O
and starting materials (folic acid, 1,10-phenanthroline, and copper(II) chloride).
Cisplatin was used as a positive control (2.5 – 100 µM) and DMSO-treated cells (0.5%)
and ethanol treated cells (0.5%) were used as negative controls. After 24 h incubation
at 37oC in 5% CO2, cell viability was measured by fluorescence using a Tecan Spark
microplate reader from 560 – 590 nm. Cell viability was calculated as a percentage of
solvent-treated control cells and expressed as a percentage of the control.

Following preliminary studies above, subsequent cell viability studies testing
[Cu(fol)(phen)(H2O)].3H2O and its non-targeted complex, [Cu(phen)]2+, were
performed in the concentration range 1 – 10 µM on SKOV-3 and A549 cell lines.
Cisplatin was used as a positive control (1 – 10 µM) and DMSO-treated cells (0.05%)
and ethanol treated cells (0.05%) were used as negative controls. In both studies, after
24 h incubation at 37oC in 5% CO2, cell viability was measured by fluorescence using
a Tecan Spark microplate reader from 560 – 590 nm. Cell viability was calculated as
a percentage of solvent-treated control cells and expressed as a percentage of the
control. Significance values were calculated using multiple t-tests (Prism V8.1)
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E.4.3.2

Effects

of

folate

saturation

on

cytotoxicity

of

[Cu(fol)(phen)(H2O)].3H2O

SKOV-3 cells were cultured as described in section E.4.1. Cells were then treated with
1 – 10 µM [Cu(fol)(phen)(H2O)].3H2O for 24 hrs in the presence or absence of 100
µM folic acid (FAH2). DMSO (0.05%) was used as a negative control. Cell viability
was measured by fluorescence using a Tecan Spark microplate reader from 560 – 590
nm and calculated as a percentage of solvent-treated control cells and expressed as a
percentage of the control.

E.4.3.3

Effects of [Mn(fol)(H2O)3].3H2O and [Mn(fol)(phen)(H2O)].4H2O
in 2D monolayer cell culture

The Alamar Blue assay was used as described in Section E.4.3.1 with the following
deviations:
Preliminary studies were conducted in the range of 3 – 100 µM using
[Mn(fol)(H2O)3].3H2O, [Mn(fol)(phen)(H2O)].4H2O, and [Mn(phen)2]2+. Cisplatin
was used as a positive control (3 – 100 µM) and DMSO-treated cells (0.5%) and
ethanol treated cells (0.5%) were used as negative controls. Cells were treated for 24
and 48 hours at 37oC and 5% CO2.

Following

preliminary

studies,

subsequent

cell

viability

studies

using

[Mn(fol)(phen)(H2O)].4H2O and its non-targeted comparator, [Mn(phen)]2+, were
performed in the concentration range 2 – 20 µM against SKOV-3 and A549 cell lines.
Bortezomib was used as a positive control (20 – 200 nM) and DMSO-treated cells
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(0.1%) and ethanol treated cells (0.1%) were used as negative controls. Cells were
treated for 48 and 72 hours at 37oC in 5% CO2. In both studies, cell viability was
measured by fluorescence using a Tecan Spark microplate reader from 560 – 590 nm.
Significance values were calculated using multiple t-tests (Prism V8.1)

E.4.3.4

Effects

of

folate

saturation

on

cytotoxicity

of

[Mn(fol)(phen)(H2O)].4H2O

SKOV-3 cells were cultured as described in section E.4.1. Cells were then treated with
2- 20 µM [Mn(fol)(phen)(H2O)].4H2O for 48 hrs in the presence or absence of 100
µM folic acid. DMSO (0.1%) was used as a negative control. Cell viability was
measured by fluorescence using a Tecan Spark microplate reader from 560 – 590 nm
and calculated as a percentage of solvent-treated control cells and expressed as a
percentage of the control.

E.4.4

Cytotoxicity of [Cu(fol)(phen)(H2O)].3H2O and
[Mn(fol)(phen)(H2O)].4H2O against 3D tumour spheroids

SKOV-3 cells were seeded at 10,000 cells per well in an ultra-low adherence, round
bottomed 96-well plate (Corning, Costar) in folate-free RPMI 1640 medium
supplemented with 10% FBS and 5% Penicillin/streptomycin. Cells were allowed to
settle at the bottom of each well at room temperature for one hour before being cultured
at 37oC for five days in a 5% CO2 humidified incubator without interference.
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Cells were treated with [Cu(fol)(phen)(H2O)].3H2O, and [Cu(phen)2]2+ at
concentrations ranging from 1 – 10 µM, and [Mn(fol)(H2O)3].3H2O, and
[Mn(phen)2]2+ at concentrations ranging from 2 – 20 µM. Bortezomib was used as a
positive control at concentrations between 30 - 100 nM. DMSO-treated cells (0.1%)
were used as a negative control. Spheroids were treated for 72 hr and imaged every
three hours using an IncuCyte-FLR 10X phase contrast/fluorescence microscope
(Essen Instruments, Ann Arbor, MI). Spheroid volume was calculated using ImageJ
software. Spheroid volume (V = 0.5 * Length * Width2)

E.4.5 Quantification of UbG76V-YFP fluorescence

MelJuSo-UbG76V-YFP cells were treated with 0.157 – 5 µM of [Cu(fol)(phen)(H2O)].3H2O,

and [Cu(phen)2]2+. Bortezomib, a clinically used proteasome inhibitor, was

used as a positive control (100 nM). Cells were treated with DMSO (0.05%) and
ethanol (0.05%) as negative controls. Fluorescence of treated MelJuSo-UbG76V-YFP
cells in 96-well plates (Corning) was recorded every three hours using an IncuCyteFLR 20X phase contrast/ fluorescence microscope (Essen Instruments, Ann Arbor,
MI).

E.4.6

Wound scratch assay

MelJuSo-UbG76V-YFP cells (300,000) were seeded into two 35 mm dishes and allowed
to reach 100% confluency as a monolayer. A sterile 1000 µL pipette tip was used to
gently scratch a straight line along the equator of each dish. After scratching, the dish
was washed carefully twice with 1X PBS to remove detached cells. To the negative
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control dish, 4 ml fresh media with 0.1% DMSO was added. To the other, 4 ml fresh
media containing 20 µM [Mn(fol)(H2O)3].3H2O was added. Media (containing either
0.1% DMSO or 20 µM [Mn(fol)(H2O)3].3H2O was replenished every 24 hours and
images of the scratch site were taken every 24 hours using an Olympus inverted
microscope for a total of 72 hours.

E.4.7

Mitochondrial membrane potential

SKOV-3 cells (500,000) were seeded into four 35 mm dishes. After 24 hours, cells in
two of the dishes were treated with 20 µM [Mn(fol)(H2O)3].3H2O, while the remaining
two dishes were replenished with media containing 0.1% DMSO. After 48 hours
treatment, cells were trypsinised, washed and fixed in 70% ice-cold ethanol for 12 h.
Cells were resuspended in 25 nM TMRE (tetramethylrhodamine, ethyl ester;
Invitrogen) in PBS for 30 min. Changes in mitochondrial membrane potential (DC)
were monitored by fluorescence using a Beckman Coulter Gallios flow cytometer.
Data was analysed using FlowJo V10 software.

E.4.8

Cell cycle analysis

SKOV-3 cells (500,000) were seeded into four 35 mm dishes. After 24 hours, cells in
two of the dishes were treated with 20 µM [Mn(fol)(H2O)3].3H2O, while the remaining
two dishes were replenished with media containing 0.1% DMSO. After 48 hours
treatment, cells were trypsinised, washed and fixed in 70% ice-cold ethanol for 12 h.
Cells were resuspended in staining solution containing propidium iodide (50 µg/ml)
and RNAse A (0.5 µg/ml) in PBS. Samples were run on Beckman Coulter Gallios flow
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cytometer. The percentage of cells in each phase of the cell cycle was determined using
FlowJo V10 software.

E.5

The Cytotoxicity of Copper(II) and Manganese(II) FIMP

Complexes
The structures of these complexes can be found in section D.4.1

E.5.1

Cell culture

Cells were cultured as described in Section E.4.1

E.5.2

Cell viability assay

The Alamar Blue assay was conducted as described in Section E.4.3.1 with the
following deviations:

A549 cells were seeded at a density of 4000 cells/well while SKOV-3 were seeded at
a density of 3000 cells/well. Cells were treated with [Cu(FIMP) 2](ClO4)2.2H2O,
[Mn(FIMP)3](ClO4)2.2H2O, or the free FIMP ligand from 10 – 100 μM. Cisplatin (100
μM) was used as a positive control and DMSO-treated cells (1.80 %) were used as a
negative control. Complexes were suspended or dissolved in either ethanol or DMSO
and diluted in culture media to the concentrations specified in Table 16. After 48 hours,
cell viability was measured by fluorescence using a Perkin Elmer Victor 3V 1420
Multilabel Plate Counter from 560 – 590 nm.

Table 18: Solvent concentration for each test compound in cell culture media.
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Compound

Solvent Concentration in Media (%)

Folic acid

DMSO (0.25 %)

1,10-Phenanthroline

Ethanol (0.03 %)

Fol-Im-Phen (FIMP)

DMSO (0.20 %)

[Mn(FIMP)3](ClO4)2.2H2O

DMSO (1.80 %)

[Cu(FIMP)2](ClO4)2.2H2O

DMSO (1.50 %)

E.6.

Statistical analysis of data

Cells were treated with complexes as described in Sections 4.3.1 and 4.3.3. Data was
obtained from three replicate wells on each plate. Each experiment was performed
three times (three independent plates n=3). All statistical analysis was performed using
multiple t-test, with the exception of EC50 and standard deviation. GraphPad Prism (V
8.1) was used to calculate the EC50 concentrations for each complex. The EC50 value
represents the concentration required to induce a 50% reduction in cell viability. The
standard deviation was calculated using Excel. Standard deviation was used to measure
the variability of the data set and provide information regarding the precision of the
experiment.
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A.1: Folic acid
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A.2 1,10-Phenanthroline
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A.3 Metal phenanthroline complexes
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IR Spectrum – [Mn(phen)2Cl2]
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A.4: Complexes 1 – 2
IR Spectrum - [Cu(fol)(H2O)3].H2O (1)
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IR Spectrum - [Mn(fol)(H2O)3].3H2O (2)
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A.5: Complexes 3 – 4
IR Spectrum - Fe(fol)(H2O)2Cl].4H2O (3)
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IR spectrum - [Zn(fol)(H2O)3].3H2O (4)
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A.6 Complex 5 – 6
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IR Spectrum - [Mn(fol)(phen)(H2O)].4H2O (6)
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A.7 Complex 7 – 8
IR Spectrum - [Fe(fol)(phen)Cl].5H2O (7)
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IR Spectrum - [Zn(fol)(phen)(H2O)].4H2O (8)
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A.8 1,10-Phenanthroline-5,6-dione (11)
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A.9 IMP-NO2 (12)
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A.10 IMP-COOH (13)
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A.11 IMP-Phenyl (14)
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A.12 IMP-NH2 (15)
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A.13 N-Boc ethylenediamine (16)
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A.14 N-Boc 2,2'-(ethylenedioxy)bis(ethylamine) (17)
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A.15 N-Boc cystamine (18)
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A.16

N-Boc-ethylenediamine-folate (19)
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A.17 N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)-folate (20)
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A.18 N-Boc-cystamine-folate (21)
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A.19 N-Boc-ethylenediamine-IMP (22)
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A.20 N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)-IMP (23)
IR Spectrum
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A.21 N-Boc-cystamine-IMP (24)
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A.22 Ethylenediamine-IMP (25)
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A.23 Folate-ethylenediamine-IMP (26)
IR Spectrum
100
95
90
85
80
75
70
Transmittance [%]

65
60
55
50
45
40
35
30
25
20
15
10
5
0
4000

3800

3600

3400

3200

Mass Spectrum

3000

2800

2600

2400
2200
Wavenumbers [1/cm]

Mass Spectrum (Zoomed)

298

2000

1800

1600

1400

1200

1000

800

A.24 Folate-ethylenediamine-IMP (26)
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A.25

Complexes 27 and 28
IR Spectrum - [Cu(FIMP-et)(H2O)2].(ClO4)2.4.5H2O (27)
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IR Spectrum - [Mn(FIMP-et)].(ClO4)2.9H2O (28)
100
95
90
85
80
75
Transmittance [%]

70
65
60
55
50
45
40
35
30
25
20
15
10
5
4000

3800

3600

3400

3200

3000

2800

2600

2400
2200
Wavenumbers [1/cm]

UV Vis spectra (200 – 700 nm)

300

2000

1800

1600

1400

1200

1000

800

PUBLICATIONS

301

P.1

Publications

McCarron, P.*; Crowley, A.*; O’Shea, D.; McCann, M.; Howe; O.; Hunt, M.;
Devereux, M. Targeting the Folate Receptor: Improving Efficacy in Inorganic
Medicinal Chemistry. Curr. Med. Chem. 2018, 25, 1-34. *Equal contribution from
authors

Crowley, A.; O’Shea, D.; D’Arcy, P.; Hunt, M..; Devereux, M. The Synthesis,
Characterisation, and Biological Activity of Copper(II) and Manganese(II) Folate
Complexes and their 1,10-Phenanthroline Derivatives. Article in preparation for
submission in Polyhedron

Crowley, A.; O’Shea, D.; Devereux, M.; D’Arcy, P.; Hunt, M. A Novel Copper(II)
Folate Phenanthroline Complex as a Potential Proteasome Inhibitor. Article in
preparation for submission in Journal of Bioinorganic Chemistry

Crowley, A.; O’Shea, D.; Devereux, M.; D’Arcy, P.; Hunt, M. A Novel Manganese(II)
Folate Phenanthroline Complex may cause ROS-Induced Autophagy. Article in
preparation for submission in Journal of Bioinorganic Chemistry

Conferences:
The Mechanism of Action of a Copper(II) Folate-Phenanthroline Complex in 2D and
3D Cellular Models. Flash presentation and poster presentation at the 1st Irish
Biological Inorganic Chemistry Society Symposium, Maynooth University,
November 2017.

302

A Comparison of Copper(II) and Manganese(II) Folate Phenanthroline Complexes and
Their Biological Activities. Oral presentation at the 2 nd Irish Biological Inorganic
Chemistry Society Symposium, National University of Ireland, Galway, November
2018.

303

